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A B S T R A C T
Background
Vitamin A deficiency (VAD) is a major public health problem in low and middle income countries affecting 190 million children under
5. VAD can lead to many adverse health consequences, including death.
Objectives
To evaluate the effect of vitamin A supplementation (VAS) for preventing morbidity and mortality in children aged 6 months to 5
years.
Search methods
We searched CENTRAL (The Cochrane Library 2010, Issue 2), MEDLINE (1950 to April Week 2 2010), EMBASE (1980 to 2010
Week 16), Global Health (1973 toMarch 2010), Latin American andCaribbean Health Sciences (LILACS), metaRegister of Controlled
Trials and African Index Medicus (27 April 2010).
Selection criteria
Randomised controlled trials (RCTs) and cluster RCTs evaluating the effect of synthetic VAS in children aged 6 months to 5 years living
in the community. We excluded studies of children in hospital and children with disease or infection. We excluded studies evaluating
the effects of food fortification, consumption of vitamin A rich foods or beta-carotene supplementation.
Data collection and analysis
Two authors independently assessed studies for inclusion. Data were double abstracted and discrepancies resolved by discussion. Meta-
analyses were performed for outcomes including all-cause and cause-specific mortality, disease, vision, and side-effects.
Main results
Forty-three trials involving 215,633 childrenwere included. Ameta-analysis for all-causemortality included 17 trials (194,795 children).
At follow-up, there was a 24% observed reduction in the risk of all-cause mortality for vitamin A compared with control (Relative risk
(RR) = 0.76 (95% confidence interval (CI) 0.69 to 0.83). Seven trials reported diarrhoea mortality and showed a 28% overall reduction
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for VAS (RR = 0.72 (95% CI 0.57 to 0.91)). There was no significant effect of VAS on cause specific mortality of measles, respiratory
disease and meningitis. VAS reduced incidence of diarrhoea (RR = 0.85 (95% CI 0.82 to 0.87)) and measles morbidity (RR = 0.50
(95% CI 0.37 to 0.67)); however, there was no significant effect on incidence of respiratory disease or hospitalisations due to diarrhoea
or pneumonia. There was an increased risk of vomiting within the first 48 hours of VAS (RR = 2.75 (95% CI 1.81 to 4.19)).
Authors’ conclusions
VAS is effective in reducing all-cause mortality and we recommend universal supplementation for children under 5 in areas at risk of
VAD. Further placebo-controlled trials of VAS in children between 6 months and 5 years of age are unnecessary, although studies that
compare different doses and delivery mechanisms are needed.
P L A I N L A N G U A G E S U M M A R Y
Vitamin A supplementation for preventing disease and death in children 6 months to five years of age
Vitamin A deficiency (VAD) is a major public health problem in low and middle income countries affecting 190 million children under
5 years of age. VAD pre-disposes children to increased risk of a range of problems, including respiratory diseases, diarrhoea, measles
and vision problems, and can lead to death.
This review, including 43 randomised trials representing 215,633 children, shows that giving vitamin A capsules to children aged 6
months to 5 years can reduce death and some diseases. The results of 17 of the studies were summarised and indicate that vitamin A
reduces the overall risk of death by 24%. Death due to measles, respiratory infections or meningitis was not specifically reduced, but
vitamin A can reduce new occurrences of diarrhoea and measles. When people take very large doses of vitamin A, they may be more
likely to vomit within two days of taking it.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Vitamin A supplementation for preventing morbidity and mortality in children from six months to five years of age
Patient or population: Children aged between 6 months and five years
Intervention: Vitamin A supplementation
Comparison: Placebo or usual care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Vitamin A
All-cause mortality
Follow-up: 12-96 weeks
Low risk population RR 0.76; 95% CI 0.69 to
0.83
194,795
(17 studies)
++++
high
The inclusion of the DE-
VTA trial reduced the ef-
fect size from 0.76 to 0.
88 (Analysis 1.4). The im-
pact on the absolute ef-
fect was to reduce the risk
of mortality by 2 per 1000
in medium risk and 11 per
1000 in high risk popula-
tions
0 per 10001 0 per 1000
(0 to 0)
Medium risk population
11 per 10001 8 per 1000
(7 to 9)
High risk population
90 per 10001 68 per 1000
(62 to 75)
Diarrhoea-related mor-
tality
Follow-up: 48-104 weeks
Low risk population RR 0.72; 95% CI 0.57 to
0.91
90,951
(7 studies)
+++O
moderate2
Total number of partic-
ipants reflects number
randomised to studies.
The analysis combined
cumulative risk and risk
per/1000 years follow-up
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3 per 10001 2 per 1000
(2 to 3)
Medium risk population
4 per 10001 3 per 1000
(2 to 4)
High risk population
9 per 10001 6 per 1000
(5 to 8)
Measles-related mortal-
ity
Follow-up: 52-104 weeks
Low risk population RR 0.80; 95% CI 0.51 to
1.24
88,261
(5 studies)
+++O
moderate2
Total number of partic-
ipants reflects number
randomised to studies.
The analysis combined
cumulative risk and risk
per/1000 years follow-up
2 per 10,0001 2 per 10,000
(1 to 3)
Medium risk population
16 per 10,0001 13 per 10,000
(8 to 20)
High risk population
44 per 10,0001 35 per 10,000
(22 to 55)
LRTI-related mortality
Follow-up: 48-104 weeks
Low risk population RR 0.78; 95% CI 0.54 to
1.14
90,951
(7 studies)
++OO
low2,3
Total number of partic-
ipants reflects number
randomised to studies.
The analysis combined
cumulative risk and risk
per/1000 years follow-up
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4 per 10,0001 3 per 10,000
(2 to 4)
Medium risk population
11 per 10,0001 9 per 10,000
(6 to 13)
High risk population
219 per 10,0001 171 per 10,000
(118 to 250)
Diarrhoea incidence
Mean episodes per child
per year
Follow-up: 24-60 weeks
Mean episodes of diar-
rhoea in control groups:
1.9/child/year in controls
VAS led to 0.29 episodes
fewer per child per year
(95% CI 0.34 episodes to
0.25 episodes fewer)
Rate ratio 0.85; 95% CI 0.
82 to 0.87
69,972
(13 studies)
++OO
low4,5
Measles-morbidity inci-
dence
Mean
episodes of measles per
child per year
Follow-up: mean 52
weeks
Mean episodes in control
groups: 0.028 event per
child per year
VAS led to 0.015 fewer
episodes per child per
year (95% CI 0.019
events fewer per child
to 0.01 events fewer per
child)
Rate ratio 0.50; 95% CI 0.
37 to 0.67
19,566
(6 studies)
++++
high
LRTI-morbidity
incidence
Mean episodes per child
per year
Follow-up: mean 52
weeks
Mean episodes in control
groups: 0.7 episodes.
VAS led to 0.1 more
episodes/child/year (95%
CI 0.04 episodes fewer
to 0.3 episodes more
episodes per child per
year
Rate ratio 1.14; 95% CI 0.
95 to 1.37
19,566
(9 studies)
+OOO
very low6,7,8
Bitot’s spots
Follow-up: mean 80.72
weeks
Low risk population RR 0.45; 95% CI 0.33 to
0.61
63,278
(4 studies)
+++O
moderate9
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4 per 10001 2 per 1000
(1 to 2)
Medium risk population
14 per 10001 6 per 1000
(5 to 9)
High risk population
203 per 10001 91 per 1000
(67 to 124)
Night blindness
Follow-up: 52 to 68
weeks
Low risk population RR 0.32; 95% CI 0.21 to
0.50
22,972
(2 studies)
+++O
moderate11
4 per 100010 1 per 1000
(1 to 2)
High risk population
7 per 100010 2 per 1000
(2 to 4)
Vitamin A deficiency
Follow-up: mean 54.5
weeks
Low risk population RR 0.71; 95% CI 0.65 to
0.78
2262
(4 studies)
++++
high
93 per 100010 66 per 1000
(60 to 72)
Medium risk population
286 per 100010 203 per 1000
(186 to 223)
High risk population
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588 per 100010 417 per 1000
(382 to 458)
Vomiting
Follow-up: 0.14 to 52
weeks
Low risk population RR 2.75; 95% CI 1.81 to
4.19
2994
(3 studies)
++OO
low 12,13
0 per 100010 0 per 1000
(0 to 0)
Medium risk population
22 per 100010 62 per 1000
(41 to 94)
High risk population
73 per 100010 200 per 1000
(132 to 305)
*The basis for the assumed risk (for example, the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk Ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1. CERs identified from the studies for this outcome which report cumulative risk.
2. The wide confidence intervals around the pooled effect estimate included both a reduction and an increase in the risk of mortality with
vitamin A.
3. The risk of bias assessments determined that Daulaire 1992 and Herrera 1992 were at high risk of selection bias. Inadequate blinding
put the results of Daulaire 1992 at a high risk of detection bias. Incomplete data was considered to put the results of Chowdhury 2002 at
a high risk of attrition bias. Baseline imbalance was noted for Agarwal 1995.
4. The risk of bias assessment determined that four studies contributing just over 25% weight of the estimated effect were at risk of
selection or attrition bias.
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5. The I square was 95%, and the results of Herrera 1992; Cheng 1993 and Chowdhury 2002 demonstrated clear evidence of benefit
and were discordant with the results of the other studies.
6. The risk of bias assessment determined that Cheng 1993; Kartasasmita 1995 and Chowdhury 2002 were at high risk of attrition bias.
7. Diagnostic procedures were not consistent across the studies.
8. The CIs around the pooled effect included small benefit and a meaningful increase in the risk of RTIs.
9. The risk of bias assessment determined that there was a risk of attrition bias in Pant 1996, which was assigned 47% weight.
10. Risk based on CERs from the included studies.
11. The larger study was not well described and was of uncertain quality; this puts the results at a high risk of selection bias.
12. The follow-up was spread between 1 day and 52 weeks.
13. There was some evidence of under-reporting of adverse events in some of the studies, and the low number of trials giving data in
relation to the large of studies included overall means that this selective reporting of adverse events cannot be excluded.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Vitamin A is required for normal functioning of the visual sys-
tem, maintenance of cell function for growth, epithelial integrity,
red blood cell production, immunity and reproduction (Sommer
1996). Vitamin A deficiency (VAD) impairs body functions and
may cause death. Adverse health consequences may also include
xerophthalmia (dry eyes), susceptibility to infection, stunting and
anaemia (Sommer 1996; Rice 2004). Chronic VAD may develop
when animal sources and fortified foods are limited, as in diets
that rely heavily on vegetables and fruits (Ramakrishnan 2002).
In poor societies, especially lower income countries, dietary defi-
ciency can begin very early in life, as when colostrum is discarded
or when breastfeeding is inadequate (Haskell 1999).
VAD is interconnected with a deprived ecological, social and eco-
nomic environment. People with VADmay be exposed tomeasles,
diarrhoea and respiratory diseases (Sommer 2002; Rice 2004).
When these problems are comorbid, intake of vitamin A may be
lowered through depressed appetite andpoor absorption, andbody
stores of vitamin A may be depleted through excessive metabolism
and excretion (Alvarez 1995; Mitra 1998). This combination of
poor diet and infection leads to a vicious cycle that particularly af-
fects young children and pregnant or lactating mothers (Sommer
2002; West KP 2003).
VAD is common in the developing world. About 19.1 million
pregnant women and 190 million children under 5 are vitamin
A deficient (i.e. serum retinol < 0.70 µmol/l), representing about
33% of children under 5 in populations at risk of VAD (WHO
2009). Based on biochemical VAD in young children, 122 coun-
tries have a moderate to severe public health problem (WHO
2009).
Africa and South-East Asia contain the highest proportions of
pregnant females and children under 5 with biochemical VAD
and night blindness (WHO 2009). Xerophthalmia is the world’s
leading preventable cause of blindness, and a cardinal indicator
of VAD (Sommer 1996). Of the world’s children with xeroph-
thalmia, nearly half reside in South or South-East Asia, with more
than 85% of these living in India (West 2002a).
Description of the intervention
Vitamin A is a term used for a subclass of retinoic acids, a family of
lipid-soluble compounds (Bates 1995). Vitamin A is found in two
main forms: provitamin A carotenoids and preformed vitamin A.
Provitamin A carotenoids are found in plants; beta-carotene is the
only one that is metabolised by mammals into vitamin A. Though
fruits and vegetables are nutritious in other ways, normal dietary
intake of plants may not deliver adequate amounts of vitamin A
because the intestinal carotenoid-to-retinol conversion ratio is 12:
1 (US Institute of Medicine, Food and Nutrition Board). Con-
sequently, VAD can exist in places with high vegetable and fruit
consumption (West 2002). Preformed vitamin A (retinol, retinal,
retinoic acid, and retinyl esters), is the most active form of vita-
min A and is found in animal sources. Supplements usually use
Preformed vitamin A (Shenai 1993; Bates 1995).
How the intervention might work
Vitamin A is an essential nutrient; it cannot be synthesised by the
human body and therefore must be obtained through diet (Bates
1995). Oral supplementation (VAS) and food fortification are the
most directmethods for providing vitamin A to people whose diets
are deficient.
Vitamin A has been described as an anti-infectious vitamin be-
cause of its role in regulating human immune function (Green
1928). Early studies in animals andhumans revealed an association
between VAD and increased susceptibility to infections (Semba
1999). In addition to its preventive and therapeutic effect against
xerophthalmia (Sommer 1996), prophylactic VAS in apparently
healthy children (over 6 months of age) residing in developing
countries may reduce childhood mortality by as much as 30%
(Beaton 1993; Fawzi 1993; Glasziou 1993), particularly by reduc-
ing diarrhoea and measles mortality.
Side effects of VAS are rare in children aged 6 months or older;
however, vitamin A toxicity can develop if large amounts of vita-
min A are used over a prolonged period of time. Symptoms of tox-
icity include liver damage, headaches, vomiting, skin desquama-
tion, bone abnormalities, joint pain and alopecia (Smith 1976). A
very high single dose can also cause transient acute toxic symptoms
that may include a bulging fontanelle in children under 1 year,
headaches, vomiting, diarrhoea, loss of appetite and irritability.
Toxicity from ingestion of food sources of preformed vitamin A is
rare (Hathcock 1997).
Why it is important to do this review
Prophylactic and therapeutic supplementation has been the sub-
ject of several reviews (Beaton 1993; Fawzi 1993; Glasziou 1993;
Gogia 2008a). Three of these are 17 years old. Themost recent one
(Gogia 2008a) included studies of maternal VAS, neonatal VAS
and childhood supplementation in a single meta-analysis. Direct
supplementation of children and indirect methods through sup-
plementation of breast-feeding mothersmay have variable impacts
on children, and supplementation may have different effects at
these key developmental stages. These systematic reviews reported
statistically significant reductions in all-cause child mortality. VAS
appears to be a very cheap intervention that can be easily admin-
istered to children. In populations with low vitamin A status and
where dietary intake of vitamin A is low, large-scale supplementa-
tion might lead to substantial public health benefits, including re-
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duced childhood mortality, infections and blindness. On the basis
of previous evidence, the WHO has long recommended VAS for
young children and pregnant or breastfeeding mothers at a dose
of 50,000 IU for infants under 6 months of age, 100,000 IU for
infants 6 to 12 months of age and 200,000 IU for children over
12 months of age, every 4 to 6 months (WHO 1997).
Several studies have been conducted since these recommendations
were made over a decade ago, and this review aims to provide an
up-to-date assessment of the best available evidence for VAS, in-
cluding subgroup analyses to identify populations most likely to
benefit and the most effective doses. Gogia 2008a did not include
several known studies of VAS, so there is a need for a systematic re-
view with a highly sensitive search strategy. The therapeutic role of
vitamin A has been evaluated for measles and non-measles pneu-
monia in two separate Cochrane reviews (Ni 2005; Yang 2009).
The prophylactic role of vitamin A has also been or is being eval-
uated in different Cochrane reviews in different subpopulations
of children and mothers (van den Broek 2002; Wiysonge 2005;
Oliveira 2006; Darlow 2007; Chen 2008; Gogia 2008; Haider
2008; Bello 2009). However, no Cochrane review has addressed
prophylactic VAS in children from 6 months to 5 years of age.
Given some of the recent controversies raised on the efficacy/ef-
fectiveness of VAS in developing countries (Latham 2010), it is
important to review the cumulative evidence to date on the impact
on health outcomes of VAS in children aged 6 months to 5 years.
O B J E C T I V E S
To evaluate the effect of vitamin A supplementation (VAS) in
children from 6 months to 5 years of age with respect to the
prevention of mortality and morbidity.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) and cluster
RCTs evaluating the effect of synthetic VAS in children aged 6
months to 5 years. We included data from the first period only
of cross-over studies. We considered studies for inclusion irrespec-
tive of publication status or language of publication. We excluded
quasi-experimental studies, such as before-after designs and obser-
vational studies.
Post hoc, we included two studies in which participants were as-
signed using a quasi-random method (Herrera 1992; Stansfield
1993). In both cases, the authors and the editorial team agreed
that the methods of assignment (i) had the desirable characteris-
tics of randomisation and (ii) were of no greater risk of bias than
other included studies. For example, Stansfield 1993 used a ran-
dom starting point and alternately assigned red or green pills. Par-
ticipants received a single mega-dose of Vitamin A, so the people
delivering the pills had no ongoing contact with participants; both
selection bias and recruitment bias seem very unlikely.
Though the authors had access to the results of these studies, the
decision to include themwas made before data were extracted and
before any analyses were undertaken. The search was comprehen-
sive and we are not aware of any other studies similar to these two
studies that could have been included in the review.
Types of participants
Children living in the community and aged 6 months to 5 years
at the time of recruitment were eligible. Children in hospital and
children with disease or infection were excluded.
We contacted trial authors if the study population included some
participants who were not eligible for this review (for example,
children over 5 years) and requested disaggregated data. If such
data were not available, we included studies if the majority of
participants (51%) met the inclusion criteria. If this could not
be determined and the participants met the inclusion criteria on
average (for example, the mean age was in the eligible range), then
we included these trials.
Types of interventions
Synthetic oral VAS was compared to either placebo or treatment-
as-usual control groups, including trials of various doses and fre-
quencies. Co-interventions (for example,multiple vitamin ormin-
eral supplementation), must have been identical in both groups.
We excluded studies evaluating the effects of (i) food fortification,
(ii) consumption of vitamin A rich foods and (iii) beta-carotene
supplementation.
If a trial included more than one eligible intervention group (for
example, different doses), we combined the groups for the main
analysis, although the groups were treated separately for subgroup
analyses where appropriate. If a trial included multiple control
groups (for example, both placebo and treatment-as-usual), we
selected the control group that most closely replicated the non-
specific treatment of the intervention group (that is, placebo).
Types of outcome measures
The following outcomes were extracted. In studies reporting
more than one measure of an outcome, measures were combined
for meta-analysis using the methods described below (see Data
synthesis).
10Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Primary outcomes
All-cause mortality
Secondary outcomes
Cause-specific mortality due to:
• diarrhoea;
• measles;
• meningitis;
• lower respiratory tract infection (LRTI).
Cause-specific morbidity (i.e. incidence and prevalence):
• diarrhoea;
• measles;
• malaria;
• meningitis;
• lower respiratory tract infection (LRTI);
• Bitot’s spots;
• night blindness;
• xerophthalmia.
Side effects (for example, vomiting or diarrhoea following supple-
mentation).
Vitamin A deficiency status (serum retinol).
Search methods for identification of studies
Electronic searches
We searched CENTRAL (The Cochrane Library 2010, Issue 2),
MEDLINE (1950 to April Week 2 2010), EMBASE (1980 to
2010 Week 16), Global Health (1973 to March 2010), Latin
American Database (LILACS), metaRegister of Controlled Trials
and African Index Medicus. All the searches were conducted on
27 April 2010.
The search strategies for each database are included in Appendix
1. Where possible, searches were limited to clinical trials involving
human subjects, andwere conductedwithout language restriction.
Searching other resources
To identify ongoing and unpublished trials, we used the World
Health Organization International Clinical Trials Registry (IC-
TRP), which searches multiple trial registries. Reference lists of
reviews, included studies and excluded studies were searched for
additional citations. We contacted organisations and researchers.
Data collection and analysis
Selection of studies
Two authors independently screened titles and abstracts for inclu-
sion in the review (AI and KH).We resolved differences of opinion
about suitability for inclusion by discussion and through consul-
tation with a third author (EMW). Studies that met the screening
criteria but did not meet the full inclusion criteria are listed in
the Characteristics of excluded studies table with the reasons for
exclusion.
Data extraction and management
We used a data extraction sheet to extract the following informa-
tion from each study:
• year
• location (country, urban/rural);
• method of recruitment;
• inclusion criteria;
• unit of analysis; and
• risk of bias (see below).
Participants:
• socio-demographics (age, sex); and
• co-morbidities.
For each intervention and comparison group of interest:
• dosage;
• duration;
• frequency;
• co-intervention (if any).
For each outcome of interest:
• time points (i) collected and (ii) reported;
• definition;
• validity;
• unit of measurement (if relevant); and
• loss to follow-up.
Data from each eligible study were extracted independently by
two people using Distiller software. Extraction was also done by
a team at the Cochrane Editorial Unit (Toby Lasserson, Rachel
Murphy andKarla Soares-Weiser), but therewas always at least one
extractor who was an author (AI, KH, YY, EMW). Discrepancies
were resolved through discussion among the authors.
Themain analyses included the longest reported follow-up in each
study. Outcomes were also grouped by time (0 to 12 months; 13
to 60 months, and greater than 60 months since randomisation);
when trials reportedmultiple time points for a period, we extracted
the longest outcome interval in a given period.
Assessment of risk of bias in included studies
Two authors independently assessed the risk of bias associated with
each included study using the Risk of Bias tool (Higgins 2008). For
all studies, the following were assessed: sequence generation; allo-
cation concealment; blinding of participants, providers and out-
come assessors; incomplete outcome data; and selective outcome
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reporting.We specifically looked for the possibility of performance
bias (differential treatment of the intervention and control groups)
and detection bias (for example, differential effort to locate death
records for the intervention and control groups). Findings are dis-
cussed below and included in the Risk of Bias tables.
Measures of treatment effect
Morbidity was measured in different ways, and we combined all
available data whenever possible. For example, for diarrhoea we
included all types of diarrhoea (mild, moderate and severe). In the
case of pneumonia, we included lower respiratory tract infection
(but not upper).
To avoid reviewer bias, we predetermined the order of preference
for extracting outcomes when data were available in several for-
mats. For studies that randomised individuals, we gave preference
to data that required the least manipulation by authors or infer-
ence by reviewers. We extracted raw values (for example, means
and standard deviations) rather than calculated effect sizes (for ex-
ample, Cohen’s d). For mortality data, we gave preference to de-
nominators in the following order: number with definite outcome
known (or imputed as described below), number randomised, and
child-years. For other dichotomous outcomes to which both sur-
vivors and non-survivors may contribute data (for example, inci-
dence of measles), we gave preference to child-years, number with
definite outcome known, and number randomised.
In the case of cluster RCTs, we (i) used adjusted estimates reported
by the authors or (ii) used raw data and inflated the standard error
(SE) using procedures described below.
Unit of analysis issues
In studies randomising units other than the individual (i.e. clus-
ters), results should be presented with controls for clustering (for
example, robust SEs or hierarchical linear models). We analysed
clustered data using procedures outlined in Higgins 2008.
Where results did not control for clustering, we contacted authors
to request an estimate of the intra-cluster correlation coefficient
(ICC). If the authors were unable to provide an ICC, we used
design effects calculated previously (Beaton 1993) to calculate the
ICC, and we estimated the ICC for studies that did not publish a
value (see below). For estimated values, we conducted sensitivity
analyses using larger and smaller design effects to determine if the
results were robust.
Dealing with missing data
Differential dropout can lead to biased estimates of effect size, and
bias may arise if reasons for dropout differ across groups.
Missing data are described, including dropouts and reasons for
dropout where given. If data were missing for some cases, or if
reasons for dropout were not reported, we contacted the authors.
When analyses were reported for completers as well as controlling
for dropout (for example, imputed using regression methods), we
extracted the latter.
Assessment of heterogeneity
Included studies were assessed for clinical heterogeneity by com-
paring the distribution of important factors, such as study partic-
ipants, study setting, dose and duration of intervention and co-
interventions. Methodological heterogeneity was assessed by com-
paring data included in the Risk of Bias tables. Statistical hetero-
geneity was assessed by visual inspection of forest plots, by per-
forming the Chi2 test (assessing the P value) and by calculating
the I2 statistic. If the P value was less than 0.10 and I2 exceeded
50%, we considered heterogeneity to be substantial.
Assessment of reporting biases
To assess the possibility of small study bias, funnel plots were
drawn for outcomes with 10 or more studies and random effects
estimates were compared to the fixed effect estimate (see below).
Data synthesis
We performedmeta-analysis using ReviewManager Software Ver-
sion 5 (RevMan 2008). When data were extracted in several for-
mats that could not be combined directly in RevMan, we used
the generic inverse variance option; data were entered into Com-
prehensive Meta-Analysis Version 2 and the log RR and SE were
entered into RevMan.
All outcomes are reported with 95% confidence intervals (CI),
and overall effects are weighted by the inverse of variance using a
fixed-effect model; although there may be some differences across
trials (for example, dose and population), the biological mecha-
nism should be similar across trials and we will explore differences
through analyses described elsewhere.
For dichotomous outcomes, we calculated the overall Risk Ratio
(RR). For incidence data, Risk Ratio (events per child) and Rate
Ratio (events per child-year) were combined because these ratios
use the same scale and can be interpreted in the same way for these
studies (the duration of studies was short, there was no interaction
between the intervention and time at risk). In some cases, we
estimated time at risk, as when authors reported incidence rate,
duration of the study and number of children in the group.
For continuous outcomes we calculated Hedges g.
Subgroup analysis and investigation of heterogeneity
Effectiveness may differ across members of populations (for ex-
ample, due to differences in baseline vitamin A status) and may
be affected by other interventions (for example, immunisation or
deficiency of other micronutrients). For example, neonatal VAS
is thought to have different effects in Asia versus Africa (Klemm
2009). Unlike trial-level factors (such as dose), associations be-
tween individual-level moderators (such as vitamin A status) and
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outcomes should be analysed using individual patient data from
RCTs and observational studies. With two exceptions, we did not
include subgroup analyses based on individual-level moderators in
this review, as such analyses are at high risk of the ecological fallacy
(for example, lack of variation between studies would not indicate
there was no variation within them). We included subgroups of
age and gender; trials commonly report separate effects for these
groups.
The following subgroup analyseswere prespecified, anddifferences
were tested using the Chi2 test in RevMan:
1. Dose: Standard (up to 100,000 IU for children 6 to 11
months of age, and 200,000 IU for children 12 months to 5
years of age) versus High (greater than standard).
2. Frequency: High (doses within 6 months) versus Low (1
dose or 6+ month interval).
3. Location: Continent.
4. Age: 6 to 12 months versus 1 to 5 years.
5. Sex: males versus females.
Sensitivity analysis
Sensitivity analyses were performed as follows:
1) To test for bias, the primary analysis was repeated without
studies at high risk of bias for sequence generation. To test for
small study bias, the analysis was repeated using a random-effects
model and funnel plots were drawn for all outcomes with 10 or
more studies.
2) Imputed ICC (a post-hoc analysis described below).
3) Studies awaiting assessment (a post-hoc analysis described be-
low).
R E S U L T S
Description of studies
Results of the search
Electronic searches identified 6683 citations; 4600 citations re-
mained after duplicates were removed.
Additionally, we reviewed 129 studies from reference lists. There
were 371 relevant citations, and all full texts were reviewed, see
Figure 1.
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Figure 1. Flow diagram for selection of studies
Included studies
Forty-three trials reported in 90 papers met the inclusion criteria,
including factorial studies that were treated as two trials for meta-
analysis (described below). More than one report was available for
16 (37%) trials. Where multiple reports existed for an included
trial, we extracted data from all reports. Further information about
individual studies is included in the Characteristics of included
studies tables.
Thirty-nine trials (91%) reported data that could be included in
a meta-analysis; four trials reported either outcomes that were
not relevant to the review (Cherian 2003), or data that were not
available by group (Lima 2010) or were incomplete (van Agtmaal
1988; Smith 1999).
Sample size
Trials assigned approximately 215,633 participants, with sample
sizes ranging between 35 (van Agtmaal 1988) and approximately
29,236 (Sommer 1986), and a median sample size of 480. The 39
trials that could be analysed included 215,043 participants (99.7%
of children included in the review).
The ten largest studies randomised about 200,214 children, 93%
of participants in the review (Sommer 1986; Rahmathullah 1990;
Vijayaraghavan 1990; West 1991; Daulaire 1992; Herrera 1992;
Ross 1993 SURVIVAL; Stansfield 1993; Agarwal 1995; Pant
1996).
Comparisons
Six (14%) studies compared VAS to treatment-as-usual; 37 (86%)
compared VAS to placebo. One large trial reported they did not
use a placebo because it was forbidden by government (Sommer
1986).
Multiple trial arms
Twelve trials (28%) had multiple arms, 7 of which were relevant
to the review (Reddy 1986; Florentino 1990; Benn 1997; Smith
1999; Rahman 2001; Long 2006; Lin 2009).
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Four trials used factorial designs, combining vitamin A with other
treatments such as zinc (Smith 1999; Rahman 2001; Long 2006)
or deworming (Reddy 1986); data were extracted for comparisons
that differed only in the provision of vitamin A (for example,
vitamin A versus placebo; and vitamin A plus zinc versus zinc
only). In one trial (Rahman 2001), rawdatawere not available and
we could not identify outcome data for an eligible comparison.
Different doses were combined in one study (Florentino 1990).
Unit of randomisation
Two studies (Herrera 1992; Stansfield 1993) randomised by house-
hold and we treated participants as if they were individually ran-
domised. A sensitivity analysis was conducted for all-cause mor-
tality, using ICCs of 0 and 0.01 for those studies in which the
mean design effect was estimated.
Previously reported design effects from Beaton 1993 were used to
calculate ICCs for clustered studies (Sommer 1986; Rahmathullah
1990; Vijayaraghavan 1990; West 1991; Daulaire 1992; Ross
1993 SURVIVAL). The ICCs were consistent around a value of
0.002. We imputed an ICC value of 0.002 for all studies in which
clustering was not accounted for in the original analysis.
Allocation ratio
Participants were evenly allocated to the intervention and control
groups in 35 studies (81%) and the number assigned to each group
was unclear in 8 trials (19%) (Reddy 1986; Ross 1993 HEALTH;
Ross 1993 SURVIVAL; Stansfield 1993; Biswas 1994; Dibley
1994; Ramakrishnan 1995; Pant 1996).
Location/setting
Trials were conducted in 19 countries: 27 (63%) in Asia, 15 of
these in India; 7 (16%) in Africa; 7 (16%) in Latin America, and
2 (5%) in Australia. Sixteen (37%) of the studies were conducted
in urban/peri-urban settings and 24 (56%) in rural settings, while
three studies did not explicitly described their urban/rural setting.
Age
Average age was reported in 19 trials (44%). The median of the
mean ages was 30.5 months.
Sex
Sex was reported in 32 trials (72%). The majority assigned ap-
proximately equal numbers of males and females. Three studies
(Semba 1992; Ranjini 2001; Lin 2008) favoured males by more
than 10%. The median study included 51% males.
Time
Outcomes measured at different times (0 to 12 months, 13 to 60
months, and 60 or more months) were collapsed for one over-
all analysis. Most studies lasted about a year, and dividing stud-
ies of similar length created potentially confusing/misleading sub-
groups. In the event that a single study reported data in more than
one time point interval, the data from the longest interval was
used in the overall analysis.
Excluded studies
After reviewing articles, 328 papers were excluded; eight nearly
met the inclusion criteria, and reasons for exclusion are provided
in Characteristics of excluded studies.
Studies awaiting assessment
Two trials could not be assessed at this time.
One trial (Aklamati 2006) was reported in a conference abstract.
It appeared to meet the inclusion criteria, but reported impossible
results. For example, the study included 36 children and reported
an outcome of 1.2% of 17; though 1 child out of 17 is nearly 6%.
We have contacted the authors for clarification and the study may
be included in future versions of this review.
Importantly, one completed trial appears likely to meet the eli-
gibility criteria and may be included in further updates of this
review (DEVTA trial 2007). DEVTA is the largest randomised
controlled trial ever conducted, including approximately one mil-
lion children. That is, the trial included four times the combined
participants of all included studies in this review. We contacted
the authors of this trial several times prior to the completion of
this review for information required to evaluate the conduct of
the study and its outcomes. They provided an early analysis of
the primary outcome, mortality, as well as cause-specific mortality
and vitamin A serum level.
To assess how the results of DEVTAmight impact the conclusions
of this review, a sensitivity analysis was conducted. Due to lack of
additional information, reasons for differences between this trial
and other trials in the review could not be assessed.
Risk of bias in included studies
The risk of bias in each of the five domains was assessed for each
study as High, Low or Unclear, see Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation
All included studies were randomised or quasi-randomised con-
trolled trials: 19 (44%) specified themethod of randomisation and
16 (37%) were at Low risk of bias for sequence generation.
Three trials (7%) were at High risk of bias for sequence genera-
tion (Herrera 1992; Stansfield 1993; Arya 2000). These included
41,139 participants (19% of those included in the review).
One described assignment as random, but participants may have
been assigned in order of arrival at hospital (Arya 2000).
Though technically quasi-random, we included two trials post hoc
(Herrera 1992; Stansfield 1993) because the generation of the al-
location sequence was not likely to result in systematically differ-
ent groups. Given the design of the interventions and the placebos
and steps to blind those administering the sequence, the reviewers
do not think these studies are meaningfully different from ran-
domised trials. In the first, participants were assigned alternately
by household (Herrera 1992). The second used a random starting
point and alternating distribution of red or green pills (Stansfield
1993). Lack of a truly random sequence was not related to other
sources of bias (for example, performance bias) as individuals de-
livering the capsules had no ongoing contact with participants
and the manufacturer (Roche) held the code until the study was
completed. Though post-hoc, the decision to include these studies
was made before data were extracted and before any analyses had
been conducted; a sensitivity analysis was conducted (below) to
determine if the decision had any impact on the results and it did
not.
Allocation concealment
Allocation concealment is adequate when (i) trial staff and po-
tential participants are unaware of assignments at the time of re-
cruitment into the trial and (ii) the generation of the allocation
sequence is protected from the influence of anyone aware of the
participants’ characteristics. Allocation concealment was coded as
High risk of bias for only one study (Daulaire 1992) and Unclear
for 27 studies (63%). In most studies it was impossible to assess al-
location concealment. Efforts to blind participants and providers
suggest the overall risk of bias is minimal, and any impact on the
primary outcome (all-cause mortality) is likely to be small.
Blinding
The interventionwas conducive to blinding. Though there is some
evidence that very large doses of vitamin A can lead to short-term
side effects, participants andproviderswouldnot normally become
aware of assignment after delivery of vitamin A in the form of
pills, capsules or liquid solution. Efforts to blind participants and
providers were described in 29 of the studies (67%), which were
at Low risk of bias. In some trials, staff delivering the intervention
also conducted assessments. Blinding of assessors was at High risk
of bias in two studies (Daulaire 1992; Lin 2009) and Unclear
in 14 (Reddy 1986; Sommer 1986; van Agtmaal 1988; Semba
1992; Agarwal 1995; Kartasasmita 1995; Stabell 1995; Pant 1996;
Donnen 1998; Smith 1999; Ranjini 2001; Chowdhury 2002;
Cherian 2003; Lin 2008).
In some trials, children interacted with researchers or clinicians
who were aware of their assignment. Two studies (5%) were at
High risk of performance bias, mostly because of failure to ad-
equately blind staff, whereas 28 (65%) were at Low risk of per-
formance bias. The reviewers considered bias due to inadequate
blinding to be low and, if anything, likely to underestimate effects;
for example, a teacher would be more likely to give extra food to
a child receiving placebo rather than the reverse.
The review authors consider the primary outcome, mortality, is
very unlikely to have been influenced by lack of blinding.
Incomplete outcome data
For incomplete outcome data, 23 trials (53%) were at Low risk
of bias; 8 (17%) were at High risk of bias (van Agtmaal 1988;
Kartasasmita 1995; Semba 1995; Pant 1996; Bahl 1999; Arya
2000; Chowdhury 2002; Cherian 2003) and 12 (28%) were Un-
clear (Sinha 1976; Reddy 1986; Sommer 1986; Vijayaraghavan
1990; West 1991; Ross 1993 HEALTH; Ross 1993 SURVIVAL;
Agarwal 1995; Stabell 1995; Venkatarao 1996; Smith 1999;
Ranjini 2001).
Missing data are much more likely to influence secondary anal-
yses than the primary outcome. Results for all-cause mortality
are known for 91% of randomised participants. Of the 17 stud-
ies (40%) that reported this outcome, 7 were Unclear, but 4 of
these had minimal attrition (Vijayaraghavan 1990; Ross 1993
HEALTH;Ross 1993 SURVIVAL;Venkatarao 1996) and the oth-
ers failed to report reasons for dropout. In 2 studies, missing data
were not adequately handled (Pant 1996; Chowdhury 2002), but
together these studies contributed only 5% to the pooled estimate.
Selective reporting
Most of the trials in the review included multiple outcome mea-
sures, and positive results are more likely to be included in reports
than negative results. Only 5 (12%) trials appeared to be free of se-
lective outcome reporting (Florentino 1990; Rahmathullah 1990;
West 1991; Dibley 1994; Benn 1997). Twenty four (56%) were
Unclear, while 14 (33%) were at High risk of bias (Pinnock 1988;
van Agtmaal 1988; Vijayaraghavan 1990; Ross 1993 HEALTH;
17Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ross 1993 SURVIVAL; Stansfield 1993; Ramakrishnan 1995;
Pant 1996; Bahl 1999; Arya 2000; Cherian 2003; Lin 2008; Lin
2009; Lima 2010).
For the primary outcome, there is no meaningful risk of bias;
the outcome was reported for large trials. Data were missing in
small studies of short duration, which likely observed few deaths.
For many of the secondary analyses, which included only a few
trials representing a small proportion of the overall sample, adding
unreported data might influence the observed effects.
Other potential sources of bias
Other potential sources of bias were extracted and are noted in the
Characteristics of included studies tables, but none were likely to
meaningfully influence the results of the review.
Effects of interventions
See: Summary of findings for the main comparison
Results for each outcome are presented below, the most important
of which are described in Summary of findings for the main
comparison.
Because most analyses contained a small number of studies, sen-
sitivity analyses were restricted to the primary outcome.
Pneumonia and lower respiratory tract infection (LRTI) outcomes
were combined post hoc. Pneumonia is a type of LRTI, and most
of the studies did not test for pneumonia specifically (with a spe-
cific clinical criteria). In the event a study reported both pneumo-
nia and LRTI outcomes, the LRTI outcome data were extracted
for combination with other studies.
Not all subgroup analyses were conducted. For the primary out-
come, only one study used a non-standard dose and this study
also used a different frequency. Other analyses with more than
10 studies contained significantly fewer participants (for example,
the analysis of serum level included less than 7000) and subgroup
analyses for dose and frequency were not conducted because the
analyses were clearly underpowered and any effects would be at-
tributable to chance. Results of some of the attempted subgroup
analyses are listed in Table 1.
1.0 All-cause mortality
Seventeen trials (Sommer
1986; Rahmathullah 1990; Vijayaraghavan 1990; West 1991;
Daulaire 1992; Herrera 1992; Ross 1993 HEALTH; Ross 1993
SURVIVAL; Barreto 1994; Dibley 1994; Agarwal 1995; Pant
1996; Venkatarao 1996; Benn 1997; Donnen 1998; Chowdhury
2002; Lin 2008) contributed 194,795 children (90% of the chil-
dren included in the review) in an overall analysis (using data from
the last follow up for trials measuring outcomes multiple times).
One reported no events (Lin 2008).
Vitamin A was associated with a 24% reduction in all-cause mor-
tality (RR = 0.76 (95% CI 0.69 to 0.83)), though there was mod-
erate heterogeneity (Chi² = 29.10, df = 15 (P = 0.02); I² = 48%)
Figure 3.
Figure 3. Forest plot of comparison: 1 Vitamin A versus Control, outcome: 1.1 Mortality (all-cause) at
Longest Follow-up.
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The effect during the first year of life was similar (RR = 0.82 (95%
CI 0.74 to 0.91)), but the statistical heterogeneity was substantial
(Chi² = 33.85, df = 11 (P = 0.0004); I² = 67%). Only 5 trials (7%)
measured mortality between 13 and 60 months, and the effect was
similar (RR = 0.75 (95% CI 0.64 to 0.88)) with moderate and
significant statistical heterogeneity (Chi² = 9.29, df = 4 (P = 0.05);
I² = 57%).
Subgroup analyses
1. Dose and frequency
Only one study reporting all-cause mortality did not use the stan-
dard dose recommended by WHO. Rahmathullah 1990 used
weekly dose for 52 weeks. The planned subgroup analysis was not
conducted.
2. Location
Eleven trials were conducted in Asia (RR = 0.69 (95% CI 0.61
to 0.79)), 5 in Africa (RR = 0.85 (0.73 to 0.98)), and 1 in Latin
America (RR = 1.00 (0.14 to 7.08)). These were not significantly
different (P = 0.12, see Table 1).
3. Age
Four trials (Rahmathullah 1990;West 1991; Daulaire 1992; Benn
1997) reported separate effects for children aged 6 to 12 months
(RR = 0.59 (95% CI 0.43 to 0.82)) and children aged 1 to 5
years (RR = 0.68 (0.57 to 0.81)); the subgroups did not differ
significantly (P = 0.46). Notably, both effect estimates are larger
than the overall result from 17 trials reporting mortality.
4. Sex
Five trials (Sommer 1986; West 1991; Daulaire 1992; Herrera
1992; Lin 2008) reported separate effects for males (RR = 0.80
(95% CI 0.66 to 0.97)) and females (RR = 0.79 95% CI 0.65 to
0.95)), which were not significantly different (P = 0.89). Notably,
both effect estimates are larger than the overall result from 17 trials
reporting mortality.
Sensitivity analyses
1. Bias
Of the trials at High risk of bias due to sequence generation,
only Herrera 1992 contributed to the main mortality analysis and
reported no effect (RR = 1.06 (95% CI 0.82 to 1.37)), indicating
that these trials were not likely to influence the results in a positive
direction.
To test for small study bias, we repeated the analysis using a ran-
dom-effects model. The overall estimate was slightly larger than
the fixed-effect estimate, suggesting that heterogeneity is partially
explained by small studies reporting larger effects (RR = 0.71 (0.61
to 0.84)).
There was some evidence of visual asymmetry on the funnel plot
we produced, but the overall effect was strongly influenced by five
studies that accounted for over 80% of the weighted mean; even
if the result was influenced by small study bias, the magnitude of
the effect was small. To impact the results, missing studies would
need to be very large and show no difference or harmful effects,
as demonstrated in the third sensitivity analysis.
2. Design effects in cluster trials
Known ICCs were remarkably consistent. For three studies for
which the ICC was not known, we estimated ICC = 0.002 and we
adjusted SEs using this value and the average cluster size. To de-
termine if this decision had any impact on the results, we repeated
the primary analysis using a much larger and much smaller ICC
estimate. The size of the effect was slightly smaller when these tri-
als were treated as if they had randomised individuals (RR = 0.81
(95% 0.75 to 0.89)). The effect was virtually unchanged when we
increased the ICC to 0.01 (RR = 0.75 (95% CI 0.68 to 0.83)),
see Table 1. These results indicate that over-weighting these three
studies in the analysis would not impact the conclusions of this
review; further inflating their SEs would increase the size of the
effect estimate.
3. Studies awaiting assessment
One study awaiting assessment was added to the analysis (DEVTA
2007). This trial found no significant effect of VAS on mortality
(RR = 0.96 (95% CI 0.89 to 1.03)).
In our analysis of 18 trials, DEVTA 2007 accounted for 65.2% of
the combined effect, which remained significant (RR = 0.88 (95%
CI 0.84 to 0.94)) with substantial and significant heterogeneity
(Chi² = 44.31, df = 16 (P = 0.0002); I² = 64%). (We assumed
the study authors adjusted for clustering. As the results were not
significant, inflating the SE would not change our interpretation
of the trial’s results, although it would decrease its weight in the
analysis.)
Including DEVTA 2007 decreased the estimated benefit of Vita-
min A by half (24% to 12%), but the result remained significant
and clinically meaningful. As we were unable to assess the trial, we
cannot explain this substantially different result.
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2.0 Diarrhoea mortality
Seven trials (Rahmathullah 1990; Daulaire 1992; Herrera
1992; Ross 1993 SURVIVAL; Agarwal 1995; Venkatarao 1996;
Chowdhury 2002) reported a combined 28% reduction in diar-
rhoea mortality (RR = 0.72 (95% CI 0.57 to 0.91)) with no im-
portant heterogeneity (Chi² = 6.12, df = 6 (P = 0.41); I² = 2%),
Figure 4.
Figure 4. Forest plot of comparison: 1 Vitamin A versus Control, outcome: 1.5 Mortality due to Diarrhoea
at Longest Follow-up.
3.0 Measles mortality
Five trials (Rahmathullah 1990; Daulaire 1992; Herrera 1992;
Ross 1993 SURVIVAL; Agarwal 1995) reported a lower risk of
measles mortality, but the effect was not statistically significant
(RR = 0.80 (95% CI 0.51 to 1.24)). There was no important
heterogeneity (Chi² = 0.40, df = 4 (P = 0.98); I² = 0%), Figure 5.
Figure 5. Forest plot of comparison: 1 Vitamin A versus Control, outcome: 1.6 Mortality due to Measles at
Longest Follow-up.
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4.0 Meningitis mortality
Three trials (Ross 1993 SURVIVAL; Agarwal 1995; Chowdhury
2002) reported a lower risk of meningitis mortality, but the effect
was not statistically significant (RR = 0.57 (95%CI 0.17 to 1.88)).
There was no important heterogeneity (Chi² = 0.75, df = 2 (P =
0.69); I² = 0%).
5.0 Lower Respiratory Tract Infection (LRTI)
mortality
Seven trials (Rahmathullah 1990; Daulaire 1992; Herrera
1992; Ross 1993 SURVIVAL; Agarwal 1995; Venkatarao 1996;
Chowdhury 2002) reported a lower risk of LRTI mortality, but
the effect was not statistically significant (RR = 0.78 (95%CI 0.54
to 1.14)). There was no important heterogeneity (Chi² = 7, df =
6 (P = 0.32); I² = 14%).
6.0 Diarrhoea
Thirteen trials (Florentino 1990; Herrera 1992; Cheng 1993;
Barreto 1994; Biswas 1994; Dibley 1994; Ramakrishnan 1995;
Venkatarao 1996; Sempertegui 1999; Shankar 1999; Arya 2000;
Chowdhury 2002; Long 2007) reported an 18% decrease in diar-
rhoea incidence (RR = 0.85 (95% CI 0.82 to 0.87)), though sta-
tistical heterogeneity was substantial and highly significant (Chi²
= 218.62, df = 11 (P < 0.00001); I² = 95%), Figure 6.
Figure 6. Forest plot of comparison: 1 Vitamin A versus Control, outcome: 1.9 Diarrhoea Incidence at
Longest Follow-up.
The results of this analysis were highly heterogenous and two stud-
ies account for the majority of the overall effect (Cheng 1993;
Chowdhury 2002). The observed heterogeneity may be due to
measurement error or differences in the effects of VAS across pop-
ulations and settings. For example, it may reduce susceptibility
to particular infections that are prevalent in some places but not
others.
Two trials (Stansfield 1993 and Long 2006/Long 2006 (2)) re-
ported no combined effect on diarrhoea prevalence (RR = 1.08
(95% CI 1.05 to 1.12)) though statistical heterogeneity was sub-
stantial and highly significant (Chi² = 15.76, df = 2 (P = 0.0004);
I² = 87%).
Sensitivity analysis
1. Bias
To test for small study bias, we repeated the analysis using a ran-
dom-effects model. The overall estimate was identical to the fixed-
effect estimate, though the result bordered on statistical signifi-
cance, suggesting that heterogeneity is not explained by small stud-
ies reporting larger effects (RR = 0.85 (95% CI 0.72 to 1.00)).
The funnel plot we produced was dominated by two studies ac-
counting for 74% of the overall effect, and the plot was relatively
flat.
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2. Design effects in cluster trials
No ICCs were imputed, so sensitivity analysis was not required.
7.0 Measles
Six trials (Herrera 1992; Barreto 1994; Semba 1995; Benn 1997;
Bahl 1999; Chowdhury 2002) reported a 50% decrease in measles
incidence (RR = 0.50 (95% CI 0.37 to 0.67)) with no important
heterogeneity (Chi² = 0.55, df = 5 (P = 0.99); I² = 0%), Figure 7.
Figure 7. Forest plot of comparison: 1 Vitamin A versus Control, outcome: 1.12 Measles Incidence at
Longest Follow-up.
No trials reported data on measles prevalence that could be anal-
ysed at follow-up.
8.0 Malaria
One trial (Shankar 1999) reported a 27% reduction in malaria
incidence (RR = 0.73 (95% CI 0.60 to 0.88)).
Two trials (Ross 1993HEALTH;Ross 1993 SURVIVAL) reported
data on malaria prevalence; the combined effect was not statis-
tically significant (RR = 0.72 (0.42 to 1.23)) and there was no
important heterogeneity (Chi² = 0.03, df = 1 (P = 0.87); I² = 0%).
Only one study reported data on malaria prevalence that could be
analysed at follow- up, the results of which were not significant
(RR = 0.73 (0.41 to 1.28)).
9.0 Meningitis
No trials reported data on meningitis incidence or prevalence that
could be analysed at follow-up.
10.0 Lower Respitatory Tract Infection
Nine trials (Rahmathullah 1990; Cheng 1993; Barreto 1994;
Biswas 1994; Kartasasmita 1995; Venkatarao 1996; Sempertegui
1999; Chowdhury 2002; Long 2007) reported no combined effect
on LRTI incidence (RR = 1.14 (0.95 to 1.37)) with no important
heterogeneity (Chi² = 7.66, df = 6 (P = 0.26); I² = 22%). LRT
prevalence was reported in a factorial trial (Long 2006) with two
relevant comparisons; the combined result of which was inconclu-
sive but suggests benefit (RR = 0.46 (95% CI 0.21 to 1.03)).
11.0 Vision
11.1 Bitot’s spots
One trial (Herrera 1992) reported no effect on Bitot’s spots inci-
dence (RR = 0.93 (95% CI 0.76 to 1.14)).
Four trials (Sinha 1976; Sommer 1986; West 1991; Pant 1996)
reported a 53% reduction in Bitot’s spots prevalence (RR = 0.45
(95% CI 0.33 to 0.61)) with substantial and significant hetero-
geneity (Chi² = 8.25, df = 3 (P = 0.04); I² = 64%).
11.2 Night blindness
One trial (Herrera 1992) reported a 47% reduction in night blind-
ness incidence (RR = 0.53 (95% CI 0.28 to 0.99)).
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Two trials (Sommer 1986; West 1991) reported a 68% reduction
night blindness prevalence (RR = 0.32 (95% CI 0.21 to 0.50))
with no heterogeneity (Chi² = 0.19, df = 1 (P = 0.66); I² = 0%).
11.3 Xerophthalmia
Three trials (West 1991; Herrera 1992; Barreto 1994) reported
no combined effect on xerophthalmia incidence (RR = 0.85 (95%
CI 0.70 to 1.03)), though statistical heterogeneity was substantial
and significant (Chi² = 2.69, df = 1 (P = 0.10); I² = 63%).
Two trials (Sommer 1986; West 1991) reported a 69% reduction
in xerophthalmia prevalence (RR = 0.31 (95% CI 0.22 to 0.45))
with no statistical heterogeneity (Chi² = 0.22, df = 1 (P = 0.64);
I² = 0%).
12.0 Vitamin A deficiency
12.1 Number deficient
Four trials (Ross 1993 HEALTH; Dibley 1994; Shankar 1999;
Ranjini 2001) reported a 29% reduction in the number of VAD
children (RR = 0.71 (95% CI 0.65 to 0.78)); however, statistical
heterogeneity was substantial and significant (Chi² = 13.58, df =
3 (P = 0.004); I² = 78%).
12.2 Serum level
Thirteen studies (Pinnock 1986; Reddy 1986; Pinnock 1988;
Semba 1992; Cheng 1993; Ross 1993 HEALTH; Ross 1993
SURVIVAL;Dibley 1994; Kartasasmita 1995; Sempertegui 1999;
Shankar 1999; Ranjini 2001; Lin 2009) reported vitamin A serum
data at follow- up, including one factorial study contributing two
comparisons. Vitamin A serum levels were higher in the Vitamin
A group (SMD = 0.31 (95% CI 0.26 to 0.36)), however statistical
heterogeneity was substantial and significant (Chi² = 270.23, df =
13 (P < 0.00001); I² = 95%).
Sensitivity analysis
1. Bias
No studies in this outcome were at high risk of bias for sequence
generation.
To test for small study bias, we repeated the analysis using a ran-
dom-effects model. The overall estimate was considerably larger
than the fixed-effect estimate, suggesting small studies report larger
effects (RR = 0.53 (95% CI 0.27 to 0.79)).
The funnel plot that we produced was highly asymmetrical.
2. Design effects in cluster trials
No ICCs were imputed, so sensitivity analysis was not required.
13.0 Hospitalisation
One trial (Ross 1993 HEALTH) reported a reduction of the like-
lihood of hospitalisations that approached statistical significance
(RR = 0.64 (95% CI 0.40 to 1.02)) and a 38% reduction in the
number of hospitalisations (RR = 0.62 (95% CI 0.42 to 0.93)).
One trial (Cheng 1993) reported inconclusive evidence on diar-
rhoea related hospitalisation (RR = 0.25 (95% CI 0.01 to 6.11)).
One trial (Cheng 1993) reported inconclusive evidence on LRTI
hospitalisation (RR = 0.11 (95% CI 0.01 to 2.06)).
14.0 Side effects
We assessed two short-term side effects:
14.1 Vomiting (within 48 hours)
Three trials (Sinha 1976; Florentino 1990; Arya 2000) reported a
significant increase in risk of vomiting (RR= 2.75 (95%CI 1.81 to
4.19)) with statistical heterogeneity that was not important (Chi²
= 2.53, df = 2 (P = 0.28); I² = 21%). Immediately following the
intervention, the rate of vomiting increased from 2% to 6%.
14.2 Fontanelle
Three trials (Stabell 1995; Bahl 1999; Arya 2000) reported
fontanelle side effects, but only one could be analysed because the
others reported insufficient data, which reported no effect (RR =
5.00 (95% CI 0.24 to 103.72)). Most studies included children
over 1 year old and would not have assessed this side effect.
Results not contained in the Data and Analyses section are listed
below in Table 1.
D I S C U S S I O N
Summary of main results
VitaminA supplementation appeared to reduce all-causemortality
by 24%. There was some statistical heterogeneity in the pooled
data.
Much of the reduction in all-cause mortality is explained by re-
ductions in death due to diarrhoea and measles, although many of
the cause-specific mortality and morbidity outcomes were char-
acterised by uncertainty. The overall effect for measles mortality
was not significant, but the trend was consistent with the overall
results and the therapeutic effects of VAS in reducing measles re-
lated mortality and morbidity are well established (Yang 2009).
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Furthermore, VAS resulted in a reduced incidence of diarrhoea
and measles. Other reviews have shown that the therapeutic use of
VADmay prevent acute diarrhoea from becoming chronic (Imdad
2010). Together, these results suggest that reductions in diarrhoea
and measles are potential pathways in the reduction of all-cause
mortality.
In addition to reducing death and illness, VAS reduces night blind-
ness and potential precursors to blindness, namely Bitot’s spots
and xerophthalmia.
Some authors hypothesise that the preventive effect of VAS against
infections is related to increased responsiveness to vaccines given
around these times, especially in infants (Benn 2003). This has
been recently challenged (Kirkwood 2010) and a meta-regression
of studies does support the direction of overall effect (Rotondi
2010). Amore detailed discussion about this hypothesis is available
in the review on neonatal VAS by our group (Haider 2008).
The current review did not locate any trials that compare different
co-interventions; policy makers and practitioners should use other
types of studies to assess how the delivery and responsiveness to
vitamin A might relate to other nutritional and health interven-
tions.
Few studies reported data about side effects, including vomiting,
bulging fontanelle and diarrhoea soon after receiving the interven-
tion. VAS may increase short-term vomiting by 4%.
Overall completeness and applicability of
evidence
This is the first published review to assess systematically both mor-
tality and morbidity associated with VAS. Other outcomes rel-
evant to VAS, including stunting, could be added to future ver-
sions, but few studies have measured these effects. Nonetheless,
observed effects onmorbidity suggest that vitamin Amay improve
overall health, and observational studies might examine the nature
of this relationship.
All included studies reporting all-cause mortality were conducted
in developing countries. The results appear applicable to develop-
ing countries with chronic VAD. The primary analysis is based on
many large trials from several countries and locations. It included
90% of the children randomised in this review; risk of selective
outcome reporting appears minimal. Statistical heterogeneity sug-
gests that themagnitude of the effectmay differ across settings and
populations, possibly due to the extent of VAD or the availability
of other nutrients. For example, dietary intake of vitamin A will
differ across locations and the effects of supplementation may be
smaller in places with greater access to vitamin A rich food. Con-
comitant nutrient deficiencies may also impair the bioavailability
of the supplements, since some of these nutrients (including fat,
protein and zinc) could be limiting factors for the absorption and
utilisation of vitamin A, which is lipid-soluble (Villamor 2000).
Comorbid illnesses could also reduce absorption of Vitamin A.
That is, if vitamin A reduces mortality by reducing susceptibility
to particular pathogens, differences in the prevalence of disease,
sanitation, etc. might contribute to heterogeneity in outcomes
across trials. Future versions of this reviewmight investigate if VAS
reduces both mild and severe episodes of diarrhoea, as the latter
are more closely linked to mortality. A few trials have measured
malaria mortality, which was not included in the review protocol;
this outcome should be added to future versions of the review.
All included studies reporting all-cause mortality were conducted
in low- and middle-income countries. The results appear applica-
ble to all such countries with chronic VAD.
Analyses for many of the cause-specific mortality and morbidity
outcomes were consistent. A general weakness of many interven-
tions is the underreporting of implementation data, such as the
core components of an intervention, the degree to which they
are delivered in practice, and what aspects of the trial may have
influenced implementation (Mayo-Wilson 2007). In theory, the
putative effect of this intervention relies little on the relationship
between the provider and participant (discussed previously in the
context of performance bias), but it is essential that large-scale
interventions effectively distribute capsules that have been stored
properly and remain active. Additionally, the degree to which chil-
dren were treated for morbidities across trials might influence in-
cidence and prevalence data collected in various trials, and this
could contribute to heterogeneity.
Some readers will undoubtedly find these results unsatisfying, par-
ticularly because the review does not explain heterogeneity in the
results. This review suggests some ways in which vitamin A might
work, but it does not describe how effects of vitamin A might
differ across subpopulations because trials did not report the data
required for such analyses. We decided a priori not to include sub-
group analyses based on individual-level moderators for reasons
described above; we could not have done much more using study-
level data. Co-interventions including other nutrients or vacci-
nations might interact with vitamin A, but we were unable to
review possible interaction effects. We were also unable to com-
pare HIV positive children to HIV negative children. Subgroup
analyses by geographical region include few studies; a few studies
disaggregated data by gender and age, but these were not repre-
sentative of the studies overall and the results. Subgroup results
were neither significant nor meaningful, and they are vulnerable
to reporting bias (i.e. differences are more likely to be reported
than similarities). Though a review with individual patient data
could be informative, systematic reviews are not the best method
for answering all questions, and other studies might explain why
results are sometimes different. Furthermore, the observed effects
are so large that heterogeneity may be considered unimportant;
vitamin A should be given to children whether it reduces child-
hood mortality by 5% or 25%.
Quality of the evidence
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The review included 43 studies and an estimated 215,633 chil-
dren. This is the largest review of VAS for children to date.
The primary outcome was at low risk of bias, and the size and the
significance of the effect cannot be explained by bias. While there
was some evidence of small study bias for secondary outcomes,
further research is unlikely to change the conclusion that VAS,
delivered with high quality and coverage, prevents death among
children aged 6 to 59 months in the developing world. Despite
sensitivity analyses and attempts to explain sources of heterogene-
ity by comparing the characteristics of the studies, we could not
explain reasons for these differences across trials. Observational
studies might investigate the mechanisms by which vitamin A re-
duces mortality.
The DEVTA trial 2007, which includes more than four times the
number of children in this review, found no benefit for vitamin A
supplementation. However, details that might explain this differ-
ence were not available. It is possible that these relatively smaller
studies were more prone to bias, but the reviewers find this ex-
planation unlikely to explain the effect in its entirety. When the
mortality data for DEVTA trial 2007 are included in the main
analysis of this review, a statistically significant benefit for vitamin
A is still observed, and that effect remains clinically meaningful.
Potential biases in the review process
This review used clearly specified inclusion and exclusion criteria,
a comprehensive search strategy for the identification of relevant
studies, and subgroup and sensitivity analyses to explore hetero-
geneity that were specified a priori. Post-hoc decisions to include
quasi-randomised trials and post-hoc analyses are noted, and sen-
sitivity analyses demonstrate that these did not change the results.
The comprehensive search strategy was devised tominimise publi-
cation bias by searching for both published and unpublished stud-
ies, though none of the included studies were unpublished. While
studies with positive results are more likely to be published than
studies with negative results, studies large enough to make a dif-
ference in this review are very likely to be published. One study
awaiting assessment is likely to be published soon (DEVTA trial
2007), and another was too small to affect any analysis (Aklamati
2006). The inclusion of DEVTA in a sensitivity analysis reduces
the threat of publication bias and provides evidence that the main
finding is robust.
Some secondary outcomes did not contain a majority of the chil-
dren randomised in the review, and these results may be vulnerable
to selective outcome reporting bias.
Agreements and disagreements with other
studies or reviews
These results are consistent with the results of other reviews assess-
ing a similar question, though the magnitude of the reduction in
risk of death was smaller. Glasziou 1993 reported a 30% reduction
in all-cause mortality; Beaton 1993, a 23% reduction, and Fawzi
1993 used an odds ratio rather than risk ratio as the effect statistic
so the reported reduction is not directly comparable.
This review contributes a timely update to the status of the evi-
dence; most previous meta-analyses were conducted before pub-
lication of the trials contributing 30% of randomised children in
the primary analysis. This effect was explored in a post-hoc cu-
mulative meta-analysis which sorted the included trials by year. As
reported in Beaton 1993, there was a 23% reduction in all-cause
mortality by 1993 (RR = 0.77 (95% CI 0.70 to 0.85)). The trials
that occurred after 1993 change the effect by only 1%.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
National and regional programmes of VAS are in place in over 70
countries worldwide and may be among the most cost-effective
public health interventions (Fawzi 2006). Worldwide, more than
190 million children are vitamin A deficient; reducing their risk
of mortality by 24% could save almost 1 million lives per year.
These interventions respond to an immediate need for adequate
nutrition, but they are not ideal long-term solutions to the under-
lying problem.
Fortification, food distribution programs and horticultural devel-
opments may provide more permanent relief. For example, vita-
min A could be added to rice or growersmay aim to increase access
to agricultural products such as the orange-fleshed sweet potato
(Klemm 2010). Furthermore, if vitamin A reduces mortality by
preventing measles, widespread vaccination will reduce the rela-
tive contribution of vitamin A supplementation. Until such long-
term solutions are in place, supplementation should continue. As
access to vitamin A increases, it will be important to continue to
identify at-risk groups and deliver supplements to them.
We strongly recommend vitamin A supplementation to children
under 5 in areas at risk of VAD. The exact nature of how these
programs should be structured and administered - the dose, fre-
quency, and duration of intervention - are less certain. As dis-
cussed above, data on implementation for the trials included in
this review (and more generally) are lacking. In the absence of
this information, concrete recommendations for practice would
be speculative at best. Comparative trials may be informative and
policymakers should consider including such trials in plans for
vitamin A distribution.
Implications for research
The effectiveness of VAS for preventing mortality is well-estab-
lished. The primary result in this review is not meaningfully dif-
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ferent from the results of reviews conducted in 1993. Not all stud-
ies conducted in the interim were required, and further placebo-
controlled studies would be unethical.
Nevertheless, this review does not answer a number of important
questions. There was little variation in dosing among studies re-
porting the primary outcome. One trial used weekly doses and
estimated a 54% reduction in all-cause mortality (Rahmathullah
1990). It would be ethical to conduct trials in which participants
receive different doses of vitamin A that are likely to be beneficial,
some of which could lead to larger benefits than those observed so
far, and might lead to fewer side effects (for example, vomiting).
Reductions inmortality are likely related to reduced incidence and
severity of diarrhoea. The effects of VAS on relevant pathogens
and disease pathways are not well understood, and these could be
examined in observational studies or in trials of other interventions
for these problems.
Growth and other developmental outcomes are less important
thanmortality and have been studied rarely. These outcomes could
be added to future versions of this review. Observational studies
might elucidate the relationship (if any), between vitamin A and
growth.
Despite the primary effect, observed increases in vitamin A serum
levels were small, and serum results are more vulnerable to bias
than the overall results. Serum level may be a poor indicator of
status, and may not be related to more meaningful outcomes like
mortality and blindness. On the other hand, oral supplementation
may not be the best pathway for delivery. For example, absorption
may be better in protein carriers compared to carbohydrate carri-
ers. Further studies might compare synthetic supplementation to
fortification or other delivery mechanisms.
Two additional Cochrane reviews have recently investigated the
effects of vitamin A during the neonatal period (Haider 2008) and
for infants 1 to 6 months of age (Gogia 2008) and will be available
shortly. Further reviews might investigate different delivery chan-
nels, including food supplementation, improved access to food,
or social programmes to increase uptake of vitamin A rich foods.
Several studies have investigated VAS for pregnant and lactating
mothers; these and other efforts to promote delivery of vitamin
A (for example, by increased rates and duration of breastfeeding)
may require further attention.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agarwal 1995
Methods Cluster randomised trial conducted in Uttar Pradesh, India, Asia
Participants All children below 6 years of age were eligible for inclusion in the trial. Children with
xerophthalmia were excluded
A total of 16 clusters (subcentres) were randomly selected. Four subdivisions (4 subcentres
in each) were made and drugs A (vitamin A) and B (placebo) distributed in two each
randomly. It was found at the end of the study that by mistake vitamin ‘A’ was distributed
in 3 subdivisions (12 subcentres) and placebo in 1 only (4 subcentres). A total of 17,778
children were approached but only 15,247 children were included in the final analysis
based on the fact that they received at least 1 dose of vitamin A
Interventions Children in experimental group received vitamin A along with small amounts of vitamin
E. The dosages were 50,000 IU of vitamin A and 10 IU of vitamin E for children 1-6
months and 100,000 IU of vitamin A and 20 IU of vitamin E for children 7-72 months.
The intervention was delivered every 4 months and continued for 12 months
Outcomes All-cause and cause specific mortality of diarrhoea, pneumonia, measles and meningitis
Notes The trial was conducted in two phases. First phase consisted of 15 months i.e. 3 months
for registration and 12 months for intervention and measurement of relevant outcomes. In
second phase, mortality was measured in a sub-sample of initially included children exactly
after 12 months of termination of first phase. The cause of death was assigned by using
a verbal autopsy tool. Baseline mortality rates for children below 6 years of age were 27.
7 and 23.3 per 1000 for intervention and control group respectively and was significantly
different in two groups (P < 0.01). According to WHO, India is a country with a high
child mortality rate (i.e. > 40/1000)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Out of the total 43 subcentres, 16were ran-
domly selected, four subdivisions (4 subcen-
tres in each) were made and drugs A and B
distributed in two each randomly”
Authors do not specify the method of se-
quence generation.
Allocation concealment? Unclear risk Insufficent information to permit judg-
ment.
Blinding?
Blinding of Participants
Unclear risk Insufficent information to permit judg-
ment.
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Agarwal 1995 (Continued)
Blinding?
Blinding of provider
Unclear risk Insufficent information to permit judg-
ment.
Blinding?
Blinding of outcome assessor
Unclear risk Insufficent information to permit judg-
ment.
Incomplete outcome data addressed? Unclear risk Insufficent information to permit judg-
ment.
Free of selective reporting? Unclear risk Insufficent information to permit judg-
ment.
Free of other bias? Unclear risk Insufficent information to permit judg-
ment.
Arya 2000
Methods Individually randomised trial conducted in New Delhi, India, Asia
Participants Infants age 9-12 months attending immunisation clinic of Safdurjung hospital in New
Delhi were eligible for inclusion in the trial. Sick infants requiring hospitalisation were
excluded
A total of 256 infants were enrolled in the study with equal numbers (i.e. 128) in vitamin
A and placebo group. Mean age of participants was 9 months
Interventions The experimental group received a single dose of 100 000 IU of vitamin A in Archis
oil. The control group received placebo in peanut oil. Both vitamin A and placebo were
administered at the time of measles vaccination. At the end of study vitamin A group
received placebo and placebo group received vitamin A
Outcomes Incidence of side effects in first 24hours: vomiting, loosemotions, fever, irritability, bulging
fontanelle
Notes Study participants were not significantly different in sex, age and weight distribution and
nutritional status at the baseline.The baseline prevalence of vomiting, loose stools, fever
and irritability during 24 hours prior to dosing was similar in both groups. 97.3% of the
included infants had normal serum retinol level before the study
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk “The infants were randomised ... accord-
ing to the order of arrival at hospital. Ran-
domisation was done by the nurse who gave
measles vaccine to these children.”
Probably not done.
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Arya 2000 (Continued)
Allocation concealment? Unclear risk Children were randomised according to
their entry into hospital
Blinding?
Blinding of Participants
Low risk “This double-blind, randomised, ... sup-
plied in small dark bottles marked ’1’ and
’2’.”
Blinding?
Blinding of provider
Low risk “This double-blind, randomised, ... sup-
plied in small dark bottles marked ’1’ and
’2’.”
Blinding?
Blinding of outcome assessor
Low risk “This double-blind, randomised, ... sup-
plied in small dark bottles marked ’1’ and
’2’ ... Two clinicians examined each of the
infants at both first and second visits. Nei-
ther clinician knew the bottle code.”
Incomplete outcome data addressed? High risk A total of 39 (15.2%) infants were lost to
follow-up with similar distribution in both
the groups. Reasons for loss to follow-up not
given
Free of selective reporting? High risk Methods describe that the clinicians did
physical examinations and recorded weight,
nutritional status, any signs of vitamin A
deficiency, heart rate, respiratory rate, tem-
perature and systemic examination espe-
cially neurological examination including
the state of the fontanelle, reflexes, mo-
tor and sensory functions, etc. But bulging
fontanelle not reported as an outcome, nei-
ther other variables mentioned in the results
Free of other bias? Low risk No other apparent bias was noted in the
study.
Bahl 1999
Methods This individually randomised study was conducted in an urban slum of Delhi, India, Asia
Participants Infants aged 6-9 months were identified and enrolled into study when they became 9
months old. Those infants were excluded who had a previous history of measles, contact
with a case of measles or measles immunisation, or if they had received a dose of vitamin
A in the previous 4 months. Participants with serious illness requiring hospitalisation or
having clinical signs of vitamin A deficiency (i.e. xerophthalmia, Bitot’s spots etc.) were
also excluded
A total of 618 infants were enrolled and randomised either to vitamin A (309) or placebo
group (309). 50% of study population consisted of male infants
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Bahl 1999 (Continued)
Interventions Participants in intervention group were given a single dose of 30 mg (100 000 IU) of
vitamin A in the form of retinol palmitate and control group received soybean oil as
placebo. Children were followed for four months
Outcomes Antibody response to measles vaccine. Incidence of measles during study period and side
effects like vomiting, drowsiness etc in first 48 hours were also reported
Notes The primary objective of the study was to determine the response to measles vaccine when
administered along with vitamin A at 9 months of age. The study found no significant
difference in antibody titers between the two groups at three months after the administra-
tion of intervention.The baseline prevalence of clinical vitamin A deficiency in children
1-5 years in study area was 3.5% and that of biochemical vitamin A deficiency of 37%
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “Infants were randomly assigned to receive
vitaminA or a placebo by using a simple ran-
domisation scheme with random permuted
blocks of size eight, i.e., four infants each
out of every eight infants enrolled were ran-
domised to receive vitamin A or a placebo.”
Probably done.
Allocation concealment? Unclear risk Insufficent information to permit judg-
ment.
Blinding?
Blinding of Participants
Low risk “This scheme ensured that all infants re-
ceived 30 mg vitamin A by 12 mo of age
without interfering with the double-blind
design of the study.”
Probably done.
Blinding?
Blinding of provider
Low risk Adequate masking of vitamin A and placebo
should have meant that providers were ade-
quately blinded
Blinding?
Blinding of outcome assessor
Low risk Adequate masking of vitamin A and placebo
should have meant that outcome assessors
were adequately blinded
Incomplete outcome data addressed? High risk Losses to follow-up and exclusions de-
scribed. Missing data excluded from the
analysis. It is not possible to ascertain
whether the exclusion of data from 17%
of participants (equally distributed between
treatment groups) would have impacted on
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Bahl 1999 (Continued)
the results. The investigators state that the
reason for their exclusion is that a follow-up
serum sample could not be ascertained
Free of selective reporting? High risk Data on harms are incompletely disclosed
in the study report
Free of other bias? Low risk This study appears to be free of other bias.
Barreto 1994
Methods Individually randomised trial conducted in Serrinha, Brazil, Latin America
Participants Children aged 6 to 48 months were eligible for inclusion in the trial. Exclusion criteria
was presence of xerophthalmia or measles infection within the previous 30 days. Children
who received a high dose of vitamin A supplementation in the previous 6 months or had
weight-for-age less than 60% of the statistical median were also excluded
A total of 1240 children were included, 620 in vitamin A group and 620 in placebo. Mean
age of participants was 28 months and the proportion of males was 52%
Interventions The experimental group received vitamin A in a dose of 100,000 IU for children younger
than 12 months and 200,000 IU for the older. The control group received placebo only.
The intervention was delivered every 4 months for 1 year
Outcomes All-cause mortality, incidence and prevalence of diarrhoea and respiratory tract disease.
Incidence of measles and xerophthalmia
Notes The study area had inadequate pubic health services. A previous survey in the area showed
biochemical deficiency (serum vitamin A concentration < 0.35 mmol/L) rate of 7.4% in
children of this age group. According to WHO criteria, vitamin A deficiency should be
considered a pubic health problem in this area. The surveillance for morbidity outcome
was done 3 times per week for 1 year, so the recall period was 48 to 72 hours. We took data
for incidence of measles and xerophthalmia from account of attrition in results section.
According to WHO, Brazil does not have a high child mortality rate (i.e. < 40/1000)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Childrenwere randomly assigned to receive
vitamin A or placebo four times-at the start
of the trial and every 4 months thereafter.”
Authors do not specify the method of se-
quence generation.
Allocation concealment? Low risk “...only an external investigator had the
codes for the individually wrapped and
numbered capsules.”
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Barreto 1994 (Continued)
Although specific details were not disclosed,
the available information suggests that allo-
cation was adequately concealed
Blinding?
Blinding of Participants
Low risk “The gelatinous capsules of vitamin A and
placebo (supplied by Hoffman La Roche)
were identical in appearance and were un-
wrapped just before administration.”
The study was double-blind, with identical
presentation and dosing of vitamin A and
placebo
Blinding?
Blinding of provider
Low risk “The gelatinous capsules of vitamin A and
placebo (supplied by Hoffman La Roche)
were identical in appearance and were un-
wrapped just before administration.”
Probably done.
Blinding?
Blinding of outcome assessor
Low risk “The study was kept double-blind and only
an external investigator had the codes for the
individually wrapped and numbered cap-
sules.”
If the assessors were not involved in the allo-
cation process as suggested by the available
information, outcome assessors were likely
to have been blinded to treatment group as-
signment
Incomplete outcome data addressed? Low risk “The total loss in follow-up time was 10.
3%, equally distributed between the study
groups.”
The rate of attrition was balanced between
the two treatment groups, and was primar-
ily attributable to migration. On that basis,
attrition bias is not likely to have impacted
on the results of the review
Free of selective reporting? Unclear risk The protocol for the study was not available
and as such, this aspect of the reporting of
the study could not be assessed
Free of other bias? Low risk This study appears to be free of other po-
tential bias.
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Benn 1997
Methods Individualy randomised trial conducted in Belem and Mindra, two districts in Bissau, the
capital of Guinea-Bissau, Africa
Participants Infants aged 6-9 months were eligible for inclusion in the trial. Those with signs of
xerophthalmia, history of previous vitaminA supplementation, history ofmeasles infection
before age 9 months or who had a positive haemagglutinin-inhibition assay (HIA) titre at
age 9 months, were excluded. All infants reported to have had measles between 9 to 18
months of age were also excluded
A total of 462 infants were randomised to either intervention or control group. The mean
age of participants was 8.7 months and proportion of males was 51%
Interventions There were three study groups:
Group 1: included ”infants aged 6 months and were randomly allocated to receive either
a dose of measles vaccine at 6 months and a dose of measles vaccine at 9 months together
with vitamin A supplement or the same dosing of measles vaccine with placebo as the
supplement“
Group 2: consisted of ”infants who were randomly allocated either poliomyelitis vaccine
at 6 months and a single dose of measles vaccine at 9 months with vitamin A supplement
or the same vaccine doings with a placebo as the supplement“
Group 3: included ”Infants who were older than 7·5 months at the beginning of the study
or who were not found at home until they reached the age of 7·5 months. They were
included in the study at age 9 months and received a measles vaccine plus vitamin A or
placebo supplement at that age
Vitamin A was supplemented in a single dose of 100 000 IU dissolved in 1 ml of vegetable
oil along with 40 IU of vitamin E. The placebo group received 40 IU of vitamin E dissolved
in vegetable oil
Outcomes Antibody response to measles vaccine, all-cause mortality, incidence of measles
Notes The primary objective of the study was to calculate the antibody response to measles
vaccine when given with vitamin A. The results for antibody response to measles vaccine
showed no significant difference between the groups. It was concluded from the study that
simultaneous administration of measles vaccine and vitamin A has no negative effect on
measles immunity. Similarly vitamin A supplementation was shown to have no significant
effect on immune response of CD4 and CD8 T-cell in children without clinical vitamin
A deficiency. Please note that vitamin A or placebo was given only at 9 months of age in
all three study groups. The only difference among the groups was the frequency and type
of vaccine administered. We therefore added all the numbers for all three intervention and
placebo groups to report the outcomes of interest to our review. We primarily took data
from trial flow diagram and calculated the effect sizes accordingly
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “The allocation sequence was computer
generated.”
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Benn 1997 (Continued)
Allocation concealment? Low risk “The allocation sequence was kept in sealed
envelopes and only released when all clinical
laboratory analyses were completed.”
Blinding?
Blinding of Participants
Low risk Identical presentation: “...because of the
young age of the participants, any difference
in taste was irrelevant...”
Probably adequate.
Blinding?
Blinding of provider
Low risk “None of the staff involved knew whether
the bottles contained vitamin A or placebo.
..”
Blinding?
Blinding of outcome assessor
Low risk “None of the staff involved knew whether
the bottles contained vitamin A or placebo.
..”
Masking of treatment group assignment and
treatment to study personnel likely to have
been maintained throughout
Incomplete outcome data addressed? Low risk Number lost to follow-up and those ex-
cluded were explicitly described and was
equal in both the groups. Loss to follow-up
exceeded the number of deaths and children
with measles. Reasons for missing data (mi-
gration) probably unrelated to treatment
Free of selective reporting? Low risk Some evidence of selective outcome report-
ing around malaria; however, deaths and
prevalence of measles reported
Free of other bias? Unclear risk Authors report imbalance in self-reported
disease in the children aged 6 months at
baseline. It is unclear how big an impact this
will have had as the variable is not specific
Biswas 1994
Methods This study was an individual randomised, placebo-controlled trial conducted in Gobinda-
Khatick slum area of eastern Calcutta, India, Asia
Participants Children aged 12-71 months were eligible for inclusion in the study. Participants with
signs of vitamin A deficiency (for example, xeropthalmia) were excluded
A total of 180 children were randomised either to vitamin A or placebo group. Mean age
of children and proportion of males were not specified in the study
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Biswas 1994 (Continued)
Interventions The experimental group received 200 000 IU of vitamin A in the form of retinyl palmitate.
The control group received placebo. Only a single dose of intervention was administered
and children were followed for 6 months
Outcomes Incidence of diarrhoea and acute respiratory tract infection
Notes The baseline age and nutritional characteristics were similar in both the groups. The
surveillance for morbidity outcomes was done fortnightly. For respiratory disease morbid-
ity, we took data for lower respiratory tract infection only
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk Block randomisation by age and weight:
“For each strata, a restricted randomisation
list was prepared (...) a random permutated
block of block length 6 was used.”
Probably done.
Allocation concealment? Low risk “...randomisation was done by a pharmacist
of the drug manufacturing company.”
Assuming that the pharmacist was indepen-
dent of the study team this was probably ad-
equate
Blinding?
Blinding of Participants
Low risk “...identical (colour and taste) placebo. Both
drug and placebo were prepared and dis-
pensed in a single dose amber coloured glass
ampoule by a local pharmaceutical com-
pany.”
Blinding?
Blinding of provider
Low risk “For keeping the trial totally blinded to all
participants (for example, patients, investi-
gators, surveyor), randomisation was done
by a pharmacist of the drug manufacturing
company. Samples of drug (or placebo) were
identified by the code number of the respec-
tive child.”
Blinding?
Blinding of outcome assessor
Low risk “For keeping the trial totally blinded to all
participants (for example, patients, investi-
gators, surveyor), randomisation was done
by a pharmacist of the drug manufacturing
company. Samples of drug (or placebo) were
identified by the code number of the respec-
tive child.”
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Biswas 1994 (Continued)
Incomplete outcome data addressed? Low risk “....data was analysed for 174 children due
to attrition of 6 children for various reasons
(for example, 5 children were hospitalised
due to illnesses unrelated to the study ob-
jectives and the death of 1 child due post-
measles bronchopneumonia).”
Attrition was low and reported not to relate
to treatment.
Free of selective reporting? Unclear risk Study protocol was not available to per-
mit a clear judgement. Study aims were to
measure diarrhoea and respiratory infection;
both outcomes were reported in full in the
study report. One child died and the treat-
ment group assignment was not disclosed
Free of other bias? Low risk This study appears to be free of other bias.
Cheng 1993
Methods This randomised trial was conducted in a rural area of China, Asia
Participants Children aged 6 months to 3 years were eligible for inclusion in the trial
A total of 198 children were randomised either to vitamin A or placebo group. There were
105 children in vitamin A and 81 in placebo group. Mean age of children and proportion
of males were not specified in the study
Interventions Vitamin A was supplemented in a dose of 200 000 IU for children > 12 months and 100
000 IU for < 12 months of age. Control group received placebo in the form of vegetable
oil. Interventions were given every 4 months for 12 months
Outcomes Incidence of diarrhoea and respiratory disease, all-cause hospitalisations, diarrhoea specific
hospitalisations, pneumonia specific hospitalisations, mean vitamin A serum levels
Notes Baseline serum levels of retinol were similar in both the groups. Measurement of bio-
chemical vitamin A levels in the study area fulfilled the WHO criteria for an action to be
triggered at a pubic health level. The morbidity surveillance was done twice a month
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “198 children who were randomly assigned
on a 3:2 allocation to treatment (105) and
control (81) groups.”
No more information was provided about
sequence generation.
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Allocation concealment? Unclear risk Insufficent information to permit judg-
ment.
Blinding?
Blinding of Participants
Low risk “Administration was double blind: neither
parents nor doctors knew whether the child
was in a treatment or control group.”
Placebo capsules contained vegetable oil and
were likely to have been indistinguishable
from intervention
Blinding?
Blinding of provider
Low risk “Placebo capsules contained vegetable oil
and were likely to have been indistinguish-
able from intervention.”
In view of the adequate blinding procedures,
performance bias was unlikely to have influ-
enced the results
Blinding?
Blinding of outcome assessor
Low risk “Data collected by doctors who were already
blind to treatment group assignment.”
Incomplete outcome data addressed? High risk Reasons for loss to follow- up were not pro-
vided. The number randomised and those
reported after loss to follow- up do not
match
Free of selective reporting? Unclear risk Protocol of studywas not available to permit
a clear judgement
Free of other bias? Low risk This study appears to be free of other bias.
Cherian 2003
Methods Individually randomised trial conducted in Vellor, India, Asia
Participants Infants aged 9-12 months were eligible for inclusion in the study. Participants with pre-
vious history of measles vaccination or an exanthematous illness, with moderate or se-
vere malnutrition, clinical signs of vitamin A deficiency, known immune deficiency or on
immunosuppressive therapy and those who had received blood or blood products in the
previous 6 months were excluded
A total of 395 infants were randomised to either vitamin A or placebo group. There were
198 infants in vitamin A group and 197 in placebo. Mean age of participants was 9.8
months and proportion of males was 52%
Interventions Infants in experimental group received a single dose of vitamin A in a dose of 100 000
IU. The control group received placebo only. Interventions were given out at the time of
measles vaccination
Outcomes Antibody response to measles vaccine.
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Cherian 2003 (Continued)
Notes The primary objective of the study was to measure the antibody response to measles vac-
cine when given with and without vitamin A. This study found no significant inhibitory
or enhancing influence on antibody response to measles vaccine when administered con-
comitantly with vitamin A
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “The infants who were immunized with
monovalent measles vaccine were randomly
assigned, in blocks of eight, to concomi-
tantly receive 100,000 IU of Vitamin A
in arachis oil or a placebo containing car-
boxymethylcellulose prepared in the hospi-
tal pharmacy.”
Authors do not specify the method of se-
quence generation.
Allocation concealment? Low risk “...arachis oil or a placebo containing car-
boxymethylcellulose prepared in the hospi-
tal pharmacy.”
Probably done since hospital pharmacy was
responsible for preparing the order of vita-
min A and placebo and not likely to have
been internal to the study team
Blinding?
Blinding of Participants
Unclear risk “...Vitamin A in arachis oil or a placebo con-
taining carboxymethylcellulose...”
Insufficent information to permit judg-
ment.
Blinding?
Blinding of provider
Unclear risk Insufficent information to permit judg-
ment.
Blinding?
Blinding of outcome assessor
Unclear risk Insufficent information to permit judg-
ment.
Incomplete outcome data addressed? High risk The proportion of children providing ade-
quate samples is low at 6 months, and there
is insufficient detail about the reasons for
missing data
Free of selective reporting? High risk There is no mention of mortality or any
morbidity of measles or diarrhoea
Free of other bias? Unclear risk Insufficent information to permit judg-
ment.
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Chowdhury 2002
Methods Individually randomised trial conducted in urban slums of Chandigarh, India, Asia
Participants Children aged less than 10 years were eligible for inclusion in the study. Children with
xerophthalmia and previous history of vitamin A supplementation were excluded
A total of 1520 children were randomised either to vitamin A or placebo group. There
were 756 children in vitamin A group and 759 in placebo group. Mean age of participants
was 51 months and proportion of males in study sample was 50%
Interventions The experimental group received vitamin A in a of 50 000 IU for children aged < 6months,
100 000 IU for 6-12 months and 200 000 for > 1 year. The control group received placebo.
The intervention was given every 4 months for 15 months
Outcomes All-cause mortality, cause specific mortality of diarrhoea, pneumonia and meningitis. In-
cidence of diarrhoea, pneumonia and measles. Measuerement of sub-clinical vitamin A
deficiency status by conjunctival impression cytology
Notes Baseline socio-demographic and anthropometric characteristics were similar in both the
groups. Study population had high prevalence of vitamin A deficiency. Children were
contacted every 15 days by home visits to obtain information on morbidity and mortality.
The study included children less than ten of years of age; however, themean age of children
was 51 months. Study methods were not explicitly described. According to WHO, India
is a country with a high child mortality rate (i.e. > 40/1000)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “From three slums of Chandigarh, 1520
non-xerophthalmic children of less than 10
years of age were individually randomised
in equal number to receive vitamin A or
placebo.”
Allocation concealment? Unclear risk Insufficent information to permit judg-
ment.
Blinding?
Blinding of Participants
Unclear risk “An equivalent volume of arachis oil was
given as placebo.”
Insufficent information to permit judg-
ment.
Blinding?
Blinding of provider
Unclear risk Insufficent information to permit judg-
ment.
Blinding?
Blinding of outcome assessor
Unclear risk Insufficent information to permit judg-
ment.
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Chowdhury 2002 (Continued)
Incomplete outcome data addressed? High risk Although attrition rates were balanced the
rates of mortality were lower than the rate
of withdrawal. This could impact on the re-
liability of the results
Free of selective reporting? Unclear risk Insufficent information to permit judg-
ment.
Free of other bias? Unclear risk Study not sufficiently reported in order to
assess this item fully
Daulaire 1992
Methods A cluster randomised, non-placebo controlled trial conducted in Jumla district, Nepal,
Asia
Participants Children 1-59 months were eligible for inclusion in the trial
A total of 16 clusters were randomly assigned either to vitamin A or control group. These
include a total of 7197 children in which 3786 children were in vitamin A group and 3411
in control group. Proportion of male participants was 51%
Interventions Children in experimental group received vitamin A in a dose of 200 000 IU for children
aged 12-59 months, 100 000 IU for those of 6-12 months and 50 000 IU for < 6 months
old. Vitamin A was supplemented once only and children were followed for 5 months
Outcomes All-cause mortality and cause specific mortality for diarrhoea, pneumonia and measles
Notes The study site was a remote mountainous region of northwestern Nepal with a total
population of about 80,000, with 12,000 children under 5 years of age. This area was
considered as one of the poorest and most medically underserved areas of the country.
Infant mortality rate was 189 deaths per 1000 live births and child (1-4 years) mortality
rate was 52 per 1000 per year. Malnutrition was prevalent in the study area, and 26% of
children aged 1-4 years were suffering from substantial malnutrition. A survey of 3651
children in children under 5 years showed active xerophthalmia in 1.3-2% of population
and 1-5% among infants, which is high for this age group. Disaggregated data onmortality
was available according to different age groups. We have used data for children 6-59
months according to the objectives of our review. According to WHO, Nepal is a country
with a high child mortality rate (i.e. > 40/1000)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “We randomly selected by card eight of the
16 sub-districts for vitamin A supplementa-
tion.”
Probably done.
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Daulaire 1992 (Continued)
Allocation concealment? High risk Author contacted and replied, “No effort
was made to conceal the allocation se-
quence.”
Blinding?
Blinding of Participants
High risk “There was no placebo or blinding.”
Blinding?
Blinding of provider
High risk “There was no placebo or blinding.”
Blinding?
Blinding of outcome assessor
High risk “There was no placebo or blinding.”
Incomplete outcome data addressed? Low risk There was no loss to follow- up. Coverage
of intervention was described in detail
Free of selective reporting? Unclear risk Insufficent information to permit judg-
ment.
Free of other bias? Low risk This study appears to be free of other bias.
DEVTA 2007
Methods
Participants
Interventions
Outcomes
Notes This study was not included, but some available data was used in a sensitivity analysis. See Characteristics of studies
awaiting classification
Dibley 1994
Methods Individually randomised trial conducted in 34 rural villages located on the southern coast
of Central Java in Indonesia, Asia
Participants Children aged 6 to 47 months were eligible for inclusion in the review. Children with
cerebral palsy, epilepsy, flaccid paralysis, mental retardation, congenital or rheumatic heart
disease were permanently excluded. Those with weight-for-height more than 3.00 SD
below the WHO growth reference mean or acute xerophthalmia were excluded for one
cycle and treated with high dose vitamin A and then included
A total of 1405 children were randomised to either vitamin A or placebo group. Proportion
of male participants was 50.9%
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Dibley 1994 (Continued)
Interventions Intervention group received 206,000 IU of vitamin A in the form of retinyl ester plus 37
IU vitamin E for children > 12 months or 103,000 IU retinyl ester plus 17 IU vitamin E
if less than 12 months of age. The control group received placebo that contained 17 or
37 IU vitamin E according to the age of the subject. The intervention was given every 4
months for 24 months. An average of 89% of the children received a treatment (vitamin
A or placebo)
Outcomes All-cause mortality, incidence of diarrhoea and respiratory disease, mean vitamin A serum
level, proportion of vitamin A deficient, growth
Notes Baseline demographic, clinical and nutritional characteristics of the participants were the
same, and the groups remained balance at the start of each of the other 5 cycles. Children
were visited every other day for 6 cycles. The longest recall period allowed was 4 days.
Observed child-days of ALRI of vitamin A group and control group were 280,186 and
273,630. According to WHO, Indonesia is a country with a high child mortality rate (i.
e. > 40/1000)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “Randomization of the treatments was done
with a 1:1 allocation ratio in blocks of eight,
based on a table of random permutations of
integers (Cochrane and Cox 1950).”
Likely to be adequate.
Allocation concealment? Low risk “All investigators, field and laboratory staff,
and participants were masked to the treat-
ment code.”
“The capsules were packaged in opaque blis-
ter packs with a unique treatment code.”
Blinding?
Blinding of Participants
Low risk “The oily contents of the vitamin A and
placebo capsules were of similar taste and
colour.”
Blinding?
Blinding of provider
Low risk “All investigators, field and laboratory staff,
and participants were masked to the treat-
ment code.”
Adequate allocation concealment and the
identical presentation of placebo and vita-
min A should have prevented providers be-
coming unblinded to treatment group as-
signment. Low risk of performance bias
Blinding?
Blinding of outcome assessor
Low risk “All investigators, field and laboratory staff,
and participants were masked to the treat-
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Dibley 1994 (Continued)
ment code.”
Adequate allocation concealment and the
identical presentation of placebo and vita-
min A should have prevented outcome as-
sessors becoming unblinded to treatment
group assignment
Incomplete outcome data addressed? Low risk Complete details of those excluded and lost
to follow-up with reason were described.
There were a low and balanced number of
withdrawals between the treatment groups.
The analytical method took account of the
time on treatment (i.e. follow-up time for
each cycle) and this may have been adequate
Free of selective reporting? Low risk Lack of trial protocol hinders full assessment
of this item. However, data on outcomes of
relevance to the review were reported
Free of other bias? Low risk This study appears to be free of other bias.
Donnen 1998
Methods Individually randomised, non-placebo controlled trial conducted in South Kivu province
of Congo, Africa
Participants Children 0-72 months were eligible for inclusion in the trial. Children were recruited
as soon they were discharged from children hospital Kotive. No exclusion criteria was
described
A total of 358 children were randomly assigned to vitamin A, mebendazole, or control
group. Vitamin A had 118 children and control group had 117
Interventions There were three study groups. The first group was supplemented with vitamin A, second
group received mebendazole for deworming and third group was simply observed as con-
trol. Children in vitamin A group received retinol palmitate in a dose of 100 000 IU for
children aged < 1 year and 200 000 IU for those > 1 year. Supplementation was repeated
after 6 months and continued for 12 months
Outcomes All-cause mortality, growth and incidence of diarrhoea and respiratory disease morbidity
Notes Morbidity surveillance was done every 2 weeks during 3 months, then every 3 months
until 12 months. Data on morbidity outcomes were presented in the form of odds ratios
based on generalised estimating equation models. As we were using the data in the form
of relative risk and no nominators were given in this study, we could not pool the data for
diarrhoea and respiratory morbidity of this study
Risk of bias
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Donnen 1998 (Continued)
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “As soon as the children were discharged
from the hospital, they were randomly as-
signed to one of the three groups.”
Probably not done
Allocation concealment? Unclear risk Insufficient details available to make a judg-
ment.
Blinding?
Blinding of Participants
Unclear risk Insufficient details available to make a judg-
ment.
Blinding?
Blinding of provider
Unclear risk Insufficient details available to make a judg-
ment.
Blinding?
Blinding of outcome assessor
Unclear risk Insufficient details available to make a judg-
ment.
Incomplete outcome data addressed? Low risk Authors indicate that 6% were lost to fol-
low- up, not discussed in detail. Number
died but not indicated howor by group data.
Overall, 6% of the children were lost to fol-
low-up, with approximately equal propor-
tions in each group
Free of selective reporting? Unclear risk Insufficient details available to make a judg-
ment.
Free of other bias? Low risk This study appears to be free of other bias.
Florentino 1990
Methods Individually randomised trial conducted in the municipalities of Pililla and Binangonan
in the province of Rizal, Philippines, Asia
Participants Children 1-6 years of age were eligible for inclusion in the study. Any child with clinical
signs of vitamin A deficiency was excluded from the trial
A total of 2471 children were randomised to three intervention groups. Mean age of
children was 3.4 years and proportion of males in study population was 49.5%
Interventions There were 3 study groups, 2 were supplemented with vitamin A and 1 with placebo. The
first group in the experimental group received a high dose of vitamin A i.e. 200 000 IU
and the second group received a medium dose of vitamin A i.e. 100 000 IU. The control
group received placebo only. Children were supplemented only once and were followed
for 1 week
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Florentino 1990 (Continued)
Outcomes Incidence of side effects within 1 week: nausea and/or vomiting, headache, diarrhoea and
fever
Notes The study area had a high prevalence of malnutrition, and therefore vitamin A deficiency
was likely to be prevalent. Study reported outcome for first 48 hours and within a week.
We have pooled the data for first week
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “By use of a double-blind study design, chil-
dren were randomly assigned to three treat-
ment groups.”
No qualifying information on what ’ran-
domly assigned’means is provided.Difficult
to assess sequence generation
Allocation concealment? Unclear risk Insufficient details available to make a judg-
ment.
Blinding?
Blinding of Participants
Low risk “Neither the researchers and field workers
nor the subjects knew the contents of the
preparations; the code was kept confidential
byHoffmanLaRoche until after the analysis
of the results was completed.”
Blinding?
Blinding of provider
Low risk “Neither the researchers and field workers
nor the subjects knew the contents of the
preparations; the code was kept confidential
byHoffmanLaRoche until after the analysis
of the results was completed.”
Blinding adequate andperformance bias un-
likely to have influenced results
Blinding?
Blinding of outcome assessor
Low risk “Neither the researchers and field workers
nor the subjects knew the contents of the
preparations; the code was kept confidential
byHoffmanLaRoche until after the analysis
of the results was completed.”
Incomplete outcome data addressed? Low risk Complete details of those excluded and lost
to follow-up were provided. Only 76 chil-
dren lost, differences slight between groups
Free of selective reporting? Low risk Though not explicitly stated all reported
measured outcomes have data reported in
results with sufficient clarity and explana-
52Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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tion
Free of other bias? Low risk No other apparent bias was noted.
Herrera 1992
Methods Cluster randomised trial was conducted in five rural councils in northern Sudan, Africa
Participants Eligibily criteria was age 9-72 months. Children with xerophthalmia were excluded
Randomisation was done by households. Study included a total of 28,753 children of
whom 14,343 were in vitamin A group and 14,149 were in placebo group. Proportion of
male children in the study was 50.7%
Interventions Children in vitamin A group received 200 000 IU of retinol palmitate along with 40 IU
of vitamin E. The comparison group received 40 IU of vitamin E only. The intervention
was given every six months for 18 months
Outcomes All-cause mortality and cause specific mortality of diarrhoea, measles, respiratory disease.
Incidence of diarrhoea, respiratory disease and measles. Incidence of xeropthalmia, Bitot’s
spots and night blindness
Notes Authors used non- specific terms for describing cause of death (in table 4) like “shortness of
breath” “convulsions” and “fever” etc.We have pooled data for “shortness of breath” under
heading of lower respiratory tract infection mortality. This is because it is highly unlikely
that a child will die of an upper respiratory tract infection and lower respiratory tract
infection is a more general term than pneumonia to cover this as it includes pneumonia as
well. According to WHO, Sudan is a country with a high child mortality rate (i.e. > 40/
1000)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk “Randomisation was done by household.
.. Assignment to treatment group was
achieved by the two interviewers visiting al-
ternate households throughout the village.
All eligible children in alternate households
were assigned to receive, every 6 months,
either a capsule of 60 mg (200 000 IU) of
vitamin A and 40 mg (40 IU) of vitamin E
or a capsule of 40 mg of vitamin E without
vitamin A.”
Does not appear to be randomised.
Allocation concealment? Unclear risk Insufficient details available to make a judg-
ment.
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Herrera 1992 (Continued)
Blinding?
Blinding of Participants
Low risk “The capsules were colour-coded to avoid
the possibility of mix ups, but none of the
study team members was aware which was
the experimental capsule and which was the
placebo until the end of data collection.
All eligible children in a household received
capsules of the same colour.”
Blinding?
Blinding of provider
Low risk “The capsules were colour-coded to avoid
the possibility of mix ups, but none of the
study team members was aware which was
the experimental capsule and which was the
placebo until the end of data collection.
All eligible children in a household received
capsules of the same colour.”
Performance bias unlikely given that trialists
and staff were blinded during the interven-
tion
Blinding?
Blinding of outcome assessor
Low risk “Only the manufacturer knew the contents
of the capsules until after data collection and
preliminary analysis of the results.”
Probably done.
Incomplete outcome data addressed? Low risk 3320 children did not receive 1 or 2 of the 3
vitamin A or placebo capsules. Most of this
non-compliant group consisted of children
absent from the household at the time of fol-
low-up, whereas others had moved away or
refused to take part further. As a group, the
non-compliant children tended to be from
poorer households than those who contin-
ued in the study.However, there were no sig-
nificant differences between vitamin A and
placebo groups in the number of non-com-
pliant subjects or in their ages, sex, or nutri-
tional status
With respect to the variables relevant to the
intervention, the losses to follow- up were
not significantly different from those that
remained in the study
Free of selective reporting? Unclear risk Does not reference a protocol or trial regis-
tration and does not state that all measured
outcomes are reported
Free of other bias? Unclear risk Insufficient details available to make a judg-
ment.
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Kartasasmita 1995
Methods Individually randomised trial conducted in a suburban community of city Bandung, In-
donesia, Asia
Participants Children aged 12-54monthswere included in the study.No exclusion criteria was specified
A total of 269 children were randomised either to vitamin A or placebo group. Vitamin A
supplemented group had 126 children while placebo group had 141 children. Mean age
of study participants was 33 months and proportion of males was 51%
Interventions The experimental group received 200 000 IU of vitamin A once every 6 months for 12
months. The comparison group received placebo only
Outcomes Incidence of respiratory disease. Mean serum retinol levels.
Notes Authors presented data on respiratory outcomes according to severity of disease. We have
included data for “severe respiratory disease” only
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “The children were selected by randomised
stratified sampling from the almost 2000
under-fives residing in Cikutra.”
Insufficient details available to make a judg-
ment.
Allocation concealment? Unclear risk Insufficient detail provided to make judge-
ment.
Blinding?
Blinding of Participants
Unclear risk “All children participated in an age- and sex-
matched randomised, double blind vitamin
A supplementation programme by receiving
vitamin A 200,000 IU or placebo capsules
orally, at the start and at the 6th month of
the study.”
Blinding?
Blinding of provider
Unclear risk Insufficient detail provided to make judge-
ment.
Blinding?
Blinding of outcome assessor
Unclear risk Insufficient detail provided to make judge-
ment.
Incomplete outcome data addressed? High risk Insufficient reporting of attrition/exclusions
to permit judgement
Free of selective reporting? Unclear risk Insufficient detail provided to make judge-
ment.
55Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kartasasmita 1995 (Continued)
Free of other bias? Unclear risk The methods of the study are not described
very clearly.
Lima 2010
Methods Individually randomised trial conducted in Fortaleza, the capital of the Ceara state in
northeastern Brazil, Latin America
Participants Children aged 2 months to 9 years were eligible for inclusion in the study. Those partici-
pants who had fever > 38 C or exclusively breastfed were excluded
A total of 79 children were randomised either to vitamin A or placebo group. There were
39 participants in vitamin A group and 40 in placebo. Mean age of participants was 43.3
months and proportion of males was 57%
Interventions Retinol palmitate was supplemented in a dose of 100 000 IU for children aged < 12months
and 200 000 IU > 12 months in experimental group. The comparison group received
Tocopherol (vitamin E) as placebo. Supplements were given at enrolment, 4 and 8 months
Outcomes Mean serum retinol levels, growth and adverse reactions to vitamin A
Notes The infant mortality rate in study are was 35/1000 live births. The primary objective of
the study was to measure the effect of vitamin A on barrier function of gastrointestinal
tract. The study concluded that the prevalence of new parasitic infection, especially with
Giardia species, was significantly decreased with vitamin A intervention, suggesting an
immune regulatory modulation of this nutrient on parasitic intestinal infections
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk 79 children were randomly selected (using
computer-generated random numbers)
Allocation concealment? Unclear risk Insufficient detail provided to make judge-
ment.
Blinding?
Blinding of Participants
Low risk The parent or guardian of the children, field
study team, and investigators were blinded
to treatment agent
Blinding?
Blinding of provider
Low risk The parent or guardian of the children, field
study team, and investigators were blinded
to treatment agent
Blinding?
Blinding of outcome assessor
Low risk The parent or guardian of the children, field
study team, and investigators were blinded
to treatment agent
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Lima 2010 (Continued)
Indication that field study teams assessed
outcomes. They were blinded
Incomplete outcome data addressed? Low risk After 12-month follow-up, a total of 22 chil-
dren were withdrawn from the study for the
following reasons: change of address (16),
parents or guardians did not co-operate with
the study (5), and 1 had above the median z
score for length or height at the time of the
study initiation. The percentage of partic-
ipants completing the study at 12 months
was 72.2%
Free of selective reporting? High risk The objective of study also included report-
ing of diarrhoea. Authors had reported the
overall incidence of diarrhoea in the whole
population but the figures had been pre-
sented in a way that they can not be used in
the meta-analysis
Free of other bias? Low risk No other apparent bias was observed.
Lin 2008
Methods This study was described as randomised, placebo-controlled trial conducted in Wuhan,
an industrial centre in central region of China, Asia
Participants Inlcusion criteria was age 2 to 7 years. children were recruited from kindergarten in the
area. Those who had fever, diarrhoea or a recent preventive injection were excluded from
the study. Underweight children with BMI age- and sex- specific 5th percentile of the
first US National Health and Nutrition Examination Survey data were excluded. Children
whose protein or energy intake of Chinese RDA were also excluded
A total of 105 children were randomised to three intervention groups (described below)
. Mean age of study participants was 55 months and proportion of male participants was
61%
Interventions There were 3 study groups. Two of these consisted of children whowere vitamin A deficient
and 1 with children who were vitamin A sufficient. Vitamin A was given only to 1 of
the group of vitamin A deficient children in a dose of 100 000 IU every month for three
months. The rest of two groups received placebo
Outcomes All-cause mortality, mean serum vitamin A levels.
Notes In this review we have included data for vitamin A deficient children who were either
supplemented with vitamin A or placebo. According to WHO, China does not have a
high child mortality rate (i.e. < 40/1000)
Risk of bias
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Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “The remaining 70 vitamin A-deficient
children were randomly and equally di-
vided into vitamin A deficient-supple-
mented group and vitamin A-deficient
placebo group.”
The term ’randomised’ is also used to de-
scribe a 3rd group that is clearly matched.
This may not be a RCT
Allocation concealment? Unclear risk Insufficient detail provided to make judge-
ment.
Blinding?
Blinding of Participants
Low risk “Children of vitamin A-deficient-supple-
mented group were given 100 000 IU
(retinol equivalent) vitamin A capsules ev-
ery 2 weeks for 3 months (Grubesic, 2004)
. Children of vitamin A-sufficient placebo
group and vitamin A-deficient placebo
group received placebo capsules in the same
way.”
Blinding?
Blinding of provider
Unclear risk Although studywas double randomised trial
but no details of how blinding was achieved
was described in the district
Blinding?
Blinding of outcome assessor
Unclear risk Insufficient detail provided to make judge-
ment.
Incomplete outcome data addressed? Low risk No attrition reported.
Free of selective reporting? High risk Main outcome data are not reported in a
manner that can be analysed
Free of other bias? Unclear risk As blinding is not described, potential per-
formance bias and other sources of bias can-
not be assessed
Lin 2009
Methods Individual randomised trial conducted in rural China, Asia.
Participants Children age 6 months to 7 years were included in the study. Those without informed
consent or with acute
and chronic diseases were excluded.
A total of 132 children were randomly allocated to three intervention groups. Mean age
of children was 36.5 months and proportion of males was 50%
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Interventions The three intervention groups included vitamin A, beta-carotene and placebo. The ex-
perimental group received 100 000 IU of vitamin A every month for 3 months. Placebo
group received biscuits
Outcomes Mean vitamin A serum levels
Notes We have included the results for vitamin A group versus placebo only
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “The 50 severe vitamin A deficient chil-
dren and 82 marginal vitamin A deficient
children were randomly divided into three
groups respectively by using a tablewith ran-
domly assorted digits.”
Probably done.
Allocation concealment? Unclear risk No methods of allocation concealment are
described in the text
Blinding?
Blinding of Participants
High risk “Vitamin A intervening group were admin-
istered 100,000 IU vitamin A capsules...the
beta-carotene intervening group...was ad-
ministered 4 mg purified beta-carotene...
dissolved in vegetable oil and dropped into
a general little biscuit...the placebo group
were just administered a general little bis-
cuit.”
VitaminA andplacebowere administered in
two different forms. Vitamin A was admin-
istered in capsule form while placebo was
given in the form of biscuits
Blinding?
Blinding of provider
High risk VitaminA andplacebowere administered in
two different forms. Vitamin A was admin-
istered in capsule form while placebo was
given in the form of biscuits
Blinding?
Blinding of outcome assessor
High risk VitaminA andplacebowere administered in
two different forms. Vitamin A was admin-
istered in capsule form while placebo was
given in the form of biscuits
Incomplete outcome data addressed? Low risk Nodropouts reported, and numbers at base-
line and follow-up appear to be the same
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Free of selective reporting? High risk Use of clinic services, hospitalisation, cause
specific morbidity not reported
Free of other bias? Low risk This study appears to be free of other bias.
Long 2006
Methods Factorial design, individually randomised trial conducted in La Magdalena Atlicpac, Mex-
ico, North America
Participants Children aged 6 to 15 months were eligible for inclusion in the review. Children who
were suffering from diseases causing immunosuppression and any congenital or acquired
alteration of the digestive tract that could alter the absorption of micronutrients, were
excluded. Children who were taking vitamin supplements were also excluded
from the study.
A total of 786 children were randomised to four intervention groups. Mean age of partic-
ipants was 9.8 months. The proportion of males in study population was 51.7%
Interventions The four intervention groups were as follows:
1) Vitamin A group that received 20,000 IU retinol every 2 months for children aged < 1
year or 45,000 IU for children aged > 1 year.
2) Zn group that received a daily dose equivalent to 20mg elemental Zn as zincmethionine
3) A group that received both the zinc supplement and the vitamin A as above
4) A placebo group
Interventions were delivered every 2 months for 12 months.
Outcomes Diarrhoea and respiratory disease morbidity.
Notes Wehave includeddata of this factorial design trial in two sets. First data set give comparisons
for vitamin A vs. placebo and the second set includes data for vitamin A + Zinc vs. zinc
only. Data on respiratory morbidity was given with three definitions. We have pooled
the data for “cough + difficulty breathing” under the heading of lower respiratory tract
infection
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “The randomisation sequence was gener-
ated by using a random-number table by
project personnel from CENSIA, a division
of the Mexican Ministry of Health.”
Allocation concealment? Low risk “These solutions were packaged in con-
secutively numbered, colour-coded, opaque
plastic droplet bottles to ensure that field
personnel and the principal investigator
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were blinded.”
Blinding?
Blinding of Participants
Low risk “The vitamin A, zinc, and vitamin A + zinc
supplements were prepared by personnel at
the National Institute of Nutrition in 5-mL
solutions that were similar in taste and ap-
pearance.”
Blinding?
Blinding of provider
Low risk “This double-blind randomised trial ...
These solutions were packaged in consecu-
tively numbered, color-coded, opaque plas-
tic droplet bottles to ensure that field per-
sonnel and the principal investigator were
blinded.”
Blinding?
Blinding of outcome assessor
Low risk “This double-blind randomised trial ...
These solutions were packaged in consecu-
tively numbered, color-coded, opaque plas-
tic droplet bottles to ensure that field per-
sonnel and the principal investigator were
blinded.”
Probably done.
Incomplete outcome data addressed? Low risk Lost to follow-up data given along with rea-
sons for lost to follow-up.Ninety- three chil-
dren were lost to follow-up or were excluded
Free of selective reporting? Unclear risk Study protocol not available so cannot assess
or make any judgement
Free of other bias? Low risk This study appears to be free of other bias.
Long 2006 (2)
Methods
Participants
Interventions
Outcomes
Notes As Long 2006 above.
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Methods Individually randomised trial conducted in Mexico, North America
Participants Children 5-15 months were eligible for inclusion in the trial. Those who were immuno-
suppressed, had any congenital abnormality or chronic diarrhoea were excluded. Those
who had a history of vitamin A supplementation were also excluded
A total of 195 children were randomised in which 97 were in vitamin A group and 98 in
placebo group. The proportion of males study population was 49.7%
Interventions The experimental group received vitamin A in a dose of 20,000 IU for those aged < 12
months and 45,000 IU for those > 12 months. Intervention was repeated every 2 months
for 12 months
Outcomes Incidence of diarrhoea and respiratory disease.
Notes The baseline socio-demographic characteristics of study children and households were
similar between children who received vitamin A and those who were given the placebo.
Children received monthly visits and referrals to the doctor, which appeared to exceed
normal treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “The randomisation sequence was gener-
ated by project personnel based at the Na-
tional Institute of Public Health.”
Probably done.
Allocation concealment? Low risk Personnel at theNational Institute of Nutri-
tion carried out the preparation of the sup-
plements to assure that field personnel and
the principal investigator were unaware of
treatment regimen. Children in the vitamin
A and placebo groups received a 5ml solu-
tion, from identical opaque plastic droplet
bottles numbered consecutively, adminis-
tered by the field team
Blinding?
Blinding of Participants
Low risk “Testing had been carried out at the Na-
tional Institute of Nutrition to assure that
the placebo and vitamin A water miscible
solution were similar in taste, viscosity and
colour.”
Blinding?
Blinding of provider
Low risk “Personnel at the National Institute of Nu-
trition carried out the preparation of the
supplements to assure that field personnel
and the principal investigator were unaware
of treatment regimen.”
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Blinding?
Blinding of outcome assessor
Low risk “Personnel at the National Institute of Nu-
trition carried out the preparation of the
supplements to assure that field personnel
and the principal investigator were unaware
of treatment regimen.”
Incomplete outcome data addressed? Low risk Unclear what was done with data for 7miss-
ing children, but dropoutwas small and sim-
ilar between groups (4 intervention, 3 con-
trol)
Free of selective reporting? Unclear risk Protocol not referenced, though the grant
applications may be available
Free of other bias? Low risk This study appears to be free of other bias.
Pant 1996
Methods Cluster randomised trial in rural Nepal, Asia.
Participants Children aged between 6 months and 10 years were eligible to participate in the study
From 100 potentially eligible cluster sites, 75 were randomised (approximately 25,301
children). Baseline data on the number in each treatment group, proportion of male
participants and mean age were not provided
Interventions The intervention groups were:
1. Vitamin A given as a single dose via a capsule (100,000 IU for children aged 6 to 12
months and 200,000 IU for children aged 1 to 10 years)
2. Control (not adequately described)
3. Nutritional education
Study duration: 24 months.
Outcomes All- cause mortality and Bitot’s spots.
Notes No details on loss to follow- up were given. Inclusion/exclusion criteria were inadequately
described. No nominators/denominators were available for Bitot’s spots
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “Using random number tables and the ref-
erence number for each block ...”
Allocation concealment? Unclear risk Insufficient detail provided to make judg-
ment.
63Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pant 1996 (Continued)
Blinding?
Blinding of Participants
Unclear risk Insufficient detail provided to make judg-
ment.
Blinding?
Blinding of provider
Unclear risk Insufficient detail provided to make judg-
ment.
Blinding?
Blinding of outcome assessor
Unclear risk Insufficient detail provided to make judg-
ment.
Incomplete outcome data addressed? High risk No information regarding incomplete out-
come data addressed given
Free of selective reporting? High risk Very specific outcomes reported. Five types
of examinations were administered to the
study children: ophthalmic, physical, an-
thropometric, blood, and faecal; while data
in results is given only for prevalence of
Bitot’s spots and all-cause mortality
Free of other bias? Unclear risk Insufficient detail provided to make judg-
ment.
Pinnock 1986
Methods Individually randomised study in urban area of Australia.
Participants Children aged between 1 and 4 years of age in three general practices from Adelaide.
Children with more than 15 days of cough or three separate episodes of respiratory illness
during the preceding 3 months were eligible
147 children were randomised to the treatment groups. Mean age was 39.3 months. 50%
of the sample was male
Interventions Vitamin A administered orally as retinyl palmitate (1160mcg) three times per week for 20
weeks versus placebo
Outcomes Acute respiratory infections, pneumonia, mean serum vitamin A
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “Randomization of treatment was achieved
by combining active and placebo bottles in a
sequence, whichwas determinedby consult-
ing a table of random numbers, and num-
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bering the bottles accordingly.”
Probably done.
Allocation concealment? Unclear risk Insufficent information to permit judg-
ment.
Blinding?
Blinding of Participants
Low risk “The placebo was a similarly constituted
syrup omitting retinyl palmitate and la-
belled and bottled identically.”
Blinding?
Blinding of provider
Low risk “All staff connectedwith the study remained
blind to the identity of the child’s medica-
tion.”
Blinding?
Blinding of outcome assessor
Low risk “All staff connectedwith the study remained
blind to the identity of the child’s medica-
tion.”
Incomplete outcome data addressed? Low risk A high rate of attrition, but reasons for with-
drawal given and that there were no signif-
icant changes in the distribution of major
potential confounding factors between the
two groups
Free of selective reporting? Unclear risk The protocol of the study not available.
Free of other bias? Low risk No other apparent bias was observed.
Pinnock 1988
Methods Individually randomised study in urban area of Australia.
Participants Children aged between 0 and 2 years with previous history of bronchiolitis and nasal
culture positive for HSV were included
Children taking vitamin A, and those with cystic fibrosis, cardiopulmonary difficulties,
major brain dysfunctions were excluded
206 children were randomised to the treatment groups. Mean age was 58 months. 60%
sample was male
Interventions Vitamin A administered as retinyl palmitate 4.2mg per week for 12 months versus placebo
Outcomes Diarrhoea, diarrhoea-related hospitalisation, acute respiratory infections, pneumonia,
pneumonia-related hospitalisation, mean serum vitamin A
Notes
Risk of bias
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Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “Randomization was achieved by randomly
allocating four of eight batch numbers to
Vitamin A supplement and the remaining
four to placebo. The batch number codewas
retained by the manufacturer.”
Allocation concealment? Low risk “The batch number code was retained by
the manufacturer. The bottles were then
distributed sequentially according to batch
number as children presented...”
Probably done.
Blinding?
Blinding of Participants
Low risk “The placebo had an identical appearance
and formulation except for the active ingre-
dient.”
Probably done.
Blinding?
Blinding of provider
Low risk “Both investigators and parents were blind
as to the treatment status of the child.”
Blinding?
Blinding of outcome assessor
Low risk “Both investigators and parents were blind
as to the treatment status of the child ...
The batch number code was retained by the
manufacturer.”
Incomplete outcome data addressed? Low risk Complete details of those excluded and lost
to follow-up were provided
Free of selective reporting? High risk Outcomes mentioned in methods not re-
ported in results.
Free of other bias? Low risk This study appears to be free of other bias.
Rahman 2001
Methods Individually randomised study conducted in an urban area of Bangladesh, Asia
Participants Children aged between 12 and 35 months were eligible for inclusion in the study
Children who had received Vitamin A within the previous 4 months, had severe malnutri-
tion, with signs or symptoms of vitamin A or zinc deficiency, or with any systemic illness
such as diarrhoea, respiratory infection, fever, or any other illness that warranted medical
intervention at the time of enrolment were excluded
800 children were enrolled (200 in each of the four treatment groups). Mean age of
participants was between 23.5 and 24.2 months across the treatment groups. 56% of the
participants were male
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Interventions There were four treatment groups:
1. Vitamin A 200,000 IU (60 mg) given as a single capsule at day 14, with placebo syrup
daily for 14 days
2. Placebo capsule at day 14 and placebo syrup for 14 days.
3. Vitamin A 200,000 IU (60 mg) given as a single capsule at day 14, with zinc syrup daily
for 14 days
4. Zinc syrup daily for 14 days, placebo capsule at day 14.
Duration of study: 6 months.
Outcomes Diarrhoea, acute respiratory infections, serum vitamin A levels and vitamin deficiency
Notes Data on treatment analysis was not presented. We have written to authors for data on each
treatment arm
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “The children were randomly assigned by a
person not involved in the study who used
permuted blocks of random numbers.”
Probably done.
Allocation concealment? Low risk “Sets of 2 bottles and 1 capsule for each child
were serially numbered ... A local pharma-
ceutical company prepared the study syrups
(zinc and placebo) which were supplied in
identical 50-mL bottles ... The vitamin A
and placebo capsules looked identical.”
Probably done.
Blinding?
Blinding of Participants
Low risk “The zinc and placebo syrups were sup-
plied in bottles that looked identical, and
the appearance and consistency of the syrups
were similar. Vitamin A and placebo cap-
sules were identical in appearance.”
Probably done.
Blinding?
Blinding of provider
Low risk Identical presentation and: ’The randomi-
sation code was kept sealed until the com-
pletion of the study.’
Probably done.
Blinding?
Blinding of outcome assessor
Low risk “The treatment allocations were disclosed
after the final analysis.”
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Incomplete outcome data addressed? Low risk Data on lost to follow-up given and also
stated that the baseline characteristics of
children who were excluded or lost to fol-
low-upwere comparable to those of the chil-
dren who continued in the study
Free of selective reporting? Unclear risk Protocol not available.
Free of other bias? Low risk No other bias was noticed.
Rahmathullah 1990
Methods Cluster-randomised trial conducted in Trichy district of Tamil Nadu in southern India,
Asia
Participants Children aged 6 to 60 months were included in the study.
Clustering unit was “panchyat” (local-government areas). A total of 206 clusters were
formed, and the majority of them consisted of 50 to 100 children.The included clusters
had a total of 15,419 children of whom 7764 were in vitamin A group and 7655 in placebo
group
Interventions Children in experimental group received weekly doses of 8333 IU vitamin A and 20 mg
vitamin E. The control group received 20 IU of vitamin E only in peanut oil. Any children
diagnosed with xerophthalmia at baseline, midterm, or final examination was given a high-
dose (200 000 IU) supplement of vitamin A and continued in the study. Supplementations
were given for 52 weeks. Children who missed 7 consecutive dosages were excluded from
the analysis
Outcomes All-cause mortality, cause specific mortality of diarrhoea, measles and respiratory disease.
Incidence of diarrhoea and respiratory disease morbidity
Notes The baseline characteristics of the two groups were similar in terms of age and sex, one-
month history of diarrhoea and respiratory disease, anthropometric indexes of nutritional
status, xerophthalmia status, five-year retrospective history of mortality of children under
five, household economic, household hygienic status, and serum retinol levels. On average
> 90% of the children were contacted each week, and the lowest coverage in any single
week was 88%. 11% had clinical evidence of xerophthalmia while about 38% had serum
retinol concentrations < 0.35 mmol/L at baseline
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “The clusters were arranged according to
population size; after a random start, they
were assigned alternately to the treated or
control groups.”
Exact method of sequence generation was
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not provided.
Allocation concealment? Low risk “...no one associated with the study was
aware of the colour code, which was held
by the Hoffmann-LaRoche until the study
ended.”
Blinding?
Blinding of Participants
Low risk “The appearance and taste of the solutions
were identical ... no one associated with the
study was aware of the colour code, which
was held by the Hoffmann-LaRoche until
the study ended.”
Probably done.
Blinding?
Blinding of provider
Low risk “The appearance and taste of the solutions
were identical ... no one associated with the
study was aware of the colour code, which
was held by the Hoffmann-LaRoche until
the study ended ... masked controlled...”
Probably done.
Blinding?
Blinding of outcome assessor
Low risk “The appearance and taste of the solutions
were identical ... no one associated with the
study was aware of the colour code, which
was held by the Hoffmann-LaRoche until
the study ended ... masked controlled...”
Incomplete outcome data addressed? Low risk “There was no difference in rates of contact
between the treated and control groups. The
reasons for lack of contact included moving
from the study area ...”
Reasons for lost to follow-up given with a
note that there was no difference in contact
rates between the two groups
Free of selective reporting? Low risk All important outcomes given in results as
mentioned in the methods section
Free of other bias? Low risk No other apparent bias was noticed.
Ramakrishnan 1995
Methods Individually randomised trial conducted in rural India, Asia
Participants Children aged 6-36 months were eligible for inclusion in the trial. Those with ophthalmic
signs of xerophthalmia, serious diseases, or severe malnutrition (< 60% of weight-for-age
or < 85% of height-for-age of the National Center for Health Statistics median) were
excluded and received appropriate treatment including vitamin A
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A total of 538 children were included, 309 in vitamin A group and 274 in placebo group.
Mean age of children was 18.6 months and proportion males was 49.9%
Interventions Children in experimental group received vitamin A in a dose of 100,000 IU for children
aged < 1 year and 200,000 IU for children aged > 1 year. The comparison group received
only placebo. The interventions were given every 4 months for 12 months
Outcomes Incidence of diarrhoea and respiratory disease.
Notes Definition used for respiratory disease was too generalised to be included under lower
respiratory tract infection. It mainly covered upper respiratory tract infections
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “The study design was a randomised, dou-
ble-blind, placebo controlled intervention
trial in which every 4 mo the treatment
group received a high-dose vitamin A sup-
plement and the control group received a
placebo.”
Insufficient detail provided.
Allocation concealment? Unclear risk Insufficent information to permit judg-
ment.
Blinding?
Blinding of Participants
Low risk “The study design was a randomised, dou-
ble-blind, placebo controlled intervention
trial in which every 4 mo the treatment
group received a high-dose vitamin A sup-
plement and the control group received a
placebo.”
Statement that blinding occurred, no fur-
ther details provided
Blinding?
Blinding of provider
Low risk “The study design was a randomised, dou-
ble-blind, placebo controlled intervention
trial in which every 4 mo the treatment
group received a high-dose vitamin A sup-
plement and the control group received a
placebo.”
Statement that blinding occurred, no fur-
ther details provided
Blinding?
Blinding of outcome assessor
Low risk “The study design was a randomised, dou-
ble-blind, placebo controlled intervention
trial in which every 4 mo the treatment
group received a high-dose vitamin A sup-
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plement and the control group received a
placebo.”
Statement that blinding occurred, no fur-
ther details provided
Incomplete outcome data addressed? Low risk “Out of the 660 children who were eligi-
ble, a final group of 592 children who had
both pre- and post-anthropometric mea-
surements were used in this analysis. The
losses at follow-up due tomigration (n = 50)
, death (n = 10) and incomplete measure-
ments (n = 8) were similar for both groups.
”
Losses were not large and balanced between
groups; unlikely to introduce substantial
bias here. Clinically relevant impact unlikely
Free of selective reporting? High risk “The examination for ophthalmic signs of
vitamin A deficiency, using WHO criteria
(27), was conducted by trained ophthalmol-
ogists from the Department of Ophthal-
mology, CMCH, at baseline and at the end
of the 1-y follow-up period. Blood samples
were also taken (from finger pricks) at the
beginning and the end of the study by us-
ing 250-pt capillary tubes. Serum retinol
concentrations were estimated by using re-
versed-phase HPLC at the Wellcome Re-
search Laboratory, CMCH, Vellore, using
retinyl acetate and all trans-retinol (Sigma
Chemical Co, St Louis) as standards.”
Though measured, serum retinol results are
never reported.
Free of other bias? Low risk This study appears to be free of other bias.
Ranjini 2001
Methods Individually randomised trial conducted in India, Asia.
Participants Children aged 12-60 months and having recurrent respiratory tract infections were eligible
for inclusion in the trial. Those with mild or moderate asthma; children who were on
vitamin supplements or who had received a massive dose of vitamin A in the previous 6
months, those with pre-existing congenital heart disease, chronic lung disease, pulmonary
tuberculosis or immunodeficiency disorders, those on immunosuppressive drugs and those
with clinically apparent vitamin A deficiency were excluded
A total of 61 children were randomised in which 30 were in vitamin A group and 31 in
placebo group. The mean age of children was 35.7 months and proportion of males was
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60.7%
Interventions Children in experimental group received a single dose of vitamin A in a dose of 200 000
IU. The comparison group was given placebo in archis oil. Follow- up period was 6months
Outcomes Incidence of respiratory disease. Mean vitamin A serum levels
Notes Definition of respiratory illness used was not specific enough
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Eligible children were randomly allocated
to receive either 200,000 IU of vitamin A in
arachis oil or a placebo containing arachis
oil without vitamin A.”
Details of sequence generationnot specified.
Allocation concealment? Unclear risk Insufficent information to permit judg-
ment.
Blinding?
Blinding of Participants
Unclear risk “Eligible children were randomly allocated
to receive either 200,000 IU of vitamin A in
arachis oil or a placebo containing arachis
oil without vitamin A.”
Blinding?
Blinding of provider
Unclear risk Not mentioned.
Blinding?
Blinding of outcome assessor
Unclear risk Not mentioned.
Incomplete outcome data addressed? Unclear risk “Of the 61 included children, seven (three
in the placebo group and four in vitamin A
group) did not return for follow-up.” (sec-
ond page)
Authors do not address the reasons for losses
to follow- up, and given the small size of
this trial, bias may ormay not be introduced
depending on why the losses occurred by
group. given this lack of discussion, it is dif-
ficult to judge weather or not there is a low
or high risk of bias, but it is likely to be high
Free of selective reporting? Unclear risk “Details of doctor or outpatient visits and
hospital cough, wheezy breathing, shortness
of breath and fever.Details of doctor or out-
patient visits and hospital admissions during
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the study period were also recorded. Dur-
ing eachmonthly follow-up visit, the entries
in the monthly calendar were reviewed with
the parent.” (1st, 2nd page)
Hospitalisation was not reported though it
was collected.
Free of other bias? Unclear risk Very little information provided in the pa-
per; difficult to assess
Reddy 1986
Methods Factorial design individually randomised trial conducted in India, Asia
Participants Children aged 1-5 years were included in the study. Those without parental consent were
excluded
A total of 487 children were randomised to four intervention groups. Mean age and
proportion of males were not described
Interventions The four intervention groups were as follows:
Group A: oral administration of L-tetramisole (50 mg) followed 3 days later by a dose of
200 000 IU of vitamin A.
Group B: massive dose of vitamin A of 200 000 IU
Group C L-tetramisole (50 mg) orally.
Group D placebo.
Outcomes Mean vitamin A serum levels.
Notes Data have been included in two sets.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “After the baseline survey, the children
were assigned, randomly, into four groups,
matched for age, anthropometry, serum vi-
tamin A, and worm infestation and the fol-
lowing treatment was given.”
Insufficient details provided to make judge-
ment.
Allocation concealment? Unclear risk Insufficent information to permit judg-
ment.
Blinding?
Blinding of Participants
Unclear risk Insufficent information to permit judgment
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Blinding?
Blinding of provider
Unclear risk Insufficent information to permit judgment
Blinding?
Blinding of outcome assessor
Unclear risk Insufficent information to permit judgment
Incomplete outcome data addressed? Unclear risk Insufficent information to permit judgment
Free of selective reporting? Unclear risk “After 6 months and 12 months, heights
and weights were measured, clinical status
was assessed and morbidity for the preced-
ing one month was recorded. Finger-prick
blood samples were collected and serum vi-
tamin A levels were estimated, stool samples
were examined for the presence of ascaris
ova and other parasites.”
Authors do not report height or weights, or
detailed data on clinical status or morbidity
Free of other bias? Unclear risk Insufficent information to permit judg-
ment.
Reddy 1986 (2)
Methods
Participants
Interventions
Outcomes
Notes As Reddy 1986 above.
Ross 1993 HEALTH
Methods Randomised double-blind controlled trial conducted in guinea savannah area of Ghana,
Africa
Participants Children aged 6 to 59 months were included. Those with active xerophthalmia or measles
were excluded from the trial the moment them were confirmed
A total of 1455 children were included. The proportion of male children was 49.5%
Interventions Children in vitamin A group received either 200,000 IU retinol equivalent for participants
aged > 12 months or 100,000 IU for aged 6-12 months. The control group received
placebo. Interventions were given every 4 months for 12 months
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Outcomes All-cause mortality. Mean daily prevalence of respiratory tract disease, diarrhoea, measles,
malaria. Mean vitamin A serum levels, all-cause hospitalisations
Notes The study populations were rural and their main staple foods are deficient in carotenoids
and vitamin A. Vitamin A deficiency and xerophthalmia were recognised as problems
locally.Children were visited weekly for 1 year. Children in theHealth Study were followed
up 596 child-years for vitamin A group and 589 for control group. According to WHO,
Ghana is a country with a high child mortality rate (i.e. > 40/1000)
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Randomisation was blocked in both stud-
ies to ensure similar numbers of children in
each group in each part of the study area.”
Explicit methods for generating allocation
sequence not available
Allocation concealment? Low risk “Randomisation was carried out in London
by an independent statistician, who held the
randomisation code and who also did an in-
terim analysis of the mortality results from
the Survival Study for the trial’s data-moni-
toring committee after a year of follow-up.”
Code was protected for the duration of the
trial.
Blinding?
Blinding of Participants
Low risk “Vitamin A and placebo were supplied by
Hoffmann-La-Roche’s Sight and Life Pro-
gramme, and were similar in taste and
colour. In the Survival Study, liquid vitamin
A or placebo was supplied in opaque 150
mL bottles containing 20 IU/mL vitamin
E alone (placebo) or plus 100 000 IU/mL
retinol equivalent as retinyl palmitate (vita-
min A) in purified peanut oil. Each bottle
had a unique number, and was labelled with
a cluster code before despatch to Ghana.”
Blinding?
Blinding of provider
Low risk As above; probably done.
Blinding?
Blinding of outcome assessor
Low risk In view of the blinding procedures in place
elsewhere in the study this was probably ad-
equate
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Incomplete outcome data addressed? Unclear risk Morbidity information was missing for 5-
7% of the weekly follow-up visits owing to
temporary absences of the study children
or their mothers, but the missing data were
equally distributed between the treatment
groups
Free of selective reporting? High risk There was an indication that xerophthalmia
data were measured, but none are reported.
No protocol is available
Free of other bias? Low risk No other apparent bias was noted.
Ross 1993 SURVIVAL
Methods Cluster randomised trial conducted Ghana, Africa.
Participants Children aged 6-90 months were eligible for inclusion in the trial. Xeropthalmic children
were excluded
Study involved 185 cluster that included 21906 children. Proprtion of male children was
51.5%
Interventions The experimental group received vitamin A supplementation in a dose of 100 000 IU for
children aged 6-11 months and 200,000 IU for older children. The comparison group
received placebo. Vitamin E in a dose of 20 IU was given to both the groups. Intervention
were delivered every 4 months for 24 months
Outcomes All-cause mortality and cause specific mortality of diarrhoea, respiratory disease, measles
and meningitis. Mean vitamin A serum levels. Malaria prevalence
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Randomisation was blocked in both stud-
ies to ensure similar numbers of children in
each group in each part of the study area.”
Explicit methods for generating allocation
sequence not available
Allocation concealment? Low risk “Randomisation was carried out in London
by an independent statistician, who held the
randomisation code and who also did an in-
terim analysis of the mortality results from
the Survival Study for the trial’s data-moni-
toring committee after a year of follow-up.”
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Code was protected for the duration of the
trial.
Blinding?
Blinding of Participants
Low risk “Vitamin A and placebo were supplied by
Hoffmann-La-Roche’s Sight and Life Pro-
gramme, and were similar in taste and
colour. In the Survival Study, liquid vitamin
A or placebo was supplied in opaque 150
mL bottles containing 20 IU/mL vitamin
E alone (placebo) or plus 100 000 IU/mL
retinol equivalent as retinyl palmitate (vita-
min A) in purified peanut oil. Each bottle
had a unique number, and was labelled with
a cluster code before despatch to Ghana.”
Probably done.
Blinding?
Blinding of provider
Low risk As above; probably done.
Blinding?
Blinding of outcome assessor
Low risk In view of the blinding procedures in place
elsewhere in the study this was probably ad-
equate
Incomplete outcome data addressed? Unclear risk 8.4% (1847) children lost to follow-up and
similar between treatment groups
The reasons for losses to follow-up are not
provided.
Free of selective reporting? High risk Authors collected data on night blindness,
Bitot’s spots, and xerophthalmia but do not
report it
Free of other bias? Unclear risk Themethod for inflating theCIs is not well-
described. No ICC reported
Semba 1992
Methods Individually randomised trial conducted in Indonesia, Asia.
Participants Children aged 3-6 years were eligible for inclusion in the study. Those who had median
weight for age <80% of the National Center for Health Statistics were excluded from
the study. Children with serious illness were also excluded from the study and treated
appropriately
A total of 236 children were randomised to four intervention groups. Mean age of partic-
ipants was 58.9 months and proportion of males was 71.6%
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Interventions There were 4 intervention groups. Two groups (vitamin A and placebo) had clinical signs
of vitamin A deficiency while two groups were clinically normal
Participants in vitamin A groups received a single dose of 60 000 microgram of retinol
equivalent. Children were followed for one month
Outcomes Mean vitamin A serum levels.
Notes The 2 vitamin A and 2 placebo groups were combined, respectively, for meta- analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “A double-masked, randomised, placebo-
controlled, clinical trial involving 236
preschool children, age 3-6 years, was car-
ried out at the outpatient clinic of the Ci-
cendo Eye Hospital in Bandung, West Java,
Indonesia.”
Details of sequence generation not pro-
vided.
Allocation concealment? Low risk “The treatment code was broken after the
conclusion of the study.”
Allocation sequence appears to have been
protected.
Blinding?
Blinding of Participants
Low risk “A double-masked, randomised, placebo-
controlled, clinical trial involving 236
preschool children.”
“The vitamin A and placebo solutions were
supplied in coded containers, and the iden-
tity of the solutions was known only to the
manufacturer... The solutions were identi-
cal in colour, taste, smell and consistency.”
Blinding?
Blinding of provider
Low risk As above; providers likely to have been ade-
quately blinded.
Blinding?
Blinding of outcome assessor
Unclear risk The provider administering vitamin A and
the outcome assessor appear to be differ-
ent individuals and it is not clearly stated if
the outcome assessors were also blinded to
group assignment
Incomplete outcome data addressed? Low risk 232/236 children enrolled at baseline com-
pleted the study protocol. (page 102)
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Free of selective reporting? Unclear risk Does not reference a protocol or trial regis-
tration and does not state that all measured
outcomes are reported
Free of other bias? Unclear risk Insufficient information to permit judg-
ment.
Semba 1995
Methods Individually randomised study in rural Indonesia, Asia.
Participants Children aged 6 months at vaccination against measles were included
Children who had measles previously were excluded.
336 children were randomised to the two treatment groups. Baseline details on age and
gender were not provided
Interventions Vitamin A given as a single dose (100,000 IU) versus placebo
Vitamin A or placebo given with measles vaccine.
Study duration: 6 months.
Outcomes Measles.
Notes The primary objective of the study was to measure the antibody response to measles
vaccine when given along with vitamin A or placebo. Trialists found a significant decrease
in seroconversion of measles vaccine in the intervention group compared to placebo
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “Treatment was assigned by random num-
ber table in blocks of ten.”
Probably done.
Allocation concealment? Low risk “Infants received identification numbers as
they were enrolled in the study, and each
identification number had an envelope with
an identical capsule containing either vita-
min A or placebo.”
Probably done.
Blinding?
Blinding of Participants
Low risk “VitaminA, 100 000 IU, or placebo in iden-
tical capsules.”
Probably done.
Blinding?
Blinding of provider
Low risk “Infants received identification numbers as
they were enrolled in the study, and each
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identification number had an envelope with
an identical capsule containing either vita-
min A or placebo.”
Probably done.
Blinding?
Blinding of outcome assessor
Low risk As above; probably done.
Incomplete outcome data addressed? High risk “Follow-up rates were 93% and 90% at one
and six months post immunisation, respec-
tively.”
The reasons for lost to follow-up not given;
only available case data given
Free of selective reporting? Unclear risk Study protocol was not available.
Free of other bias? Unclear risk Inadequate information presented to assess
this formally.
Sempertegui 1999
Methods Indivdualy randomised trial conducted in the northwestern region of the Quito, Ecuador,
South America
Participants Children aged 6 to 36 months were eligible for inclusion in the review. Those children
who had clinical vitamin A deficiency, who did not reliably stayed at home or at day care
centres during weekdays or who had been given multivitamins in the last 3 months, were
excluded
A total of 400 children were randomised either to vitamin A or placebo group with equal
(200 each) in both the groups. Mean age of participants was 21.1 months and half of the
study population was male
Interventions Children in the supplement-treated group received a weekly dose of 10,000 IU of vitamin
A for 40 weeks, and children in the non-supplement group received a weekly placebo for
the same period
Outcomes Incidence of diarrhoea and respiratory disease morbidity. Mean vitamin A serum levels
Notes The baseline study characteristics were comparable in both the groups. Study was con-
ducted in a slum with substantial rates of malnutrition and subclinical vitamin A defi-
ciency. Morbidity surveillance was done weekly
Risk of bias
Bias Authors’ judgement Support for judgement
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Adequate sequence generation? Low risk “For random allocation of each child to
treatment or placebo group the following
procedure was performed. Identical flasks
containing vitamin A or placebo were num-
bered from 1 to 400 by members of the
study team in Boston, Massachusetts. The
local Ethical Committee of the Ecuado-
rian Biotechnology Corporation in Quito
did not know the identity of the active or
placebo flasks, because they did not have the
code. Then, this committee assigned each
flask to a specific child from a random list by
using a table of random numbers. After ran-
domisation, the ethical committee received
the confidential code from Boston.”
Allocation concealment? Low risk “After randomisation, the ethical committee
received the confidential code from Boston
and kept it for the remainder of the study,
when it was revealed.”
Blinding?
Blinding of Participants
Low risk “Identical flasks containing vitamin A or
placebo were numbered from 1 to 400 by
members of the study team in Boston, Mas-
sachusetts.”
Trial described as double blind; given pro-
cedures used for ensuring that intervention
and placebo were identical, it is very likely
that blinding of children was maintained
Blinding?
Blinding of provider
Low risk “The syrups were administered at home and
at day care centres by study researchers who
were blinded to the presence or absence of
active drug.”
Blinding?
Blinding of outcome assessor
Low risk Outcome assessors were the same as the
providers, therefore blinded
Incomplete outcome data addressed? Low risk “A total of 306 children finished the study,
because 50 children from the supplement-
treated group and 44 from the non- supple-
mented group were lost to follow-up when
their families moved to other neighbour-
hoods.Of all children, 70%, including those
lost to follow-up, accumulated >30 weeks
of observation... Children with incomplete
follow-upwere distributed evenly in relation
to the baseline variables (Table 2).”
Loss to follow-up similar in magnitude in
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both groups and for similar reasons. Some
lost still contributed data
Free of selective reporting? Unclear risk Protocol referred to but not referenced. Not
explicitly stated if all measured outcomes
were reported
Free of other bias? Low risk No other apparent bias was noted
Shankar 1999
Methods This study was an individually randomised trial conducted in Guinea Bissau, Africa
Participants Children aged 6-60 months and those who plan to reside within the study area for at
least 1 year were eligible for inclusion in the trial. Those with ocular signs of vitamin A
deficiency or history of night blindness were excluded
A total of 480 children were randomised either to vitamin A or placebo group. The vitamin
A group had 239 participants whole placebo group 241. Proportion of males in the study
population was 51%
Interventions The experimental group received vitamin A supplementation in a dose of 100 000 IU for
children aged < 1 year and 200,000 IU for older children. The comparison group received
placebo. Both the groups received 20 IU of vitamin E. Intervention was given every 4
months for 13 months
Outcomes Incidence of diarrhoea and malaria morbidity. Mean vitamin A serum levels
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk “Within these strata, children were indi-
vidually allocated vitamin A or placebo in
blocks of four (two vitamin A, two placebo)
by computer generated randomly permu-
tated codes.”
Allocation concealment? Low risk “Capsules were encoded into four groups;
two placebo and two vitamin A, and the
code was kept offsite by personnel who were
not involved in the study.”
Blinding?
Blinding of Participants
Low risk Identical capsules, and allocation was con-
cealed and code kept off site. Described as
double-blind
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Blinding?
Blinding of provider
Low risk As above; probably done.
Blinding?
Blinding of outcome assessor
Low risk Unlikely that the trained village-based mor-
bidity worker knew the assignments, how-
ever this is never stated explicitly
Probably done.
Incomplete outcome data addressed? Low risk “Cross sectional follow-up rates for mid-
study and end of study were 428 of
480 (89%) and 410 of 480 (85%), re-
spectively, and similar for vitamin A and
placebo groups. During the trial two chil-
dren dropped out, 66 moved out of the
study area, and two died.”
Intention-to-treat used. Missing outcome
data balanced in numbers across groups
Free of selective reporting? Unclear risk Protocol not referenced and not stated that
all measured outcomes were reported. Data
at 7 months not completely reported
Free of other bias? Low risk No other apparent bias was noted.
Sinha 1976
Methods Individually randomised trial conducted in India, Asia.
Participants Children aged 2 months to 4.5 years were eligible for inclusion in the trial. No exclusion
criteria was described
A total of 306 children were randomised either to vitamin A or placebo group in equal
numbers (153 in each group)
Interventions Children in experimental group received vitamin A in a dose of 200 000 IU every 4months
for 12 months. The comparison group received placebo only
Outcomes Bitot spots. Side effects; vomiting.
Notes The people in the study population were extremely poor.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “The children were divided in two groups
of 153 each (two of the children died in the
1st year and two left the village) and were
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matched for age, sex, socioeconomic status,
and playmate contacts. One of the children
of each matched pair was selected randomly
for receiving vitamin A and the other child
received a placebo.”
Nodetail about randomisationmethod pro-
vided.
Allocation concealment? Unclear risk “In a separate laboratory, the designated 2-
ml dose of vitamin A or placebo for each
child was put into a vial labelled with the
child’s number and the vials were then
shipped to the field station for distribution.
Neither the clinician nor the paramedical
workers, who personally fed vitamin A and
placebo or examined the children for the
signs and symptoms of vitaminA deficiency,
knew which children received vitamin A.”
Insufficient details provided.
Blinding?
Blinding of Participants
Low risk “Neither the clinician nor the paramedical
workers, who personally fed vitamin A and
placebo or examined the children for the
signs and symptoms of vitaminA deficiency,
knew which children received vitamin A.”
Probably done.
Blinding?
Blinding of provider
Low risk “Neither the clinician nor the paramedi-
cal workers, who personally fed vitamin A
and placebo or examined the children for
the signs and symptoms of vitamin A de-
ficiency, knew which children received vi-
tamin A.” “The placebo consisted of de-
odorized arachis oil which was coloured and
favoured with orange to match exactly the
vitamin A preparation.”
Provider blinded.
Blinding?
Blinding of outcome assessor
Low risk “Neither the clinician nor the paramedical
workers, who personally fed vitamin A and
placebo or examined the children for the
signs and symptoms of vitaminA deficiency,
knew which children received vitamin A.”
Incomplete outcome data addressed? Unclear risk Based on the outcome data reported it does
not seem that any children dropped out (i.
e., there were no losses); however, this could
be because the authors are conducting an in-
tent-to-treat analysis but never say so. They
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are not explicit in this regard, as such the
risk of bias due to incomplete outcome data
is unclear
Free of selective reporting? Unclear risk Does not reference a protocol or trial regis-
tration and does not state that all measured
outcomes are reported
Free of other bias? Low risk No other apparent bias was noted.
Smith 1999
Methods Factorial design, individually randomised trial conducted in Belize, Central America
Participants Children aged 2.2 to 5.5 years were eligible for inclusion in the trial. Those with fever or
serious respiratory illness were excluded
A total of 51 children were randomised to four intervention groups. Mean age of children
were 46.3 months
Interventions The four intervention groups were as follow:
Vitamin A only; received 10 000 IU vitamin A
Zinc only; received 70 mg zinc
Vitamin A + Zinc; received vitamin A and zinc in above mentioned dosage
Placebo
Duration of study was for 6 months.
Outcomes Vitamin A serum level.
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “The children selected were randomly as-
signed to receive one of the following sup-
plements once per week: placebo; Zn, 70
mg as Zn gluconate; vitamin A, 3030 RE as
retinyl palmitate; or a combination of vita-
min A and Zn.”
Stated to be randomised, but no further data
reported.
Allocation concealment? Unclear risk Insufficient details provided.
Blinding?
Blinding of Participants
Unclear risk “Supplements were ingested orally in an
orange flavoured powder (10 g), Tangt
(Kraft General Foods Inc,White Plains, NY
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10625) prepared as a beverage dissolved in
approximately 120 mL of water.”
Stated to be “double-blind” in the article
keywords, but there appear to be no de-
tails about blinding methods in the text.
The intervention (or no intervention in the
placebo group) were diluted in the same so-
lution, so presumably all groups were iden-
tical
Blinding?
Blinding of provider
Unclear risk Not adequately reported.
Blinding?
Blinding of outcome assessor
Unclear risk Not adequately reported.
Incomplete outcome data addressed? Unclear risk Insufficient details provided; losses not ac-
counted for by group and small sample size
makes this especially relevant
Free of selective reporting? Unclear risk Does not reference a protocol or trial regis-
tration and does not state that all measured
outcomes are reported
Free of other bias? Unclear risk Insufficient details provided.
Sommer 1986
Methods Cluster randomised trial conducted in a rural area of Indonesia, Asia
Participants Children aged between 0 and 5 years were included. Children with active xerophthalmia
were excluded from the study
29,236 children from 450 villages (cluster sites) in Java. 50% of the sample were male
Interventions Vitamin A (capsules administered twice over the course of the study: 200,000 IU of
Vitamin A) was compared with a no treatment control group that served as a waiting list
control
40 IU of vitamin E was also administered with vitamin A.
Duration of study: 9-13 months.
Outcomes Mortality, diarrhoea, Bitot’s spots, night blindness, xerophthalmia
Notes ICC not reported (confidence intervals from analyses reported to have been adjusted for
design effect). TJL back-calculated an ICC of 0.008307 from effect estimate provided in
paper
Vitamin A was not intended to have been distributed to children under the age of 12
months, but it would appear that some 0 to 12 month old children received the vitamin
A capsule. Outcome data were reported on a cohort of 0 to 12 month old children
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Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “From a random start, 450 villages were sys-
tematically selected for the study; these were
then randomised for capsule distribution af-
ter the baseline examination...”
Inadequate information provided.
Allocation concealment? Unclear risk Inadequate informationwas presented in or-
der to assess this item in relation to timing
of recruitment into the study
Blinding?
Blinding of Participants
Unclear risk “The Government of Indonesia would not
condone the use of placebos but field-work-
ers collecting demographic data were un-
aware that mortality was a research issue.”
Described as a controlled study, without ad-
equate description of what control group re-
ceived
Blinding?
Blinding of provider
Unclear risk “The Government of Indonesia would not
condone the use of placebos but field-work-
ers collecting demographic data were un-
aware that mortality was a research issue.”
Described as a controlled study, without ad-
equate description of what control group re-
ceived
Blinding?
Blinding of outcome assessor
Unclear risk “The Government of Indonesia would not
condone the use of placebos but field-work-
ers collecting demographic data were un-
aware that mortality was a research issue.”
Described as a controlled study, without ad-
equate description of what control group re-
ceived
Incomplete outcome data addressed? Unclear risk “Follow-up information was available on
89% of the programme children and 88.4%
of the controls.”
Authors indicate percent remaining per
group at follow- up, but nothing more de-
tailed
Free of selective reporting? Unclear risk Trial protocol not available.
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Free of other bias? Unclear risk Insufficent information to permit judge-
ment.
Stabell 1995
Methods Individually randomised trial conducted in Guinea Bissau, Africa
Participants Children aged 6 months of age years were eligible for inclusion in the trial
A total of 68 children were included in which 32 were in vitamin A group and 36 in
placebo
Interventions Children in the intervention group received vitamin A in a dose of 100 000 IU at the time
of measles vaccination at age of 6 and 9 months. The comparison group received placebo
only
Outcomes Side effects: Bulging fontanelle.
Notes Denominator data not entirely clear in Table 1 of the study.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Carrying out a double-blinded, ran-
domised, placebo-controlled trial.”
Sequence generation not mentioned in the
paper.
Allocation concealment? Unclear risk Nothing mentioned regarding allocation
concealment.
Blinding?
Blinding of Participants
Unclear risk Claimed it was blinded but no detail pro-
vided.
Blinding?
Blinding of provider
Unclear risk Claimed it was blinded but no detail pro-
vided.
Blinding?
Blinding of outcome assessor
Unclear risk Children were examined by one of us (C.S.)
to see if their fontanelle was normal, sunken
or bulging
Appears outcome assessors were the same in-
dividuals as the investigators
Incomplete outcome data addressed? Unclear risk Losses to follow-up by group indicated but
no detail provided. Unclear what losses ac-
tually occurred in Table 1
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Free of selective reporting? Unclear risk No protocol referenced, nor statement that
all measured outcomes were reported
Free of other bias? Unclear risk Short communication, insufficient detail to
make an informed judgment
Stansfield 1993
Methods This randomised, placebo-controlled was conducted north west of Haiti, Latin America
Participants Children aged 6 to 83 months were included in the study. Those with corneal changes
consistent with vitamin A deficiency, withmeasles and those had received vitamin Awithin
the past 4 months were excluded
A total of 13651 childrenwere found to be eligible for inclusion in the trial. The proportion
of males in the study population was 49%
Interventions The vitamin A group received 100,000 IU supplements every 4 months for 3 distribution
cycle for those 6 to 11 months and 200,000 IU for the older, while the other group only
received placebo
Outcomes 2 week prevalence of signs of respiratory tract infections: cold, cough and rapid breathing
and diarrhoea
Notes A slightly larger number of children (55%) were assigned to vitamin A group. There was
a significant difference between 2 study groups with respect to age. Study area had a high
prevalence of malnutrition and xerophthalmia in the study population. Children were
visited every 2 weeks for 12 months. The respiratory disease morbidity was reported with
respect to cold, cough and rapid breathing which were too non- specific for inclusion
under umbrella of pneumonia or lower respiratory tract infection morbidity in our review
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? High risk Quote from the author: “A random num-
ber generator was used to number the first
household and the households were num-
bered sequentially thereafter. Every other
household was given a green capsule, while
the rest were given red capsules.”
Alternate allocation.
Allocation concealment? Low risk Quote from the author: “The manufacturer
(Roche) held the code until the study was
completed.”
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Blinding?
Blinding of Participants
Low risk “The colour code was held only by theman-
ufacturer until the study was completed.”
Probably done.
Blinding?
Blinding of provider
Low risk “Before the study inquiries among health
workers and community members had indi-
cated no symbolism associated with or pref-
erence for either green or red.”
Highly unlikely that providers would be bi-
ased about a single intervention
Blinding?
Blinding of outcome assessor
Low risk “The colour code was held only by theman-
ufacturer until the study was completed.”
Probably done.
Incomplete outcome data addressed? Low risk “The frequency of non-participation was es-
sentially identical among children fromeven
and odd-numbered households.”
Probably done.
Free of selective reporting? High risk “We did not collect data on the impact of
supplementation on vitamin A status, or on
the incidence, duration, or severity of symp-
toms of infection.”
Only mortality and morbidity outcomes
given. Protocol not available
Free of other bias? Low risk This study appears to be free of other bias.
van Agtmaal 1988
Methods Individually randomised, non-placebo trial conducted in Thailand, Asia
Participants Participants had a mean age of 3.1 years. No exclusion criteria was described
Study included 30 children in which 14 were in vitamin A group and 21 in control group
Interventions Children in experimental group received a single dose vitamin A in a dose of 200 000 IU.
Study participants were followed for 4 months
Outcomes Mean vitamin A serum levels.
Notes Children were recruited from three rural day care centres.
Risk of bias
Bias Authors’ judgement Support for judgement
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Adequate sequence generation? Unclear risk “After selection, 14 children were randomly
supplemented with a single, oral dose of
vitamin A (110 mg retinylpalmitate, 200,
000 IU),according to WHO recommenda-
tions (9). and 21 children served as a control
group.”
Inadequate information provided.
Allocation concealment? Unclear risk Inadequate information provided.
Blinding?
Blinding of Participants
Unclear risk Inadequate information provided.
Blinding?
Blinding of provider
Unclear risk Inadequate information provided.
Blinding?
Blinding of outcome assessor
Unclear risk Inadequate information provided.
Incomplete outcome data addressed? High risk “Due to the absence of some children at the
different time points the number of data
available for statistical analysis was less than
the total number of children involved in this
study ... the number of children fromwhom
complete data sets could be collected was
rather low.”
No comprehensive data given on lost to fol-
low-up nor reasons for loss
Free of selective reporting? High risk Does not report data on serum retinol levels,
which were collected/measured
Free of other bias? Unclear risk Inadequate information provided.
Venkatarao 1996
Methods Individual randomised trial conducted in India, Asia.
Participants Infants aged 6 months were included. Proportion of males in the study was 50%
A total of 909 infants were randomised to three intervention groups
Interventions The three intervention groups were as follows:
Group AA: Mother received and infants both received vitamin A
Group AP: Mother received vitamin A while infant received placebo
Group PP: Both mother and infant received placebo.
Dose of vitamin A for infant was 200 000 IU.
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Outcomes All-cause mortality and cause specific mortality of diarrhoea and respiratory disease. Inci-
dence of diarrhoea and respiratory disease morbidity
Notes We have included the data for groups AA vs. AP.
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “Each pair of subjects enrolled for the study
was randomly allocated to one of the follow-
ing three groups: (i) AA-Both mother and
infant received Vitamin A, the former soon
after delivery and the latter at 6 months;
(ii) AP: Mother received Vitamin A but her
infant received a placebo (Sesame oil); and
(iii) PP: Both mother and infant received
placebo, the former Vitamin E and the lat-
ter Sesame oil.”
Insufficient detail to form judgment.
Allocation concealment? Unclear risk Insufficient detail to form judgment.
Blinding?
Blinding of Participants
Low risk “At the age of 6 to 6Vi months, the infant
was weighed again and given the appropri-
ate syrup by theMedical Officer from coded
bottles, supplied again by the Statistical Sec-
tion at the Camp Office.”
Probably done.
Blinding?
Blinding of provider
Low risk As above; probably done.
Blinding?
Blinding of outcome assessor
Low risk As above; probably done.
Incomplete outcome data addressed? Unclear risk “4 each in the AA and AP groups and 5 in
the PP group were withdrawn from the trial
on medical grounds such as congenital ab-
normalities, epileptic fits or jaundice. Mi-
gration accounted for the loss of 34 infants
in the AA group, 25 in the AP group and 20
in the PP group while 7, 9 and 7 were ex-
cluded due to other miscellaneous reasons.
Of the remaining 263, 255 and 256 infants
in the three group, 233 in the AA and 228
each in theAP andPPgroupswere followed-
up very regularly and form the basis for anal-
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yses in this report.”
They provided specific information about
losses by group. However, it is unclear why
263, 255 and 256 infants that remain in the
three group after attrition is described results
in only 233 in the AA and 228 each in the
AP and PP groups being used as the basis
for analysis
Free of selective reporting? Low risk Does not reference a protocol or trial reg-
istration and do not state that all measured
outcomes are reported
Free of other bias? Low risk “Quality control of the morbidity data col-
lected by the field investigators was under-
taken throughout. As long recall periods
pose problems, the collection of morbidity
data was intensified from once a fortnight
to once a week when the study had been in
progress for 9 months.”
Authors attempted to minimise other biases
such as recall bias, though specific details of
“quality control” are not provided
Vijayaraghavan 1990
Methods Cluster randomised study in rural India, Asia.
Participants Children aged 1-5 years were eligible for entry in the study. Children with corneal involve-
ment were excluded from the review
15,775 children in 84 clusters were randomised to the treatment groups. 50.4% partici-
pants were male
Interventions Vitamin A given twice (200,000 IU) versus placebo (archis oil)
Study duration: not clear.
Outcomes Mortality, diarrhoea, acute respiratory infections, measles.
Notes Respiratory infection has non-specific definition of “clinically significant cough”
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “The villages were allocated randomly into
two groups-treatment and control.”
Insufficient detail to form judgment.
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Vijayaraghavan 1990 (Continued)
Allocation concealment? Unclear risk Insufficient detail provided.
Blinding?
Blinding of Participants
Low risk “The trial was double blind: the investi-
gators and medical officers did not know
which were the treatment and which were
the control areas. They were not aware
whether the dose they were distributing was
vitamin A or placebo. Decoding was done
only after data had been collected.”
Blinding?
Blinding of provider
Low risk As above; probably done.
Blinding?
Blinding of outcome assessor
Low risk As above probably done.
Incomplete outcome data addressed? Unclear risk Insufficient detail provided.
Free of selective reporting? High risk Incidence of infections outcome not given
with respect to vitamin A and control
groups. Given according to the clinical vita-
min A status of all the study children
Free of other bias? Low risk This study appears to be free of other bias.
West 1991
Methods Cluster randomised study in rural Nepal, Asia.
Participants Children aged between 0 and 5 years were eligible for the study. Children with xeroph-
thalmia were included. Children who had recently participated in a Vitamin A programme
were excluded from the study
28,630 children in 261 clusters were recruited. 51.3% sample was male
Interventions Vitamin A (100,000 IU for 6-11 months and 200,000 IU for children 12 months and
older) administered 1 to 3 times was compared with a very low dose of vitamin A (1000
IU). Both supplements contained 40 IU vitamin E
Study duration:16 months.
Outcomes Mortality, cause-specific mortality, Bitot’s spots, night blindness, xerophthalmia
Notes ICC not disclosed, although study estimates reported to have been adjusted for the unit
of allocation
Study had additional recruitment phases in second and third treatment cycles. 1807 and
2018 children entered at 4 and 8 months
Risk of bias
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West 1991 (Continued)
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Unclear risk “After blocking on the local development
area, the 261 wards were randomly assigned
to receive vitamin A supplementation or
placebos at 4-month intervals.”
Inadequately described to permit judgment.
Allocation concealment? Unclear risk “Both the investigators and communities
were masked to the random assignment.”
The study was a cluster-designed trial and
there was insufficient information to de-
termine whether allocation took place be-
fore or after treatment group assignmentwas
known
Blinding?
Blinding of Participants
Low risk “The supplements were given as single-dose
gelatin capsules of identical taste and ap-
pearance.”
Blinding?
Blinding of provider
Low risk As above; probably done.
Blinding?
Blinding of outcome assessor
Low risk As above; probably done.
Incomplete outcome data addressed? Unclear risk “All analyses were carried out on an in-
tention-to-treat basis. Computed mortality
rates were based on child-years of observa-
tion.”
“...all children living in wards which re-
ceived high dose vitamin A every 4 months
were considered to have been treated with
vitamin A, and all children living in wards
which received placebowere considered ’un-
treated.”’
The rates of withdrawal were balanced be-
tween the treatment groups and the data
were analysed based on patient years of ob-
servation. The unclear reasons for with-
drawals, variable duration of follow-up due
to more than recruitment cycle and the
low rate of mortality in relation to the
withdrawal rates mean that it is uncertain
whether the study is at risk of attrition bias
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West 1991 (Continued)
Free of selective reporting? Low risk Complete data for all time points were avail-
able for the review. The last available obser-
vation reported in a follow-up article gave
a RR for mortality slightly higher than that
for the 12 month data given in the primary
study report (0.74 versus 0.7)
Free of other bias? Low risk A method for estimating the ICCs was re-
ported in Katz 1988 (Journal of interna-
tional epidemiology)
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bahl 1997 The study included children currently having diarrhoea.
Bhaskaram 1997 The study was not a randomised controlled trial.
Bloem 1990 The study was not a randomised controlled trial. The mean age of children was 6.6 years (range 3-9 years)
Kothari 1991 The study was not a randomised controlled trial.
Semba 1990 Vitamin A was given as a therapeutic intervention for Bitot’s spots
Semba 2005 The study population consisted of children infected with HIV
Wu 2007 The study was not a randomised controlled trial.
Yang 2002 Other micronutrients were supplemented with vitamin A and these supplements were not balanced out in the
control group. It was difficult to disaggregate the effect of vitamin A
Characteristics of studies awaiting assessment [ordered by study ID]
Aklamati 2006
Methods Individually randomised, placebo-controlled trial conducted in Zambia, Africa
Participants Boys 3-4 years old were eligible for inclusion in the trial. A total of 36 children were included in the trial in which
19 were in vitamin A and 17 in placebo group
Interventions The intervention group received a single dose of 60 mg vitamin A and control group received the same amount of
placebo
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Aklamati 2006 (Continued)
Outcomes Mean plasma retinol levels, prevalence of fever, diarrhoea, rhinorrhoea, cough and malaria
Notes Data were available only in the form of abstract and the numbers do not match given in the results section of abstract.
It was decided among the group to wait for publication of this study before we include it in the review
DEVTA trial 2007
Methods Cluster-randomised trial conducted in Northern India, Asia.
Participants Children aged 1-6 years were eligible for inclusion in the review. Total clusters were 72 in which 36 clusters received
vitamin A supplementation while 36 acted as control. Authors claim to include a total of 1 million children in the
trial
Interventions Children in experimental group received 200,000 IU of vitamin A every 6-months for 5 years. Vitamin A was
supplemented on mass treatment days by village child care workers
Outcomes All-cause mortality, cause specific mortality of diarrhoea, pneumonia, measles and malnutrition. Mean vitamin A
serum levels, incidence of Bitot’s spots and prevalence of measles and pneumonia morbidity
Notes This is the largest randomised controlled trial conducted on vitamin A but has not been published yet. The current
data is based on the abstract presented in ILSI Micronutrient Forum, Istanbul, 16-18 April 2007. It does not contain
detail information on conduct of trial neither it give details on attrition of the study. We contacted all the authors of
the trial multiple times and asked for more details on methods and results but did not receive any positive response.
As we did not have sufficient information on methods and outcome we decided to wait for publication of results of
this large trial. We aim to include that in the next update of this review
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D A T A A N D A N A L Y S E S
Comparison 1. Vitamin A versus Control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality (all-cause) at Longest
Follow-up
17 Risk Ratio (Fixed, 95% CI) 0.76 [0.69, 0.83]
2 Mortality (all-cause) at Longest
Follow-up (by Age)
5 Risk Ratio (Fixed, 95% CI) Subtotals only
2.1 6 to 12 months old 4 Risk Ratio (Fixed, 95% CI) 0.59 [0.43, 0.82]
2.2 1 to 5 years old 4 Risk Ratio (Fixed, 95% CI) 0.68 [0.57, 0.81]
3 Mortality (all-cause) at Longest
Follow-up (by Sex)
5 Risk Ratio (Fixed, 95% CI) Subtotals only
3.1 Males 5 Risk Ratio (Fixed, 95% CI) 0.80 [0.66, 0.97]
3.2 Females 5 Risk Ratio (Fixed, 95% CI) 0.79 [0.65, 0.95]
4 Mortality (all-cause) at Longest
Follow-up (Sensitivity Analysis
including DEVTA trial)
18 Risk Ratio (Fixed, 95% CI) 0.88 [0.84, 0.94]
5 Mortality due to Diarrhoea at
Longest Follow-up
7 Risk Ratio (Fixed, 95% CI) 0.72 [0.57, 0.91]
6 Mortality due to Measles at
Longest Follow-up
5 Risk Ratio (Fixed, 95% CI) 0.80 [0.51, 1.24]
7 Mortality due to Meningitis at
Longest Follow-up
3 Risk Ratio (Fixed, 95% CI) 0.57 [0.17, 1.88]
8 Mortality due to LRTI at
Longest Follow-up
7 Risk Ratio (Fixed, 95% CI) 0.78 [0.54, 1.14]
9 Diarrhoea Incidence at Longest
Follow-up
13 Risk Ratio (Fixed, 95% CI) 0.85 [0.82, 0.87]
10 Diarrhoea Prevalence at
Longest Follow-up
3 Risk Ratio (Fixed, 95% CI) 1.08 [1.05, 1.12]
11 Measles Incidence at Longest
Follow-up
6 Risk Ratio (Fixed, 95% CI) 0.50 [0.37, 0.67]
12 Malaria Incidence at Longest
Follow-up
1 174132 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.60, 0.88]
13 Malaria Prevalence at Longest
Follow-up
2 Risk Ratio (Fixed, 95% CI) 0.73 [0.41, 1.28]
14 Lower Respiratory Tract
Infection Incidence at Longest
Follow-up
9 Risk Ratio (Fixed, 95% CI) 1.14 [0.95, 1.37]
15 Bitot’s Spots Prevalence at
Longest Follow-up
4 Risk Ratio (Fixed, 95% CI) 0.45 [0.33, 0.61]
16 Night Blindness Incidence at
Longest Follow-up
1 Risk Ratio (Fixed, 95% CI) 0.53 [0.28, 0.99]
17 Night Blindness Prevalence at
Longest Follow-up
2 Risk Ratio (Fixed, 95% CI) 0.32 [0.21, 0.50]
18 Xerophthalmia Incidence at
Longest Follow-up
3 Risk Ratio (Fixed, 95% CI) 0.85 [0.70, 1.03]
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19 Xerophthalmia Prevalence at
Longest Follow-up
2 Risk Ratio (Fixed, 95% CI) 0.31 [0.22, 0.45]
20 Vitamin A Deficient at Longest
Follow-up
4 2262 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.65, 0.78]
21 Vitamin A Serum Level at
Longest Follow-up
14 6623 Std. Mean Difference (IV, Fixed, 95% CI) 0.31 [0.26, 0.36]
22 Hospitalisation, Number of
Children Hospitalised Once or
More at Longest Follow-up
1 1185 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.40, 1.02]
23 Hospitalisation due to
Diarrhoea at Longest Follow-up
1 172 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.01, 6.11]
24 Hospitalisation due to Lower
Respiratory Tract Infection at
Longest Follow-up
1 172 Risk Ratio (M-H, Fixed, 95% CI) 0.11 [0.01, 2.06]
25 Side effect - Bulging Fontanelle 3 885 Risk Ratio (M-H, Fixed, 95% CI) 5.0 [0.24, 103.72]
26 Side effect - Vomiting 3 2994 Risk Ratio (M-H, Fixed, 95% CI) 2.75 [1.81, 4.19]
Analysis 1.1. Comparison 1 Vitamin A versus Control, Outcome 1 Mortality (all-cause) at Longest Follow-
up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 1 Mortality (all-cause) at Longest Follow-up
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Lin 2008 0 (0) Not estimable
Dibley 1994 -1.12232882 (1.63299316) 0.1 % 0.33 [ 0.01, 7.99 ]
Barreto 1994 0 (0.99838579) 0.2 % 1.00 [ 0.14, 7.08 ]
Chowdhury 2002 -1.94194975 (0.75418055) 0.4 % 0.14 [ 0.03, 0.63 ]
Venkatarao 1996 -1.00252208 (0.67056359) 0.5 % 0.37 [ 0.10, 1.37 ]
Benn 1997 -0.77629472 (0.59367542) 0.7 % 0.46 [ 0.14, 1.47 ]
Donnen 1998 -0.51082562 (0.48464603) 1.0 % 0.60 [ 0.23, 1.55 ]
Ross 1993 HEALTH -1.21578729 (0.46547467) 1.1 % 0.30 [ 0.12, 0.74 ]
Agarwal 1995 0.19717994 (0.31208317) 2.5 % 1.22 [ 0.66, 2.25 ]
Vijayaraghavan 1990 0.01685569 (0.2971801) 2.7 % 1.02 [ 0.57, 1.82 ]
Pant 1996 -0.56211892 (0.222204) 4.9 % 0.57 [ 0.37, 0.88 ]
Rahmathullah 1990 -0.77652879 (0.21976998) 5.0 % 0.46 [ 0.30, 0.71 ]
0.005 0.1 1 10 200
Favours experimental Favours control
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Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Sommer 1986 -0.30788478 (0.15462932) 10.1 % 0.73 [ 0.54, 1.00 ]
Daulaire 1992 -0.30110509 (0.14994833) 10.7 % 0.74 [ 0.55, 0.99 ]
Herrera 1992 0.05826891 (0.13093651) 14.1 % 1.06 [ 0.82, 1.37 ]
West 1991 -0.35667494 (0.11530445) 18.1 % 0.70 [ 0.56, 0.88 ]
Ross 1993 SURVIVAL -0.21072103 (0.09323125) 27.8 % 0.81 [ 0.67, 0.97 ]
Total (95% CI) 100.0 % 0.76 [ 0.69, 0.83 ]
Heterogeneity: Chi2 = 29.10, df = 15 (P = 0.02); I2 =48%
Test for overall effect: Z = 5.66 (P < 0.00001)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours experimental Favours control
Analysis 1.2. Comparison 1 Vitamin A versus Control, Outcome 2 Mortality (all-cause) at Longest Follow-
up (by Age).
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 2 Mortality (all-cause) at Longest Follow-up (by Age)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 6 to 12 months old
Benn 1997 -0.77629472 (0.59367542) 7.8 % 0.46 [ 0.14, 1.47 ]
Rahmathullah 1990 -1.27296568 (0.57282345) 8.4 % 0.28 [ 0.09, 0.86 ]
Daulaire 1992 -0.67334455 (0.277413) 35.7 % 0.51 [ 0.30, 0.88 ]
West 1991 -0.24846136 (0.23890578) 48.1 % 0.78 [ 0.49, 1.25 ]
Subtotal (95% CI) 100.0 % 0.59 [ 0.43, 0.82 ]
Heterogeneity: Chi2 = 3.51, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 3.18 (P = 0.0015)
2 1 to 5 years old
0.2 0.5 1 2 5
Favours experimental Favours control
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Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Rahmathullah 1990 -0.7070956 (0.22771697) 15.6 % 0.49 [ 0.32, 0.77 ]
Sommer 1986 -0.29453409 (0.20231495) 19.7 % 0.74 [ 0.50, 1.11 ]
Daulaire 1992 -0.24486372 (0.19475576) 21.3 % 0.78 [ 0.53, 1.15 ]
West 1991 -0.38720694 (0.13644798) 43.4 % 0.68 [ 0.52, 0.89 ]
Subtotal (95% CI) 100.0 % 0.68 [ 0.57, 0.81 ]
Heterogeneity: Chi2 = 2.72, df = 3 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 4.32 (P = 0.000015)
Test for subgroup differences: Chi2 = 0.54, df = 1 (P = 0.46), I2 =0.0%
0.2 0.5 1 2 5
Favours experimental Favours control
Analysis 1.3. Comparison 1 Vitamin A versus Control, Outcome 3 Mortality (all-cause) at Longest Follow-
up (by Sex).
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 3 Mortality (all-cause) at Longest Follow-up (by Sex)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Males
Lin 2008 0 (0) Not estimable
Daulaire 1992 -0.32850407 (0.20687375) 21.8 % 0.72 [ 0.48, 1.08 ]
Sommer 1986 -0.52763274 (0.20154834) 23.0 % 0.59 [ 0.40, 0.88 ]
Herrera 1992 0.22314355 (0.19562474) 24.4 % 1.25 [ 0.85, 1.83 ]
West 1991 -0.26136476 (0.17449675) 30.7 % 0.77 [ 0.55, 1.08 ]
Subtotal (95% CI) 100.0 % 0.80 [ 0.66, 0.97 ]
Heterogeneity: Chi2 = 7.79, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 2.26 (P = 0.024)
2 Females
0.2 0.5 1 2 5
Favours Vitamin A Favours control
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Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Lin 2008 0 (0) Not estimable
Daulaire 1992 -0.27443685 (0.23161713) 16.7 % 0.76 [ 0.48, 1.20 ]
Sommer 1986 -0.08664781 (0.22406373) 17.9 % 0.92 [ 0.59, 1.42 ]
Herrera 1992 -0.07257069 (0.17488653) 29.3 % 0.93 [ 0.66, 1.31 ]
West 1991 -0.43078292 (0.15751191) 36.1 % 0.65 [ 0.48, 0.89 ]
Subtotal (95% CI) 100.0 % 0.79 [ 0.65, 0.95 ]
Heterogeneity: Chi2 = 2.87, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.52 (P = 0.012)
Test for subgroup differences: Chi2 = 0.02, df = 1 (P = 0.89), I2 =0.0%
0.2 0.5 1 2 5
Favours Vitamin A Favours control
Analysis 1.4. Comparison 1 Vitamin A versus Control, Outcome 4 Mortality (all-cause) at Longest Follow-
up (Sensitivity Analysis including DEVTA trial).
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 4 Mortality (all-cause) at Longest Follow-up (Sensitivity Analysis including DEVTA trial)
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Lin 2008 0 (0) Not estimable
Dibley 1994 -1.12232882 (1.63299316) 0.0 % 0.33 [ 0.01, 7.99 ]
Barreto 1994 0 (0.99838579) 0.1 % 1.00 [ 0.14, 7.08 ]
Chowdhury 2002 -1.94194975 (0.75418055) 0.1 % 0.14 [ 0.03, 0.63 ]
Venkatarao 1996 -1.00252208 (0.67056359) 0.2 % 0.37 [ 0.10, 1.37 ]
Benn 1997 -0.77629472 (0.59367542) 0.2 % 0.46 [ 0.14, 1.47 ]
Donnen 1998 -0.51082562 (0.48464603) 0.4 % 0.60 [ 0.23, 1.55 ]
Ross 1993 HEALTH -1.21578729 (0.46547467) 0.4 % 0.30 [ 0.12, 0.74 ]
0.02 0.1 1 10 50
Favours experimental Favours control
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Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Agarwal 1995 0.19717994 (0.31208317) 0.9 % 1.22 [ 0.66, 2.25 ]
Vijayaraghavan 1990 0.01685569 (0.2971801) 1.0 % 1.02 [ 0.57, 1.82 ]
Pant 1996 -0.56211892 (0.222204) 1.7 % 0.57 [ 0.37, 0.88 ]
Rahmathullah 1990 -0.77652879 (0.21976998) 1.7 % 0.46 [ 0.30, 0.71 ]
Sommer 1986 -0.30788478 (0.15462932) 3.5 % 0.73 [ 0.54, 1.00 ]
Daulaire 1992 -0.30110509 (0.14994833) 3.7 % 0.74 [ 0.55, 0.99 ]
Herrera 1992 0.05826891 (0.13093651) 4.9 % 1.06 [ 0.82, 1.37 ]
West 1991 -0.35667494 (0.11530445) 6.3 % 0.70 [ 0.56, 0.88 ]
Ross 1993 SURVIVAL -0.21072103 (0.09323125) 9.7 % 0.81 [ 0.67, 0.97 ]
DEVTA 2007 -0.040821 (0.03587) 65.2 % 0.96 [ 0.89, 1.03 ]
Total (95% CI) 100.0 % 0.88 [ 0.84, 0.94 ]
Heterogeneity: Chi2 = 44.31, df = 16 (P = 0.00018); I2 =64%
Test for overall effect: Z = 4.26 (P = 0.000021)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours experimental Favours control
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Analysis 1.5. Comparison 1 Vitamin A versus Control, Outcome 5 Mortality due to Diarrhoea at Longest
Follow-up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 5 Mortality due to Diarrhoea at Longest Follow-up
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Venkatarao 1996 -1.63103702 (1.54640217) 0.6 % 0.20 [ 0.01, 4.05 ]
Agarwal 1995 -0.20721746 (0.97927464) 1.4 % 0.81 [ 0.12, 5.54 ]
Chowdhury 2002 -1.09465189 (0.81487815) 2.0 % 0.33 [ 0.07, 1.65 ]
Rahmathullah 1990 -0.73396918 (0.35365302) 10.8 % 0.48 [ 0.24, 0.96 ]
Ross 1993 SURVIVAL -0.40047757 (0.28906104) 16.2 % 0.67 [ 0.38, 1.18 ]
Herrera 1992 0.00995033 (0.20011557) 33.8 % 1.01 [ 0.68, 1.50 ]
Daulaire 1992 -0.43078292 (0.1963524) 35.1 % 0.65 [ 0.44, 0.96 ]
Total (95% CI) 100.0 % 0.72 [ 0.57, 0.91 ]
Heterogeneity: Chi2 = 6.12, df = 6 (P = 0.41); I2 =2%
Test for overall effect: Z = 2.81 (P = 0.0050)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours experimental Favours control
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Analysis 1.6. Comparison 1 Vitamin A versus Control, Outcome 6 Mortality due to Measles at Longest
Follow-up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 6 Mortality due to Measles at Longest Follow-up
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Daulaire 1992 -0.40047757 (1.15075061) 3.8 % 0.67 [ 0.07, 6.39 ]
Agarwal 1995 -0.08776798 (0.82108156) 7.5 % 0.92 [ 0.18, 4.58 ]
Herrera 1992 -0.01005034 (0.81548188) 7.6 % 0.99 [ 0.20, 4.90 ]
Rahmathullah 1990 -0.54472718 (0.61845066) 13.2 % 0.58 [ 0.17, 1.95 ]
Ross 1993 SURVIVAL -0.19845094 (0.27307681) 67.8 % 0.82 [ 0.48, 1.40 ]
Total (95% CI) 100.0 % 0.80 [ 0.51, 1.24 ]
Heterogeneity: Chi2 = 0.40, df = 4 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours experimental Favours control
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Analysis 1.7. Comparison 1 Vitamin A versus Control, Outcome 7 Mortality due to Meningitis at Longest
Follow-up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 7 Mortality due to Meningitis at Longest Follow-up
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Agarwal 1995 1.75683202 (4.64421868) 1.7 % 5.79 [ 0.00, 52017.39 ]
Chowdhury 2002 -1.60548273 (1.54834208) 15.5 % 0.20 [ 0.01, 4.18 ]
Ross 1993 SURVIVAL -0.41551544 (0.67018608) 82.8 % 0.66 [ 0.18, 2.45 ]
Total (95% CI) 100.0 % 0.57 [ 0.17, 1.88 ]
Heterogeneity: Chi2 = 0.75, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours experimental Favours control
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Analysis 1.8. Comparison 1 Vitamin A versus Control, Outcome 8 Mortality due to LRTI at Longest Follow-
up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 8 Mortality due to LRTI at Longest Follow-up
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Agarwal 1995 0.65812976 (2.04734345) 0.9 % 1.93 [ 0.03, 106.79 ]
Chowdhury 2002 -2.1932694 (1.48982732) 1.6 % 0.11 [ 0.01, 2.07 ]
Venkatarao 1996 -2.41949439 (1.47417023) 1.7 % 0.09 [ 0.00, 1.60 ]
Rahmathullah 1990 -0.41960374 (0.97794112) 3.8 % 0.66 [ 0.10, 4.47 ]
Daulaire 1992 -0.0512933 (0.46262388) 17.0 % 0.95 [ 0.38, 2.35 ]
Herrera 1992 -0.84397007 (0.44990332) 18.0 % 0.43 [ 0.18, 1.04 ]
Ross 1993 SURVIVAL 0 (0.25229866) 57.1 % 1.00 [ 0.61, 1.64 ]
Total (95% CI) 100.0 % 0.78 [ 0.54, 1.14 ]
Heterogeneity: Chi2 = 7.00, df = 6 (P = 0.32); I2 =14%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Vitamin A versus Control, Outcome 9 Diarrhoea Incidence at Longest Follow-
up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 9 Diarrhoea Incidence at Longest Follow-up
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Ramakrishnan 1995 0 (0) Not estimable
Arya 2000 -0.05239118 (0.37658957) 0.2 % 0.95 [ 0.45, 1.99 ]
Florentino 1990 0.06586282 (0.17621784) 0.8 % 1.07 [ 0.76, 1.51 ]
Cheng 1993 -0.908 (0.148) 1.1 % 0.40 [ 0.30, 0.54 ]
Herrera 1992 -0.56211892 (0.14529176) 1.2 % 0.57 [ 0.43, 0.76 ]
Biswas 1994 -0.24965025 (0.12277836) 1.6 % 0.78 [ 0.61, 0.99 ]
Venkatarao 1996 0.00509449 (0.09449959) 2.7 % 1.01 [ 0.84, 1.21 ]
Long 2007 -0.08320386 (0.09312839) 2.8 % 0.92 [ 0.77, 1.10 ]
Sempertegui 1999 0.07696104 (0.08224603) 3.6 % 1.08 [ 0.92, 1.27 ]
Shankar 1999 0.15829506 (0.08218736) 3.6 % 1.17 [ 1.00, 1.38 ]
Dibley 1994 0.06023817 (0.05528549) 8.0 % 1.06 [ 0.95, 1.18 ]
Chowdhury 2002 -0.483344 (0.0297044) 27.6 % 0.62 [ 0.58, 0.65 ]
Barreto 1994 -0.05304077 (0.02280902) 46.8 % 0.95 [ 0.91, 0.99 ]
Total (95% CI) 100.0 % 0.85 [ 0.82, 0.87 ]
Heterogeneity: Chi2 = 218.62, df = 11 (P<0.00001); I2 =95%
Test for overall effect: Z = 10.73 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Vitamin A versus Control, Outcome 10 Diarrhoea Prevalence at Longest
Follow-up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 10 Diarrhoea Prevalence at Longest Follow-up
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Long 2006 (2) -0.14912003 (0.07061765) 6.1 % 0.86 [ 0.75, 0.99 ]
Long 2006 0.23629885 (0.06888881) 6.5 % 1.27 [ 1.11, 1.45 ]
Stansfield 1993 0.0861777 (0.01873184) 87.4 % 1.09 [ 1.05, 1.13 ]
Total (95% CI) 100.0 % 1.08 [ 1.05, 1.12 ]
Heterogeneity: Chi2 = 15.78, df = 2 (P = 0.00038); I2 =87%
Test for overall effect: Z = 4.65 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Vitamin A versus Control, Outcome 11 Measles Incidence at Longest Follow-
up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 11 Measles Incidence at Longest Follow-up
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Bahl 1999 -0.84729786 (0.68535975) 4.9 % 0.43 [ 0.11, 1.64 ]
Barreto 1994 -0.58778667 (0.55487413) 7.5 % 0.56 [ 0.19, 1.65 ]
Benn 1997 -0.75382186 (0.53127063) 8.2 % 0.47 [ 0.17, 1.33 ]
Herrera 1992 -0.51082562 (0.46579746) 10.7 % 0.60 [ 0.24, 1.49 ]
Semba 1995 -0.59969157 (0.30298271) 25.2 % 0.55 [ 0.30, 0.99 ]
Chowdhury 2002 -0.79838607 (0.2303533) 43.6 % 0.45 [ 0.29, 0.71 ]
Total (95% CI) 100.0 % 0.50 [ 0.37, 0.67 ]
Heterogeneity: Chi2 = 0.55, df = 5 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 4.61 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Vitamin A versus Control, Outcome 12 Malaria Incidence at Longest Follow-
up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 12 Malaria Incidence at Longest Follow-up
Study or subgroup Vitamin A Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shankar 1999 178/86184 249/87948 100.0 % 0.73 [ 0.60, 0.88 ]
Total (95% CI) 86184 87948 100.0 % 0.73 [ 0.60, 0.88 ]
Total events: 178 (Vitamin A), 249 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.22 (P = 0.0013)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Vitamin A versus Control, Outcome 13 Malaria Prevalence at Longest Follow-
up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 13 Malaria Prevalence at Longest Follow-up
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Ross 1993 HEALTH -0.26678172 (0.44848533) 41.9 % 0.77 [ 0.32, 1.84 ]
Ross 1993 SURVIVAL -0.35762368 (0.38106886) 58.1 % 0.70 [ 0.33, 1.48 ]
Total (95% CI) 100.0 % 0.73 [ 0.41, 1.28 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Vitamin A versus Control, Outcome 14 Lower Respiratory Tract Infection
Incidence at Longest Follow-up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 14 Lower Respiratory Tract Infection Incidence at Longest Follow-up
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Barreto 1994 0 (0) Not estimable
Venkatarao 1996 0 (0) Not estimable
Cheng 1993 -1.37951467 (1.14438444) 0.7 % 0.25 [ 0.03, 2.37 ]
Kartasasmita 1995 0.12656272 (0.35766972) 6.7 % 1.13 [ 0.56, 2.29 ]
Biswas 1994 -0.37970097 (0.35042279) 7.0 % 0.68 [ 0.34, 1.36 ]
Long 2007 0.4069042 (0.31700189) 8.6 % 1.50 [ 0.81, 2.80 ]
Rahmathullah 1990 0.00995033 (0.27014451) 11.8 % 1.01 [ 0.59, 1.72 ]
Sempertegui 1999 -0.05286182 (0.19176712) 23.5 % 0.95 [ 0.65, 1.38 ]
Chowdhury 2002 0.33021493 (0.14380055) 41.7 % 1.39 [ 1.05, 1.84 ]
Total (95% CI) 100.0 % 1.14 [ 0.95, 1.37 ]
Heterogeneity: Chi2 = 7.66, df = 6 (P = 0.26); I2 =22%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Vitamin A versus Control, Outcome 15 Bitot’s Spots Prevalence at Longest
Follow-up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 15 Bitot’s Spots Prevalence at Longest Follow-up
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
West 1991 -1.07022431 (0.42961474) 13.3 % 0.34 [ 0.15, 0.80 ]
Sommer 1986 -1.64309041 (0.36822214) 18.1 % 0.19 [ 0.09, 0.40 ]
Sinha 1976 -0.54361545 (0.27338933) 32.9 % 0.58 [ 0.34, 0.99 ]
Pant 1996 -0.52763274 (0.26293555) 35.6 % 0.59 [ 0.35, 0.99 ]
Total (95% CI) 100.0 % 0.45 [ 0.33, 0.61 ]
Heterogeneity: Chi2 = 7.59, df = 3 (P = 0.06); I2 =60%
Test for overall effect: Z = 5.15 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 Vitamin A versus Control, Outcome 16 Night Blindness Incidence at Longest
Follow-up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 16 Night Blindness Incidence at Longest Follow-up
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Herrera 1992 -0.63638856 (0.31997024) 100.0 % 0.53 [ 0.28, 0.99 ]
Total (95% CI) 100.0 % 0.53 [ 0.28, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.047)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 Vitamin A versus Control, Outcome 17 Night Blindness Prevalence at Longest
Follow-up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 17 Night Blindness Prevalence at Longest Follow-up
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
West 1991 -0.99425227 (0.39190376) 33.9 % 0.37 [ 0.17, 0.80 ]
Sommer 1986 -1.2039728 (0.28074884) 66.1 % 0.30 [ 0.17, 0.52 ]
Total (95% CI) 100.0 % 0.32 [ 0.21, 0.50 ]
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 4.96 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.18. Comparison 1 Vitamin A versus Control, Outcome 18 Xerophthalmia Incidence at Longest
Follow-up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 18 Xerophthalmia Incidence at Longest Follow-up
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Barreto 1994 0 (0) Not estimable
West 1991 -0.96758403 (0.50156862) 3.9 % 0.38 [ 0.14, 1.02 ]
Herrera 1992 -0.12783337 (0.10106377) 96.1 % 0.88 [ 0.72, 1.07 ]
Total (95% CI) 100.0 % 0.85 [ 0.70, 1.03 ]
Heterogeneity: Chi2 = 2.69, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 1.62 (P = 0.11)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Vitamin A versus Control, Outcome 19 Xerophthalmia Prevalence at Longest
Follow-up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 19 Xerophthalmia Prevalence at Longest Follow-up
Study or subgroup log [Risk Ratio] Risk Ratio Weight Risk Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
West 1991 -0.99425227 (0.39190376) 21.8 % 0.37 [ 0.17, 0.80 ]
Sommer 1986 -1.2039728 (0.20687375) 78.2 % 0.30 [ 0.20, 0.45 ]
Total (95% CI) 100.0 % 0.31 [ 0.22, 0.45 ]
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 6.33 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.20. Comparison 1 Vitamin A versus Control, Outcome 20 Vitamin A Deficient at Longest
Follow-up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 20 Vitamin A Deficient at Longest Follow-up
Study or subgroup Vitamin A Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ranjini 2001 6/26 8/28 1.3 % 0.81 [ 0.32, 2.01 ]
Shankar 1999 7/125 13/140 2.1 % 0.60 [ 0.25, 1.46 ]
Dibley 1994 135/423 237/423 40.9 % 0.57 [ 0.48, 0.67 ]
Ross 1993 HEALTH 268/556 318/541 55.6 % 0.82 [ 0.73, 0.92 ]
Total (95% CI) 1130 1132 100.0 % 0.71 [ 0.65, 0.78 ]
Total events: 416 (Vitamin A), 576 (Control)
Heterogeneity: Chi2 = 13.58, df = 3 (P = 0.004); I2 =78%
Test for overall effect: Z = 7.23 (P < 0.00001)
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Analysis 1.21. Comparison 1 Vitamin A versus Control, Outcome 21 Vitamin A Serum Level at Longest
Follow-up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 21 Vitamin A Serum Level at Longest Follow-up
Study or subgroup Experimental Control
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ranjini 2001 26 33.9 (10.5) 28 32.3 (7) 0.9 % 0.18 [ -0.36, 0.71 ]
Lin 2009 35.3977273 (29.152) 44 42 23 (35.726) 1.4 % 0.38 [ -0.05, 0.80 ]
Sempertegui 1999 46 48.5 (12.6) 43 42.9 (10.5) 1.4 % 0.48 [ 0.06, 0.90 ]
Cheng 1993 56 30.89 (12.24) 40 23.32 (13.39) 1.5 % 0.59 [ 0.18, 1.00 ]
Pinnock 1986 47 50.2 (11.65) 43 49.9 (10.49) 1.5 % 0.03 [ -0.39, 0.44 ]
Reddy 1986 (2) 98 31.6 (9.44) 53 23.6 (5.53) 2.0 % 0.96 [ 0.61, 1.31 ]
Semba 1992 117 1.7 (0.5) 115 0.7 (0.2) 2.0 % 2.61 [ 2.26, 2.96 ]
Pinnock 1988 68 36.5 (8.2462113) 62 35.5 (7.0866) 2.1 % 0.13 [ -0.22, 0.47 ]
Reddy 1986 110 30.1 (10.83) 66 24.5 (6.31) 2.6 % 0.59 [ 0.28, 0.90 ]
Kartasasmita 1995 103 26.6 (9.4) 101 25.9 (9.1) 3.3 % 0.08 [ -0.20, 0.35 ]
Shankar 1999 201 21.9 (7.2) 209 19.2 (7.8) 6.6 % 0.36 [ 0.16, 0.55 ]
Dibley 1994 423 0.89 (0.255) 426 0.71 (0.228) 12.9 % 0.74 [ 0.60, 0.88 ]
Ross 1993 HEALTH 556 0.68 (0.294746) 541 0.6 (0.290743) 17.7 % 0.27 [ 0.15, 0.39 ]
Ross 1993 SURVIVAL 1894 0.7 (1.741068) 1065 0.61 (1.142576) 44.3 % 0.06 [ -0.02, 0.13 ]
Total (95% CI) 3789 2834 100.0 % 0.31 [ 0.26, 0.36 ]
Heterogeneity: Chi2 = 270.23, df = 13 (P<0.00001); I2 =95%
Test for overall effect: Z = 12.09 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Vitamin A versus Control, Outcome 22 Hospitalisation, Number of Children
Hospitalised Once or More at Longest Follow-up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 22 Hospitalisation, Number of Children Hospitalised Once or More at Longest Follow-up
Study or subgroup Vitamin A Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ross 1993 HEALTH 27/596 42/589 100.0 % 0.64 [ 0.40, 1.02 ]
Total (95% CI) 596 589 100.0 % 0.64 [ 0.40, 1.02 ]
Total events: 27 (Vitamin A), 42 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.058)
Test for subgroup differences: Not applicable
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Analysis 1.23. Comparison 1 Vitamin A versus Control, Outcome 23 Hospitalisation due to Diarrhoea at
Longest Follow-up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 23 Hospitalisation due to Diarrhoea at Longest Follow-up
Study or subgroup Vitamin A Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cheng 1993 0/98 1/74 100.0 % 0.25 [ 0.01, 6.11 ]
Total (95% CI) 98 74 100.0 % 0.25 [ 0.01, 6.11 ]
Total events: 0 (Vitamin A), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours experimental Favours control
118Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.24. Comparison 1 Vitamin A versus Control, Outcome 24 Hospitalisation due to Lower
Respiratory Tract Infection at Longest Follow-up.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 24 Hospitalisation due to Lower Respiratory Tract Infection at Longest Follow-up
Study or subgroup Vitamin A Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Cheng 1993 0/98 3/74 100.0 % 0.11 [ 0.01, 2.06 ]
Total (95% CI) 98 74 100.0 % 0.11 [ 0.01, 2.06 ]
Total events: 0 (Vitamin A), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 1.25. Comparison 1 Vitamin A versus Control, Outcome 25 Side effect - Bulging Fontanelle.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 25 Side effect - Bulging Fontanelle
Study or subgroup Vitamin A Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stabell 1995 0/30 0/20 Not estimable
Arya 2000 0/107 0/110 Not estimable
Bahl 1999 2/309 0/309 100.0 % 5.00 [ 0.24, 103.72 ]
Total (95% CI) 446 439 100.0 % 5.00 [ 0.24, 103.72 ]
Total events: 2 (Vitamin A), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Not applicable
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Analysis 1.26. Comparison 1 Vitamin A versus Control, Outcome 26 Side effect - Vomiting.
Review: Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age
Comparison: 1 Vitamin A versus Control
Outcome: 26 Side effect - Vomiting
Study or subgroup Vitamin A Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sinha 1976 6/153 0/153 1.6 % 13.00 [ 0.74, 228.77 ]
Arya 2000 13/107 8/110 24.5 % 1.67 [ 0.72, 3.87 ]
Florentino 1990 102/1635 18/836 74.0 % 2.90 [ 1.77, 4.75 ]
Total (95% CI) 1895 1099 100.0 % 2.75 [ 1.81, 4.19 ]
Total events: 121 (Vitamin A), 26 (Control)
Heterogeneity: Chi2 = 2.53, df = 2 (P = 0.28); I2 =21%
Test for overall effect: Z = 4.74 (P < 0.00001)
Test for subgroup differences: Not applicable
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A D D I T I O N A L T A B L E S
Table 1. Sensitivity and subgroup analyses
Outcome or Sub-
group
Studies Heterogeneity Statistical Method Effect Estimate Test for Subgroup dif-
ference
(p-value)
Mor-
tality (all-cause) at
Longest Follow-up
(Sensitivity analysis
using random ef-
fects model)
17 Heterogeneity: Tau² =
0.04; Chi² = 29.10, df
= 15 (P = 0.02); I² =
48%
Risk Ratio (IV, Ran-
dom, 95% CI)
0.71 [0.61, 0.84] NA
120Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Sensitivity and subgroup analyses (Continued)
Mor-
tality (all-cause) at
Longest Follow-up
(Sensitivity Analysis
assumes NO im-
pact of clustering
for studies with un-
known ICC)
17 Heterogeneity: Chi² =
48.83, df = 15 (P < 0.
0001); I² = 69%
Risk Ratio (IV, Fixed,
95% CI)
0.81 [0.75, 0.89] NA
Mor-
tality (all-cause) at
Longest Follow-up
(Sensitivity Analysis
assumes HIGH im-
pact of clustering
for studies with un-
known ICC)
17 Heterogeneity: Chi² =
25.67, df = 15 (P = 0.
04); I² = 42%
Risk Ratio (IV, Fixed,
95% CI)
0.75 [0.68, 0.83]) NA
Mortality (all-
cause) at Longest
Follow-up (by Na-
tional Child Mor-
tality Rate): High (>
40/1000)
15 Heterogeneity: Chi² =
29.02, df = 14 (P = 0.
01); I² = 52%
Risk Ratio (IV, Fixed,
95% CI)
0.76 [0.69, 0.83] 0.78
Mortality (all-
cause) at Longest
Follow-up (by Na-
tional Child Mor-
tality Rate): Low
(<40/1000)
2 Heterogeneity:Not ap-
plicable
Risk Ratio (IV, Fixed,
95% CI)
1.00 [0.14, 7.08]
Mor-
tality (all-cause) at
Longest Follow-up
(by Region): Asia
11 Heterogeneity: Chi² =
15.00, df = 9 (P = 0.09)
; I² = 40%
Risk Ratio (IV, Fixed,
95% CI)
0.69 [0.61, 0.79] 0.12
Mor-
tality (all-cause) at
Longest Follow-up
(by Region): Africa
5 Heterogeneity: Chi² =
9.81, df = 4 (P = 0.04)
; I² = 59%
Risk Ratio (IV, Fixed,
95% CI)
0.85 [0.73, 0.98]
Mor-
tality (all-cause) at
Longest Follow-up
(by Region): Latin
America
1 Heterogeneity: Not
applicable
Risk Ratio (IV, Fixed,
95% CI)
1.00 [0.14, 7.08]
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Table 1. Sensitivity and subgroup analyses (Continued)
Mortal-
ity (all-cause), out-
comes < 1 year since
randomisation
13 Heterogeneity: Chi² =
33.85, df = 11 (P = 0.
0004); I² = 67%
Risk Ratio (IV, Fixed,
95% CI)
0.82 [0.74, 0.91] NA
Mortality due toDi-
arrhoea, outcomes <
1 year since ran-
domisation
5 Heterogeneity: Chi² =
5.14, df = 4 (P = 0.27)
; I² = 22%
Risk Ratio (IV, Fixed,
95% CI)
0.75 [0.59, 0.96] NA
Mortality due to
LRTI, outcomes < 1
year since randomi-
sation
5 Heterogeneity: Chi² =
5.70, df = 6 (P = 0.46)
; I² = 0%
Risk Ratio (IV, Fixed,
95% CI)
0.71 [0.41, 1.21] NA
Mortality due to
Measles, outcomes <
1 year since ran-
domisation
4 Heterogeneity: Chi² =
0.52, df = 3 (P = 0.91)
; I² = 0%
Risk Ratio (IV, Fixed,
95% CI)
0.85 [0.52, 1.37] NA
Mor-
tality due to Menin-
gitis, outcomes < 1
year since randomi-
sation
1 Heterogeneity:Not ap-
plicable
Risk Ratio (IV, Fixed,
95% CI)
5.79 [0.22, 153.24] NA
Di-
arrhoea Incidence at
Longest Follow-up
(Sensitivity analysis
using random ef-
fects model)
13 Heterogeneity: Chi² =
218.62, df = 11 (P<0.
00001); I² = 95%
Risk Ratio (IV, Ran-
dom, 95% CI)
0.85 [0.72, 1.00] NA
Diarrhoea Inci-
dence, outcomes < 1
year since randomi-
sation
10 Heterogeneity: Chi² =
49.93, df = 8 (P<0.
00001); I² = 84%
Risk Ratio (IV, Fixed,
95% CI)
0.93 [0.89, 0.97] NA
Lower Respiratory
Tract Infection Inci-
dence, outcomes <1
year since randomi-
sation
8 Heterogeneity: Chi² =
4.47, df = 5 (P = 0.48)
; I² = 0%
Risk Ratio (IV, Fixed,
95% CI)
0.99 [0.78, 1.26] NA
Malaria Incidence,
outcomes 1+ year
since randomisation
(by Age)
1 Heterogeneity:Not ap-
plicable
Risk Ratio (M-H,
Fixed, 95% CI)
0.73 [0.60, 0.88] NA
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Table 1. Sensitivity and subgroup analyses (Continued)
Measles Incidence,
outcomes < 1 year
since randomisation
5 Heterogeneity: Chi² =
0.24, df = 4 (P = 0.99)
; I² = 0%
Risk Ratio (IV, Fixed,
95% CI)
0.54 [0.36, 0.80] NA
Bitot’s Spots Inci-
dence, outcomes < 1
year since randomi-
sation
1 Heterogeneity:Not ap-
plicable
Risk Ratio (IV, Fixed,
95% CI)
0.93 [0.76, 1.14] NA
Bitot’s Spots Preva-
lence, outcomes < 1
year since randomi-
sation
3 Heterogeneity: Chi² =
6.06, df = 2 (P = 0.05)
; I² = 67%
Risk Ratio (IV, Fixed,
95% CI)
0.43 [0.33, 0.56] NA
Night Blindness
Prevalence, out-
comes < 1 year since
randomisation
1 Heterogeneity: Not
applicable
Risk Ratio (IV, Fixed,
95% CI)
0.30 [0.17, 0.52] NA
Xerophthalmia In-
cidence, outcomes <
1 year since ran-
domisation
2 Heterogeneity: Not
applicable
Risk Ratio (IV, Fixed,
95% CI)
0.88 [0.72, 1.07] NA
Vita-
min A Serum Level
at Longest Follow-
up (Sensitivity anal-
ysis using random
effects model)
14 Heterogeneity: Tau² =
0.22; Chi² = 270.23, df
= 13 (P < 0.000001); I²
= 95%
Std. Mean Difference
(IV, Random, 95% CI)
0.53 [0.27, 0.79] NA
Vitamin A Serum
Level, outcomes < 1
year since randomi-
sation
11 Heterogeneity: Chi² =
178.42, df 10, (P<0.
000001), I² = 94%
Std. Mean Difference
(IV, Fixed, 95% CI)
0.45 [0.37, 0.53] NA
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A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE (1950 to April Week 2 2010)
1 exp infant/ or exp child/ or exp child, preschool/
2 (baby or babies or infant$ or toddler$ or child$ or girl$ or boy$ or pre school$ or pre-school$ or preschool$).tw.
3 1 or 2
4 exp Vitamin A/
5 (retinol$ or retinal$ or aquasol a or vitamin a).ab,ti.
6 4 or 5
7 randomised controlled trial.pt.
8 controlled clinical trial.pt.
9 randomized.ab.
10 placebo.ab.
11 drug therapy.fs.
12 randomly.ab.
13 trial.ab.
14 groups.ab.
15 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16 exp animals/ not humans.sh.
17 15 not 16
18 3 and 6 and 17
Global Health (1973 to March 2010)
For the search of Global Health database, replacement subject headings mapped to the Global Health database were used when possible,
otherwise the text was used similar to the MEDLINE searches conducted previously.
1 exp school children/ or exp children/ or exp preschool children/
2 (baby or babies or infant$ or toddler$ or child$ or girl$ or boy$ or pre school$ or pre-school$ or preschool$).tw.
3 1 or 2
4 retinol.sh.
5 (retinol$ or retinal$ or aquasol a or vitamin a).ab,ti.
6 4 or 5
7 exp randomized controlled trials/ or exp clinical trials/
8 random*.mp.
9 placebo.mp.
10 trial.mp.
11 7 or 8 or 9 or 10
12 3 and 6 and 11
EMBASE (1980 to 2010 Week 16)
EMTREE index terms were used when possible. The UK Cochrane Centre’s suggested combination of EMTREE and free text words
were used to search for randomized-controlled trials.
1 exp infant/ or exp child/ or exp child, preschool/
2 (baby or babies or infant$ or toddler$ or child$ or girl$ or boy$ or pre school$ or pre-school$ or preschool$).tw.
3 1 or 2
4 exp Vitamin A/
5 (retinol$ or retinal$ or aquasol a or vitamin a).ab,ti.
6 4 or 5
7 exp crossover-procedure/ or exp double-blind procedure/ or exp randomized controlled trial/ or exp single-blind procedure/
8 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind$) or (singl$ adj blind$) or
assign$ or allocat$ or volunteer$).mp.
9 7 or 8
10 3 and 6 and 9
The Cochrane Central Register of Controlled Trials (CENTRAL) 27 April 2010
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#1 MeSH descriptor Child explode all trees
#2 MeSH descriptor Infant explode all trees
#3 MeSH descriptor Child, Preschool explode all trees
#4 (baby or babies or infant* or toddler* or child* or (pre next school*) or preschool* or girl* or boy*):ti,ab,kw
#5 (#1 OR #2 OR #3 OR #4)
#6 MeSH descriptor Vitamin A explode all trees
#7 retinol* or retinal$ or “aquasol a” or “vitamin a”
#8 (#6 OR #7)
#9 (#5 AND #8)
Latino Americana e do Caribe em Ciências da Saúde (LILACS) 27 April 2010
Mh vitamin a or tw retinol$ or tw aquasol$ or tw retinal$ [Words] AND [Tw baby or Tw babies or Tw child$ or Tw infant$ or Tw
toddler$ or Tw girl$ or Tw boy$ or Tw prescshool$ or Tw pre-school$ or Tw niño or Tw niños or Tw niña or Tw niñas or Tw bebé or
Tw bebés or Tw preescolar or Tw prescolares [Words]
AND ((Pt randomized controlled trial OR Pt controlled clinical trial OR Mh randomized controlled trials ORMh random allocation
OR Mh double-blind method OR Mh single-blind method) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR
(Pt clinical trial OR Ex E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw
investiga$)) OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw
blind$ OR Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) OR Mh placebos OR Tw placebo$ OR (Tw random$ OR Tw
randon$ OR Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR Mh research design) AND NOT (Ct animal AND NOT
(Ct human and Ct animal)) OR (Ct comparative study OR Ex E05.337$ OR Mh follow-up studies OR Mh prospective studies OR
Tw control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) ANDNOT (Ct animal ANDNOT (Ct human and Ct animal)))
[Words]
African Index Medicus 27 April 2010
1. retinol$ or retinal$ or aquasol a or vitamin a [Descriptor]
metaRegister of Controlled Trials 27 April 2010
(baby or babies or infant or child) and (vitamin a or aquasol or retinol or retinal)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
1) Sensitivity analyses are performed only for all-cause mortality, diarrhoea incidence and vitamin A serum levels.
2) Post-hoc analyses were performed for Imputed ICC and studies awaiting assessment.
3) Subgroup analysis based on baseline HIV status was not performed as none of the included studies gave a baseline status of study
population on HIV and we excluded studies conducted on children with HIV.
4) Post-hoc, we included two studies in which participants were assigned using a quasi-random method.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Cause of Death; Diarrhea [mortality]; Measles [mortality]; Meningitis [mortality]; Randomized Controlled Trials as Topic; Respiration
Disorders [mortality]; Vitamin A [∗administration & dosage; adverse effects]; Vitamin A Deficiency [complications; ∗drug therapy;
mortality]; Vitamins [∗administration & dosage; adverse effects]
MeSH check words
Child, Preschool; Humans; Infant
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